CD3-binding polypeptide constructs
Patent Information
- Application Number
- JP2023526543
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-08
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-11-08
AI Technical Summary
Existing T cell engagers (TCEs) face challenges in maintaining stability and efficacy due to insufficient hydrophobic interactions between VH and VL domains, leading to instability in both in vitro and in vivo applications, which affects their ability to form an effective immune synapse with target cells.
A polypeptide construct comprising specific VH and VL regions with defined CDR sequences, including amino acid substitutions, is designed to enhance the stability and binding affinity to the human CD3 epsilon chain, thereby improving the thermal stability and reducing the formation of high molecular weight aggregates.
The enhanced stability of the polypeptide construct maintains its biological activity and reduces immunogenicity, ensuring effective target cell killing while providing a more favorable therapeutic profile.
Smart Images

Figure 00000231_0000 
Figure 00000231_0001 
Figure 00000231_0002
Abstract
Description
[Technical Field]
[0001] The present invention relates to a polypeptide or polypeptide construct comprising a binding domain that binds to an extracellular epitope of a human CD3ε chain, comprising or consisting of a VH region and a VL region, i) the VH region being a CDR-H1 sequence of X1YAX2N (wherein X1 is K, V, S, G, R, T or I; and X2 is M or I); RIRSKYNNYATYYADX1VKX2 (wherein X1 is S or Q; and ii) The VL region comprises the CDR-H2 sequence of X2 (where X2 is D, G, K, S, or E); and the CDR-H3 sequence of HX1NFGNSYX2SX3X4AY (where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W, or F; and X4 is W, F, or Y); ii) the VL region comprises X1SSTGAVTX2X3X4YX5N (where X1 is G, R, or A; X2 is S, or T; X3 The CDR-L1 sequence is X1TX2X3X4X5X6 (where X1 is G or A; X2 is K, D or N; X3 is F, M or K; X4 is L or R; X5 is A, P or V; and X6 is P or S); and X1LWYSNX2WV (where X1 is V, A or T; and The present invention relates to a polypeptide or polypeptide construct comprising the CDR-L3 sequence of (i) where X2 is R or L; and one or more CDR sequences of the VH region of (i) and / or the VL region of (ii) comprising one amino acid substitution or combination thereof selected from X24V and X24F of CDR-H1; D15 and X116A of CDR-H2; H1, X12E, F4 and N6 of CDR-H3; and X11L and W3 of CDR-L3. The present invention also relates to a polynucleotide encoding the polypeptide or polypeptide construct of the present invention, a vector comprising the polynucleotide, and host cells transformed or transfected with the polynucleotide or the vector. Furthermore, the present invention also provides a process for producing the polypeptide or polypeptide construct and a pharmaceutical composition comprising the polypeptide or polypeptide construct of the present invention. Furthermore, the present invention relates to the medical use of the polypeptide or polypeptide construct and a kit comprising the polypeptide or polypeptide construct. [Background technology]
[0002] T cell engagers (TCEs) utilize the ability of T cells to recognize exogenous peptides on mutant or infected cells via T cell receptors. T cell recognition is mediated by clonal distributed alpha-beta and gamma-delta T cell receptors (TcRs) that interact with low-affinity peptide MHC (pMHC) peptide loading molecules. The antigen-specific chain of TcRs lacks a signaling domain and instead binds to the conserved multi-subunit signaling apparatus CD3. The mechanism by which TcR ligation is directly transmitted to the signaling apparatus is a fundamental interest in T cell biology. Briefly, it is the CD3 subunit that translates cell surface antigen binding into an intracellular phosphorylation signaling cascade. These phosphorylation events lead to the activation of transcription factors such as NFAT and NFκB, resulting in increased expression of cytokines and effector proteins such as granzymes and perforins. It is this feature that is utilized by TCEs to simultaneously bind target antigens on tumor cells to CD3 on T cells to form artificial immune synapses, ultimately leading to the destruction of cells expressing the target antigen.
[0003] From a clinical standpoint, TCEs need to exhibit efficient cytotoxic activity, but at the same time, other properties such as a manageable side effect profile are desirable. However, these aspects are not the only ones to consider in TCE development. Another important area for drug development is the pre-patient stage, i.e., the in vitro concern properties of TCEs, such as shelf life, production scalability, solubility, stability, and ease of formulation. In other words, a key feature from a pharmaceutical standpoint is the developmentability of a given TCE or part thereof to address specific needs, such as in drug manufacturing or administration. Summarizing the requirements from clinical and pharmacological perspectives is crucial for the advancement of TCE platforms related to commercialization. Given the biological complexity of having a TCE that induces the formation of immune synapses, manipulating TCEs with respect to other properties such as shelf life, production scalability, solubility, stability, and ease of formulation while maintaining their efficacy in mediating the death of target cells can be challenging.
[0004] The thermal stability of TCE is a crucial characteristic both in and out of the patient's body. Higher thermal stability of TCE reduces the formation of high molecular weight aggregates, thereby providing TCE that remains active for longer periods in the body but is more stable during storage. Furthermore, the reduction in high molecular weight aggregates also results in a more favorable immunogenicity profile of TCE upon administration, thereby reducing the risk of side effects. [Overview of the project] [Problems that the invention aims to solve]
[0005] Traditionally, the VH and VL domains constituting the anti-target and anti-CD3 binding domains of TCEs have been areas of focus for improving stability. This is particularly true for Fv, which is part of a TCE. The hydrophobic interaction between VH and VL is thought to strongly determine the stability of Fv. In many Fvs, the interaction may not be strong enough to be stable for in vitro and / or in vivo applications. This has led to the coupling of the V domain of Fv by linkers, resulting in single-chain Fv (scFv). While linkers have been shown to be effective in holding the V domain (variable domain) together, it is not always effective to keep scFv active or sufficiently active for a given application, and therefore further improvement in stability is needed. One approach to increasing stability is to increase the stability of a biologically active Fv so that it remains target-binding monomer by increasing the interaction between the two V domains. While approaches to improving the stability of scFv have been described in the art, improving the stability of Fv, which is part of a TCE, remains a need in the art. [Means for solving the problem]
[0006] The present invention relates to a polypeptide or polypeptide construct comprising a binding domain that binds to an extracellular epitope of a human CD3ε chain, which includes or consists of a VH region and a VL region. i) The VH region is CDR-H1 sequence of X1YAX2N (where X1 is K, V, S, G, R, T, or I; and X2 is M or I); The CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2 (where X1 is S or Q; and X2 is D, G, K, S or E); and CDR-H3 array HX1NFGNSYX2SX3X4AY (where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W, or F; and X4 is W, F, or Y) Includes; ii) The VL region is, CDR-L1 sequence of X1SSTGAVTX2X3X4YX5N (where X1 is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y; and X5 is P or A); The CDR-L2 sequence of X1TX2X3X4X5X6 (where X1 is G or A; X2 is K, D or N; X3 is F, M or K; X4 is L or R; X5 is A, P or V; and X6 is P or S); and CDR-L3 sequence X1LWYSNX2WV (where X1 is V, A, or T; and X2 is R or L) Includes; iii)i) One or more CDR sequences of the VH region and / or ii) VL region are CDR-H1 X24V and X24F; D15 (preferably E) and X116A of CDR-H2; H1 (preferably A or N), X12E, F4 (preferably I), and N6 (preferably S or T) of CDR-H3; and X11L and W3 (preferably Y) of CDR-L3 The present invention relates to polypeptides or polypeptide constructs comprising one or more amino acids selected from the following.
[0007] The term “polypeptide construct” (also referred to herein as “compound” instead) refers to an antigen-binding (or epitope-binding) molecule that includes the paratope-containing domain itself. In connection with the present invention, a polypeptide construct is understood as an organic polymer that does not exist in nature and contains at least one sequential, unbranched amino acid chain that has been manipulated. An example of a polypeptide construct that is a single polypeptide is the BiTE® molecule, which contains a core structure on a single polypeptide chain containing at least one functional target-binding domain together with at least one fully functional CD3-binding domain, where these domains are directly linked by a flexible peptide ("linker") without any insertion domains, unlike, for example, Xmab, which contains the target-binding factor and the CD3-binding factor on different polypeptide chains. In connection with the present invention, similar polypeptide constructs containing multiple amino acid chains are also envisioned. The term “polypeptide” is preferably used in relation to the single-chain form of the compounds of the present invention, but “polypeptide construct” may be more appropriately used to describe polypeptides containing multiple polypeptide chains, for example two, three, or four polypeptide chains. Furthermore, the term “polypeptide construct” is also suitable for describing the compounds of the present invention that include one or more non-amino acid components, such as human serum albumin (HSA). The amino acid chain of the polypeptide typically contains at least 50 amino acids, preferably at least 100, 200, 300, 400, or 500 amino acids. In connection with the present invention, it is also conceivable that the amino acid chain of the polymer is linked to entities that are not composed of amino acids.
[0008] This polypeptide comprises structural and / or functional features based on the structure and / or function of an antibody, such as a full-length immunoglobulin molecule. Therefore, the polypeptide construct binds specifically, preferably selectively, or immunospecifically to its target or antigen, more precisely to the epitope of the target or target antigen, and / or contains a naturally occurring heavy chain variable region (VH) and / or light chain variable region (VL) in the antibody, or a domain derived from the antibody. Thus, the construct may instead be considered to comprise a paratope-like structure and an epitope-binding structure, as found in a natural antibody or fragment thereof. The polypeptide construct according to the present invention comprises the minimum structural requirements of an antibody that enables immunospecific target binding, i.e., a paratope that, unless otherwise specified, immunospecifically or immunoselectively recognizes an epitope on a target antigen. This minimum requirement can be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VL region, also referred to as CDR-L1, CDRL2, and CDR-L3) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VH region, also referred to as CDR-H1, CDR-H2, and CDR-H3), preferably all six CDRs. Thus, polypeptide constructs may be characterized by the presence of three or six CDRs in the binding domain, and those skilled in the art will know where (in what order) these CDRs are located within the paratopic binding structure. In relation to the CD3 binding domain of a polypeptide or polypeptide construct, the paratopic binding structure is identified as a binding domain characterized by the presence of VH and VL regions containing CDRs. Therefore, the polypeptide / polypeptide construct according to the present invention comprises at least one paratopic binding structure which is a binding domain that selectively, immunospecifically, and / or immunoselectively binds to an extracellular epitope of a human CD3ε (hereinafter also referred to as CD3ε or "CD3 epsilon") chain containing a VH region and a VL region having a CDR. Therefore, the polypeptide / polypeptide construct according to the present invention comprises a paratope that binds immunospecifically and / or immunoselectively to human CD3ε.The term "CDR" and its plural forms refer to complementarity-determining regions, three of which constitute the binding properties of the light chain variable region (CDR-L1, CDR-L2, and CDR-L3), and three of which constitute the binding properties of the heavy chain variable region (CDR-H1, CDR-H2, and CDR-H3). Because CDRs contain the majority of the residues responsible for the specific interaction between the antibody (or construct or binding domain) and the antigen, they contribute to the functional activity of the antibody molecule; CDRs are the primary determinants of antigen specificity. The precise definition of CDR boundaries and lengths depends on different classification and numbering schemes. Therefore, CDRs may be referred to by any other boundary definition, including Kabat, Chothia, Contact, or the numbering systems described herein. Despite the different boundaries, each of these systems has some overlap with those constituting the so-called "hypervariable regions" within the variable sequence. Therefore, the definitions of CDRs according to these systems may differ in length and boundary regions with respect to adjacent framework regions. For example, Kabat (an approach based on interspecies sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes), and / or MacCallum (Kabat et al., op. cit.; Chothia et al., J.Mol.Biol, 1987, 196:901-917; and MacCallum et al., J.Mol.Biol, 1996, 262:732). Yet another criterion for characterizing antigen-binding sites is the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Two residue identification techniques can be combined to define hybrid CDRs, insofar as they define overlapping but non-identical regions. However, numbering by the so-called Kabat system is preferred.As used herein, the term “antigen-binding structure” refers to any polypeptide / polypeptide construct comprising either an antigen-binding structure or a molecule having binding activity to a particular target antigen. The antigen-binding structure or antigen-binding molecule is not limited to those of biological origin and may, for example, be a polypeptide resulting from an artificially designed sequence. These antigen-binding structures or antigen-binding molecules may be any of the following: natural polypeptides, synthetic polypeptides, recombinant polypeptides, etc. Because the antigen-binding structures according to the present invention specifically bind to a portion of an antigen, i.e., specifically to the CD3ε epitope, the antigen (epitope)-binding structure may also be broadly defined herein as a “paratope structure.” Therefore, the polypeptide / polypeptide construct according to the present invention may also be defined as a domain comprising a paratope that preferably binds immunospecifically or immunoselectively to a target antigen / target epitope, and in certain embodiments comprising at least one further paratope, preferably binds immunospecifically or immunoselectively to further, different or the same target antigen / target epitope. Therefore, whenever this specification refers to a construct or molecular domain of the present invention, the construct comprises at least one paratope structure (or paratope) that binds to human CD3ε, as specifically identified herein by any one of the appended claims. In certain embodiments, the construct comprises at least one further paratope that also binds to human CD3ε or different target antigens as defined herein.
[0009] As used in accordance with the present invention, the term "antibody" includes full-length antibodies, including camel antibodies and other immunoglobulins produced by biotechnological or protein engineering methods or processes. These full-length antibodies may be, for example, monoclonal antibodies, recombinant antibodies, chimeric antibodies, deimmunized antibodies, humanized antibodies and human antibodies, as well as antibodies derived from other species such as mice, hamsters, rabbits, rats, goats or non-human primates.
[0010] The polypeptide / polypeptide constructs of the present invention may also include structures of naturally occurring full-length immunoglobulins. For example, an antibody construct may include (at least) two full-length antibody heavy chains and two full-length antibody light chains. However, given that the polypeptide / polypeptide constructs according to the present invention preferably include a linker that ligates the VH and VL regions of the CD3 binding domain, preferably resulting in an scFv, and / or in other embodiments, include at least one further binding domain including a paratope, these of which do not exist in nature and whose function differs significantly from that of naturally occurring products, the polypeptides or polypeptide constructs of the present invention are preferably artificial "complex" molecules that include an scFv and / or, in some embodiments, separate paratope / binding domains having different specificities and / or selectivity.
[0011] As described above, the polypeptides of the present invention may contain more than one polypeptide chain; that is, polypeptides containing two or more polypeptide chains, particularly polypeptides that form a three-dimensional protein-like structure enabling immunospecific binding to CD3ε, are also subject to the present invention. Therefore, the definition of the term "polypeptide construct" includes molecules consisting of only one polypeptide chain and molecules consisting of two, three, four or more polypeptide chains that may be identical (homodimers, homotrimers, or homooligomers) or different (heterodimers, heterotrimers, or heterooligomers). Examples of the antibodies identified above and their fragments, variants, derivatives, and constructs derived therefrom are described, in particular, in Harlow and Lane, Antibodies: A laboratory manual, CSHL Press (1988); Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010; and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009.
[0012] The "polypeptide / polypeptide constructs" of the present invention may also include fragments of full-length antibodies such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd(VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "rIgG" (a "half-antibody" consisting of a heavy chain and a light chain), but since they are defined as including the VH and VL regions, not all of the above fragments are applicable to the CD3ε binding domain, although they are applicable to embodiments relating to at least one further binding domain. The polypeptide / polypeptide constructs according to the present invention may also include modified fragments of antibodies, also called antibody variants or antibody derivatives. Examples include scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabody, single-chain diabody, tandem diabody (Tandab), tandem-di-scFv, tandem-tri-scFv, structures such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2, multibodies such as triabody or tetrabody, and VHH, VH Examples include, but are not limited to, "minibodies" embodied by structures that are nanobodies or single-domain antibodies, such as single-variable-domain antibodies, which contain only one variable region that selectively and preferably specifically binds to an antigen or target independently of other variable regions or domains, and which may be VL. Not all of the above fragments are applicable to the CD3ε binding domain, but are applicable to embodiments relating to at least one further binding domain, as they are defined as containing VH and VL regions. Further possible forms of polypeptide / polypeptide constructs according to the present invention are crossbodies, maxibodies, hetero-Fc constructs, mono-Fc constructs and scFc constructs. Examples of these forms are described below herein.
[0013] Furthermore, the definition of the term “polypeptide construct” includes divalent and polyvalent / multivalent polypeptide / polypeptide constructs, as well as bispecific and polyspecific / multispecific polypeptide / polypeptide constructs that selectively and preferably specifically bind to two, three, or more antigenic structures (epitopes) via different binding domains. For example, if a polypeptide construct has two binding domains for one target (CD3 epsilon) and one binding domain for another target, e.g., those described herein, or vice versa, the polypeptide construct may have a binding value greater than its specificity, and in either case, the polypeptide construct is trivalent and bispecific. Generally, the term “bispecificity” includes the meaning that the polypeptide construct binds to at least two different antigens, e.g., the aforementioned CD3ε and further targets, e.g., those specified herein below.
[0014] The terms “paratope,” “antigen-binding domain,” “epitope-binding domain,” “binding domain,” or “domain that binds to ~” are, in connection with the present invention, characterized domains of a construct that selectively and preferably specifically or immunospecifically bind to an epitope on a target or on an antigen (here, CD3) / selectively and preferably specifically or immunospecifically interact with an epitope / selectively and preferably specifically or immunospecifically recognize an epitope. The terms “binding domain,” or “domain that binds to ~,” or “domain,” in connection with the present invention, characterized domains of a construct that immunospecifically binds to an epitope on a target or on an antigen / immunospecifically interacts with an epitope / immunospecifically recognizes an epitope. The structure and function of the CD3ε-binding domain (also referred to as the first binding domain in the case of a polypeptide / polypeptide construct that further consequently includes second, third, etc. binding domains), preferably the structure and / or function of any further binding domains (e.g., that which bind to cell surface antigens, e.g., tumor antigens, etc.), are also based on the structure and / or function of an antibody, e.g., a full-length immunoglobulin polypeptide. Therefore, a “binding domain” or “~binding domain” may include the minimum structural requirements of an antibody that enable immune-specific target binding. The structural requirements of a CD3ε binding domain are specified to include VH and VL regions, each having three corresponding CDRs, but the minimum structural requirements for any further binding domain may be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VH region), preferably all six CDRs. A “~binding domain” (or “binding domain”) may typically include the antibody light chain variable region (VL) and the antibody heavy chain variable region (VH), but it is not necessary to include both, and it may include only VH or VL. The Fd fragment often retains some antigen-binding function of, for example, an intact antigen-binding domain.The terms “paratope,” “antigen-binding structure,” and “epitope-binding structure,” as used herein, also refer to a portion of an antibody (or molecule according to the present invention) that contains a region that specifically binds to all or part of an antigen or a portion thereof, and is complementary to all or part thereof; that is, the antibody can bind to only a specific portion of the antigen. The specific portion is called an “epitope.” The antigen-binding domain can be provided from one or more antibody variable domains. Preferably, the antigen-binding domain contains an antibody variable region that includes both an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). Examples of such preferred antigen-binding domains include “single-chain Fv(scFv),” “single-chain antibody,” “Fv,” “single-chain Fv2(scFv2),” “Fab,” and “F(ab')2.” For the CD3ε-binding domain, it is preferable to take the form of scFv.
[0015] Examples of the forms "~binding domain," "paratope-containing domain" (or "binding domain," "antigen-binding structure," "epitope-binding structure"), unless otherwise defined, include, but are not limited to, the following: full-length antibody, fragments of full-length antibody (e.g., VH, VHH, VL), (s)dAb, Fv, light chain (VL-CL), Fd(VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "r IgG ("half-antibody"), antibody variants or antibody derivatives, e.g., scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabody, single-chain diabody, tandem diabody (Tandab's), tandem di-scFv, tandem tri-scFv, "minibody" (selected from forms such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2), multibody (e.g., triabody or tetrabody), and single-domain antibodies (e.g., nanobody or single-variable-domain antibody containing only one variable region which may be VHH, VH, or VL). Further examples of the form "~binding domain" (or "binding domain") include: (1) antibody fragments or antibody variants containing VL, VH, CL and CH1 (e.g., Fab); (2) antibody fragments or antibody variants containing two linked Fab fragments (e.g., F(ab')2); (3) antibody fragments or antibody variants containing VH and CH1 (e.g., Fd); (4) antibody fragments or antibody variants containing VL and CL (e.g., light chain); (5) antibody fragments or antibody variants containing VL and VH (e.g., Fv); (5) dAb fragments having a VH domain (Ward et al., (1989) Nature 341:544-546); (6) antibody variants containing at least three isolated CDRs of heavy chain and / or light chain; and (7) single-chain Fv (scFv).Examples of embodiments of the constructs or binding domains according to the present invention are described, for example, in International Publication No. 00 / 006605, International Publication No. 2005 / 040220, International Publication No. 2008 / 119567, International Publication No. 2010 / 037838, International Publication No. 2013 / 026837, International Publication No. 2013 / 026833, U.S. Patent Application Publication No. 2014 / 0308285, U.S. Patent Application Publication No. 2014 / 0302037, International Publication No. 2014 / 144722, International Publication No. 2014 / 151910, and International Publication No. 2015 / 048272. In relation to the present invention, a paratope is understood to be a part of the polypeptide described herein and an antigenic site that recognizes and binds to an antigen. A paratope is typically a small region of at least about five amino acids. Paratopes as understood herein typically include portions of the heavy chain (VH) and light chain (VL) sequences derived from an antibody. Each binding domain of the polypeptide according to the present invention comprises a paratope containing three sets of six complementarity-determining regions (CDR loops) contained within the antibody-derived VH and VL sequences.
[0016] With respect to compounds, particularly constructs of the present invention, a) the construct is a single-chain polypeptide or single-chain construct; b) the CD3ε-binding domain is in the form of scFv; c) any further, e.g., a second binding domain and / or a third domain, is in the form of scFv; d) the first and the further, e.g., the second and / or third domains are bound via a linker, preferably a peptide linker, more preferably a glycine / serine or glycine / glutamine linker; and / or e) the construct is assumed to include a domain that provides an extension of the serum half-life, e.g., an Fc-based domain or human serum albumin (HSA). In the latter case, the term “polypeptide construct” is a preferred embodiment that clarifies that it includes more than one peptide chain. A preferred Fc-based domain (also called the "HLE" domain) that extends the serum half-life comprises two polypeptide monomers, each containing a hinge, a CH2 domain, and a CH3 domain, the two polypeptide monomers fused to each other via a peptide linker (see, e.g., SEQ ID NOs. 18 and 19); the configuration, in N-terminus to C-terminus, is hinge-CH2-CH3-linker-hinge-CH2-CH3.
[0017] The constructs of the present invention are preferably “in vitro-generated constructs” and / or “recombinant constructs.” In relation to the present invention, the term “in vitro-generated” refers to a construct as defined above, in which all or part of the binding domain or variable region (e.g., at least one CDR) is generated by non-immune cell selection on a protein chip, e.g., in vitro phage display, or any other method that allows a candidate amino acid sequence to be tested for its ability to bind to an antigen. Thus, the term preferably excludes sequences that are generated only by genomic rearrangement in animal immune cells. The first and / or second domains of the construct are assumed to be produced or obtainable by phage display or library screening, rather than by transplanting a CDR sequence from an existing (monoclonal) antibody onto a scaffold. “Recombinant constructs” are constructs generated or manufactured using (among other) recombinant DNA technology or genetic engineering.
[0018] The constructs of the present invention are assumed to be monoclonal. As used herein, a polypeptide or construct referred to as “monoclonal” (mAb) is obtained from a substantially homogeneous population of antibodies / constructs, i.e., the individual antibodies / constructs in this population are identical (particularly with respect to their amino acid sequence) except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in trace amounts. Monoclonal antibodies / constructs are highly specific, targeting a single epitope within an antigen, in contrast to polyclonal antibody preparations, which typically contain different antibodies targeting different determinants (or epitopes). In addition to this specificity, monoclonal antibodies are advantageous because they are synthesized by hybridoma culture and are therefore free from contamination by other immunoglobulins. The modifier “monoclonal” indicates a characteristic of antibodies / constructs obtained from a substantially homogeneous population of antibodies and is not to be interpreted as requiring antibody production by any particular method.
[0019] For the preparation of monoclonal antibodies, any technique that provides antibodies produced by serial cell line culture can be used. For example, the monoclonal antibodies used may be produced by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or by the recombinant DNA method (see, for example, U.S. Patent No. 4,816,567). Further examples of techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96).
[0020] Next, hybridomas can be screened using standard methods such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (BIACORE®) analysis to identify one or more hybridomas that produce antibodies that selectively and preferably specifically or immunospecifically bind to a particular antigen. For example, any form of the relevant antigen can be used as an immunogen, such as recombinant antigen, its naturally occurring form, any variant or fragment, and their antigenic peptides. Surface plasmon resonance, as employed in the BIAcore® system, can be used to enhance the efficiency of phage antibody / construct binding to the epitope of the target antigen (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).
[0021] Another exemplary method for constructing constructs or binding domains is the screening of protein expression libraries, such as phage display or ribosome display libraries. Phage display is described, for example, in Ladner et al., U.S. Patent No. 5,223,409; Smith (1985), Science 228:1315-1317; Clackson et al., Nature, 352:624-628 (1991); and Marks et al., J.Mol.Biol., 222:581-597 (1991).
[0022] In addition to using display libraries, non-human animals, such as rodents (e.g., mice, hamsters, rabbits, or rats), can be immunized using relevant antigens. In one embodiment, the non-human animal contains at least a portion of the human immunoglobulin gene. For example, a mouse strain lacking mouse antibody production can be modified using a large fragment of the human Ig (immunoglobulin) locus. Using hybridoma technology, antigen-specific monoclonal antibodies derived from genes with desired specificity can be produced and selected. See, for example, Xenomouse® mouse, Green et al. (1994) Nature Genetics 7:13-21, U.S. Patent Application Publication No. 2003-0070185, International Publication No. 96 / 34096 and International Publication No. 96 / 33735.
[0023] Monoclonal antibodies can also be obtained from non-human animals and subsequently modified, for example, by humanization, deimmunization, or chimerization, using recombinant DNA techniques known in the art. Examples of modified constructs or binding domains include humanized variants of non-human antibody / constructs, "affinity-matured" constructs or binding domains (see, e.g., Hawkins et al. J.Mol.Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody variants or mutants with altered effector function (see, e.g., U.S. Patent No. 5,648,260, Kontermann and Duebel (2010) and Little (2009) cited above).
[0024] In immunology, affinity maturation is the process by which B cells produce antibodies with increased affinity to an antigen during the course of an immune response. Repeated exposure to the same antigen causes the host to continuously produce antibodies with higher affinity. Similar to natural prototypes, in vitro affinity maturation is based on the principles of mutation and selection. In vitro affinity maturation has been successfully used to optimize antibodies, antibody fragments, antibody variants, constructs, or binding domains. Random mutations within CDRs are introduced using radiation, chemical mutagens, or error-prone PCR. In addition, genetic diversity can be increased by chain shuffling. Two or three mutations and selections using display methods such as phage display typically yield antibodies, antibody fragments, antibody variants, constructs, or binding domains with affinity in the low nanomolar concentration range.
[0025] Preferred types of amino acid substitution mutations for the constructs or binding domains of the present invention involve substituting one or more residues within the hypervariable region of the parental antibody structure (e.g., a humanized antibody or human antibody structure). Generally, the resulting mutants selected for further development have improved biological properties compared to the parental antibody structure from which they were generated. A simple method for producing such substitution mutants involves affinity maturation using phage display. Briefly, several sites (e.g., 6-7 sites) in the hypervariable region are mutated to generate all possible amino acid substitutions at each site. The mutants thus generated are presented in a monovalent state from filamentous phage particles as fusions with the M13 gene III product packaged within each particle. The phage-presented mutants are then screened for their biological activity (e.g., binding affinity) as disclosed herein. Alanine scanning mutagenesis can also be performed to identify candidate hypervariable region sites (candidates for modification) that significantly contribute to antigen binding. Alternatively, or in addition, analysis of the crystal structure of the complex between the antigen and the construct or binding domain may be useful for identifying contact points between the binding domain and its specific antigen. Such contact residues and adjacent residues are candidates for substitution by the techniques detailed herein. Once such variants are generated, a panel of variants may be subjected to screening as described herein, and antibodies, their antigen-binding fragments, constructs, or binding domains exhibiting superior properties in one or more relevant assays may be selected for further development.
[0026] The constructs and binding domains of the present invention particularly include “chimeric” versions in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular class or subclass of antibodies, and the remainder of this chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another class or subclass of antibodies, as well as in fragments or variants of such antibodies, insofar as the remainder of this chain exhibits the desired biological activity (U.S. Patent No. 4,816,567, Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). The chimeric constructs or binding domains of interest herein include “primatized” constructs that include a variable domain antigen-binding sequence derived from a non-human primate (e.g., Old World monkeys, apes, etc.) and a human constant region sequence. Various methods for producing chimeric antibodies or constructs are described. For example, see Morrison et al., Proc. Natl. Acad. ScL USA 81:6851, 1985; Takeda et al., Nature 314:452, 1985; Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent No. 0171496, European Patent No. 0173494, and British Patent No. 2177096.
[0027] Antibodies, polypeptide constructs, antibody fragments, antibody variants, or binding domains can also be modified by specific deletion of human T cell epitopes (a method called "deimmunization") using methods disclosed, for example, in International Publication No. 98 / 52976 or International Publication No. 00 / 34317. In short, the heavy and light chain variable regions of antibodies, constructs, or binding domains can be analyzed with respect to peptides that bind to MHC class II. These peptides correspond to potential T cell epitopes (as defined, for example, in International Publication No. 98 / 52976 and International Publication No. 00 / 34317). For the detection of potential T cell epitopes, a computer modeling technique called "peptide threading" can be applied, as described in International Publication No. 98 / 52976 and International Publication No. 00 / 34317, and in addition, motifs present in VH and VL sequences can be searched in databases of human MHC class II binding peptides. These motifs bind to any of the 18 major MHC class I DR allotypes and thus constitute potential T cell epitopes. Detected potential T cell epitopes can be removed by substitution of a few amino acid residues within a variable domain or variable region, or preferably by single amino acid substitution. Typically, conservative substitutions are performed. In many cases, but not limited to, amino acids common to the position in human germline antibody sequences may be used. Human germline sequences are disclosed, for example, in Tomlinson, et al. (1992) J.Mol.Biol.227:776-798; Cook, GP et al. (1995) Immunol.Today Vol.16(5):237-242; and Tomlinson et al. (1995) EMBO J.14:14:4628-4638. The V BASE directory (www2.mrc-lmb.cam.ac.uk / vbase / list2.php) provides a comprehensive overview of human immunoglobulin variable region sequences (edited by Tomlinson, LA. et al., MRC Centre for Protein Engineering, Cambridge, UK).These sequences can be used as a source of human sequences, for example, in framework regions and CDRs. For example, the consensus human framework region described in U.S. Patent No. 6,300,064 can also be used.
[0028] Humanized antibodies, their variants or fragments, constructs, and binding domains are primarily based on human immunoglobulin sequences, which contain minimal sequences derived from non-human immunoglobulins. In most cases, humanized antibodies, their variants or fragments, constructs, and binding domains are based on human immunoglobulins (recipient antibodies), in which residues from the hypervariable region or CDR are replaced with residues from the hypervariable region or CDR of a non-human species (donor antibody), such as a rodent (e.g., mouse, hamster, rat, or rabbit), to achieve the desired specificity, affinity, ability, and / or biological activity. In some examples, Fv framework region (FR) residues of human immunoglobulins are replaced with corresponding non-human residues. Furthermore, the humanized antibodies, their variants or fragments, constructs, and binding domains used herein may also contain residues not found in either the recipient or donor antibody. These modifications are made to further improve and optimize the performance of the antibody. Humanized antibodies, their variants or fragments, constructs, and binding domains may also include at least a portion of the constant region of immunoglobulins (e.g., Fc), typically that of human immunoglobulins. For further details, see Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).
[0029] Humanized antibodies, their variants or fragments, constructs, and binding domains can be created by replacing the sequence of the immunoglobulin (Fv) variable region that is not directly involved in antigen binding with an equivalent sequence from the human (Fv) variable region. Exemplary methods for generating such molecules are provided by Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214, and U.S. Patents 5,585,089, 5,693,761, 5,693,762, 5,859,205, and 6,407,213. These methods involve isolating, manipulating, and expressing nucleic acid sequences encoding all or part of the immunoglobulin (Fv) variable region from at least one of the heavy or light chains. Such nucleic acids can be obtained from hybridomas and other sources that produce antibodies against a given target, as described above. Next, recombinant DNA encoding a humanized antibody, its variant or fragment, construct, or binding domain can be cloned into a suitable expression vector.
[0030] Humanized antibodies, their variants or fragments, constructs, and binding domains can also be prepared using transgenic animals (e.g., mice) that express human heavy and light chain genes but lack the ability to express endogenous mouse immunoglobulin heavy and light chain genes. Winter describes exemplary CDR grafting methods that can be used for the preparation of the humanized molecules described herein (U.S. Patent No. 5,225,539). All of the CDRs of a given human sequence may be replaced with at least some of the non-human CDRs, or only some of the CDRs may be replaced with non-human CDRs. It is sufficient to replace only the number of CDRs necessary for the humanized molecule to bind to a given antigen.
[0031] Humanized antibodies, their variants or fragments, constructs, or binding domains can be optimized by introducing conservative substitutions, consensus sequence substitutions, germline substitutions, and / or reverse mutations. Such modified immunoglobulin molecules can be prepared by any of several techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. USA, 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:7279, 1983; Olsson et al., Meth. Enzymol., 92:3-16, 1982 and European Patent No. 239400).
[0032] Human anti-mouse antibody (HAMA) responses have led the industry to prepare chimeric antibodies or other humanized antibodies / constructs. However, certain human anti-chimeric antibody (HACA) reactions are expected to be observed, particularly in chronic or high-dose use of antibodies or constructs. Therefore, it would be desirable to provide constructs containing human-binding domains to targets in order to eliminate concerns and / or effects of HAMA or HACA reactions.
[0033] Therefore, according to one embodiment, the polypeptide construct has at least one further binding domain, the binding domain being "human". The terms "human antibody", "human construct", and "human binding domain" include antibodies, constructs, and binding domains having antibody-derived regions such as variable regions and constant regions or domains, respectively, which substantially correspond to human germline immunoglobulin sequences known in the art, including, for example, those described by Kabat et al. (1991) (cited above). The human construct or binding domain of the present invention may include amino acid residues not encoded by the human germline immunoglobulin sequence (e.g., mutations introduced in vitro by random or site-directed mutagenesis, or in vivo by somatic mutation), for example, in the CDR, particularly CDR3. The human construct or binding domain may have at least one, two, three, four, five or more positions replaced by amino acid residues not encoded by the human germline immunoglobulin sequence. The definitions of human antibodies, constructs, and binding domains as used herein also refer to fully human antibodies, constructs, and binding domains that consist solely of human sequences that have not been artificially and / or genetically modified, such as those that can be derived using technologies or systems such as Xenomouse® mice.
[0034] Polypeptides / polypeptide constructs containing at least one human-binding domain avoid some of the problems associated with antibodies or constructs that have non-human variable and / or constant regions, such as those derived from rodents (e.g., mice, rats, hamsters, or rabbits). The presence of such rodent-derived proteins may lead to rapid clearance of the antibody or construct, or to an immune response by the patient to the antibody or construct. To avoid the use of rodent-derived constructs, humanized or fully human constructs can be created by introducing human antibody function into rodents so that the rodents produce fully human antibodies.
[0035] The ability of YAC to clone and reconstruct megabase-sized human loci and to introduce them into mouse germline cells provides a powerful method for elucidating the functional elements of very large or coarsely mapped loci and for creating useful models of human diseases. Furthermore, the use of such techniques to replace mouse loci with their human equivalents can provide unique insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.
[0036] A key practical application of such strategies is the "humanization" of the mouse humoral immune system. Introducing human Ig loci into mice with inactivated endogenous immunoglobulin (Ig) genes provides an opportunity to study the mechanisms underlying programmed antibody expression and construction, as well as their roles in B cell development. Furthermore, such strategies could provide an ideal source for producing fully human monoclonal antibodies (mAbs), a crucial milestone in realizing the potential of antibody therapy in human diseases. Fully human antibodies or their constructs are expected to minimize the immunogenicity and allergic reactions inherent in mouse mAbs or mouse-derived mAbs, thereby increasing the efficacy and safety of the administered antibody / construct. The use of fully human antibodies or constructs is anticipated to offer substantial advantages in the treatment of chronic and recurrent human diseases requiring repeated administration of compounds, such as inflammation, autoimmunity, and cancer.
[0037] One approach to this goal was to manipulate mouse strains lacking mouse antibody production using large fragments of the human Ig locus, anticipating that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve greater variable gene diversity and appropriate regulation of antibody production and expression. By leveraging mouse mechanisms for antibody diversification and selection, and the lack of immune tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should produce high-affinity antibodies against any target antigen, including human antigens. Using hybridoma technology, antigen-specific human mAbs with desired specificity could be easily produced and selected. This general strategy was demonstrated in connection with the development of the first XenoMouse® mouse strain (see Green et al. Nature Genetics 7:13-21 (1994)). The XenoMouse® strain was engineered using yeast artificial chromosomes (YACs) containing germline arrangement fragments of 245kb and 190kb sizes, respectively, of the human heavy chain locus and kappa light chain locus, containing core sequences of the variable and constant regions. Human Ig containing YACs proved compatible with the mouse strain for both antibody rearrangement and expression, and was able to replace inactivated mouse Ig genes. This was demonstrated by their ability to induce B cell development to produce an adult-like human repertoire of fully human antibodies and antigen-specific human mAbs. These results also suggested that the introduction of a large portion of the human Ig locus, containing numerous V genes, additional regulatory elements, and the human Ig constant region, could reproduce a substantially complete repertoire characterized by the human humoral response to infection and immunization. The study by Green et al. extended to the introduction of over 80% of the human antibody repertoire by introducing megabase-sized germline arrangement YAC fragments of the human heavy chain locus and kappa light chain locus, respectively. See Mendez et al. Nature Genetics 15:146-156 (1997) and U.S. Patent Application Publication No. 08 / 759,620.
[0038] The XenoMouse™ model was created using U.S. Patent Publication Nos. 07 / 466,008, 07 / 610,515, 07 / 919,297, 07 / 922,649, 08 / 031,801, 08 / 112,848, 08 / 234,145, 08 / 376,279, 08 / 430,938, 08 / 464,584, 08 / 464,582, 08 / 463,191, 08 / 462,837, and This is further discussed and detailed in Patent Nos. 08 / 486,853, 08 / 486,857, 08 / 486,859, 08 / 462,513, 08 / 724,752, 08 / 759,620, and in U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181 and 5,939,598, and in Japanese Patent Publication Nos. 3068180B2, 3068506B2 and 3068507B2. See also Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovits J. Exp. Med. 188:483-495 (1998), European Patent No. 0463151B1, International Publication Nos. 94 / 02602, 96 / 34096, 98 / 24893, 00 / 76310, and 03 / 47336.
[0039] Another approach, particularly that used by other companies including GenPharm International, Inc., is the "minilocus" approach. In the minilocus method, an exogenous Ig locus is mimicked by including fragments (individual genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a μ constant region, and a second constant region (preferably a γ constant region) are formed as an insertion construct into the animal. This method is based on U.S. Patent No. 5,545,807 to Surani et al., and U.S. Patents No. 5,545,806, No. 5,625,825, No. 5,625,126, No. 5,633,425, No. 5,661,016, No. 5,770,429, No. 5,789,650, No. 5,814,318, No. 5,877,397, No. 5,874,299 and No. 6,255,458 to Lonberg and Kay respectively, and U.S. Patents No. 5,591,669 and No. 6,023,010 to Krimpenfort and Berns, and Berns et al. U.S. Patent Nos. 5,612,205, 5,721,367 and 5,789,215 for al., and U.S. Patent Nos. 5,643,763 for Choi and Dunn, and GenPharm This is described in U.S. Patent Publication Nos. 07 / 574,748, 07 / 575,962, 07 / 810,279, 07 / 853,408, 07 / 904,068, 07 / 990,860, 08 / 053,131, 08 / 096,762, 08 / 155,301, 08 / 161,739, 08 / 165,699, and 08 / 209,741 of International.See also European Patent No. 0546073B1, International Publication No. 92 / 03918, International Publication No. 92 / 22645, International Publication No. 92 / 22647, International Publication No. 92 / 22670, International Publication No. 93 / 12227, International Publication No. 94 / 00569, International Publication No. 94 / 25585, International Publication No. 96 / 14436, International Publication No. 97 / 13852, and International Publication No. 98 / 24884, as well as U.S. Patent No. 5,981,175. Furthermore, see Taylor et al. (1992), Chen et al. (1993), Tuaillon et al. (1993), Choi et al. (1993), Lonberg et al. (1994), Taylor et al. (1994), Tuaillon et al. (1995), and Fishwild et al. (1996).
[0040] Kirin has also demonstrated the production of human antibodies from mice by introducing large chromosome fragments or entire chromosomes via microcell fusion. See European Patent Publications No. 773288 and 843961. Xenerex Biosciences is developing a technology for the potential production of human antibodies. This technology involves reconstituting SCID mice with human lymphocytes, such as B cells and / or T cells. The mice can then be immunized with an antigen to induce an immune response to the antigen. See U.S. Patents No. 5,476,996, 5,698,767 and 5,958,765.
[0041] In some embodiments, the constructs of the present invention are “isolated” or “substantially pure” constructs. “Isolated” or “substantially pure,” as used in the description of constructs disclosed herein, means a construct that has been identified, separated, and / or recovered from the components of its production environment. Preferably, the construct is unrelated, or substantially unrelated, to all other components from its production environment. Contaminating components of its production environment, such as those arising from recombinant transfected cells, are materials that may interfere with the diagnostic or therapeutic use of the construct and include enzymes, hormones, and other proteinaceous or non-proteinaceous compounds. It is understood that isolated or substantially pure constructs may, depending on the context, account for 5% to 99.9% by weight of the total protein / polypeptide content in a given sample. The desired construct may be produced at significantly higher concentrations using an inducible promoter or a high-expression promoter. This definition includes the production of constructs in a wide variety of organisms and / or host cells known in the art. In certain embodiments, the construct is purified to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence by (1) using a spinning cup sequencer, or to a degree of homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or preferably silver staining. However, typically, the isolated construct is prepared by at least one purification step.
[0042] According to one embodiment, the entire construct and / or the binding domain is in the form of one or more polypeptides or proteins. In addition to the proteinaceous portion, such polypeptides or proteins may include non-proteinaceous portions (e.g., chemical linkers or chemical crosslinking agents, e.g., glutaraldehyde).
[0043] Peptides are short chains of amino acid monomers linked by covalent peptide (amide) bonds. Therefore, peptides are classified into a broad chemical class of biological oligomers and polymers. Amino acids that are part of a peptide or polypeptide chain are called "residues" and can be sequentially numbered. All peptides except cyclic peptides have an N-terminal residue at one end and a C-terminal residue at the other. Oligopeptides consist of a very small number of amino acids (usually 2 to 20). Polypeptides are longer, continuous, unbranched peptide chains. Peptides are distinguished from proteins based on size and can be understood as containing approximately 50 or fewer amino acids as an arbitrary criterion. Proteins typically consist of one or more polypeptides arranged in a biologically functional manner. While the aspects of experimental techniques applied to peptides, polypeptides, and proteins differ (e.g., details of electrophoresis, chromatography, etc.), the size boundary distinguishing peptides from polypeptides and proteins is not absolute. Therefore, in relation to this invention, the terms "peptide," "polypeptide," and "protein" can be used interchangeably, and the term "polypeptide" is often preferred.
[0044] Polypeptides, as described above, can further form multimers such as dimers, trimers, and higher-order oligomers, consisting of two or more polypeptide molecules. The polypeptide molecules forming such dimers, trimers, etc., may or may not be identical. The corresponding higher-order structures of such multimers are consequently referred to as homodimers or heterodimers, homotrimers or heterotrimers, etc. An example of a heteromultimer is an antibody or immunoglobulin molecule, in its naturally occurring form, consisting of two identical polypeptide light chains and two identical polypeptide heavy chains. The terms “peptide,” “polypeptide,” and “protein” also refer to naturally modified peptides / polypeptides / proteins, where modifications are achieved by post-translational modifications such as glycosylation, acetylation, and phosphorylation. “Peptides,” “polypeptides,” or “proteins,” as used herein, can also be chemically modified, such as pegylation. Such modifications are well known in the art and will be described later herein.
[0045] The terms “selectively,” “preferably selectively,” “(specifically or immunospecifically) bind,” “(specifically or immunospecifically) recognize,” or “(specifically or immunospecifically) react,” in accordance with the present invention, mean that a construct or binding domain selectively interacts with or (immunologically) specifically interacts with a target molecule (antigen), respectively, a given epitope on CD3. This selective interaction or association occurs more frequently, more rapidly, for a longer duration, with higher affinity, or with some combination of these parameters, to an epitope on a particular target (CD3ε) compared to an alternative substance (a non-target molecule, e.g., CD3γ). However, due to sequence similarities between homologous proteins in different species, a construct or binding domain that selectively and / or immunospecifically binds to a target (e.g., a human target) may cross-react with homologous target molecules from different species (e.g., non-human primates). Therefore, terms such as “selective binding” and “specific / immunospecific binding” may include the binding of a construct or binding domain to two or more species of epitopes or structurally related epitopes. In relation to the present invention, the polypeptides of the present invention bind to their respective target structures in a specific manner. Preferably, the polypeptides according to the present invention include one paratope per binding domain that “specifically or immunospecifically binds” to, “(specifically or immunospecifically) recognizes,” or “(specifically or immunospecifically) reacts” with, their respective target structures. This means that, in accordance with the present invention, the polypeptide or its binding domain interacts with or (immunely)-specifically with a given epitope on a target molecule (antigen), i.e., CD3ε, and in certain embodiments, interacts with a given epitope on at least one further target molecule, such as a second and / or third target molecule. This interaction or association occurs more frequently, more rapidly, for longer durations, with greater affinity, or with some combination of these parameters, towards an epitope on a specific target compared to an alternative substance (non-target molecule).However, due to sequence similarities between homologous proteins in different species, antibody constructs or binding domains that immunospecifically bind to their targets (such as human targets) may cross-react with homologous target molecules from different species (such as non-human primates). Therefore, the term "specific / immunospecific binding" may include the binding of antibody constructs or binding domains to epitopes and / or structurally related epitopes in multiple species. The term "(immuno)selective binding" excludes binding to structurally related epitopes.
[0046] In relation to the present invention, the term “epitope” refers to a portion or region of an antigen that is selectively recognized / immunospecifically by a binding structure, i.e., a paratope. “Epitope” is antigenic, and therefore the term “epitope” may also be referred to herein as “antigenic structure” or “antigenic determinant.” The portion of the binding domain that binds to an epitope is called a paratope. Specific binding is thought to be achieved by the binding domain and specific motifs in the amino acid sequence of the antigen. Thus, binding is achieved due to its primary, secondary, and / or tertiary structure, as well as as a result of potential secondary modifications of said structure. When a paratope specifically interacts with its antigenic determinant, the site may simply bind to the antigen. In some cases, instead or in addition, specific interaction may result in signal initiation, for example, due to the induction of conformational changes of the antigen, oligomerization of the antigen, etc.
[0047] Epitopes of protein antigens are classified into two categories, stereoepitopes and linear epitopes, based on their structure and interaction with paratopes. Conformational epitopes consist of discontinuous sections of the antigen's amino acid sequence. These epitopes interact with paratopes based on the characteristics and shape or tertiary structure (folding) of the antigen's three-dimensional surface. Methods for determining the conformation of an epitope include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy. In contrast, linear epitopes interact with paratopes based on their primary structure. Linear epitopes are formed by a continuous sequence of amino acids derived from the antigen and typically contain at least three or at least four, more commonly at least five, at least six, or at least seven, for example, about 8 to about 10 amino acids within a specific sequence.
[0048] A method for epitope mapping for a given human target protein is described below. A predetermined region (a continuous amino acid stretch) within the given human target protein is exchanged / replaced with the corresponding region of the target protein paralog (provided that the binding domain does not cross-react with the paralog used). These human target / paralog chimeras are expressed on the surface of host cells (e.g., CHO cells). Binding of an antibody or construct can be tested via FACS analysis. If the binding of the antibody or construct to this chimeric molecule is completely absent or a significant decrease in binding is observed, it can be concluded that the region of the human target removed from this chimeric molecule is associated with immunospecific epitope-paratope recognition. The decrease in binding is preferably at least 10%, 20%, 30%, 40%, or 50%, more preferably at least 60%, 70%, or 80%, most preferably 90%, 95%, or even 100%, compared to binding to the human (wild-type) target, thereby setting the binding to the human target to 100%. Alternatively, the epitope mapping analysis described above can be modified by introducing one or more point mutations into the sequence of a human target. These point mutations may, for example, reflect differences between the human target and its paralog.
[0049] A further method for determining the contribution of specific residues of a target antigen to recognition by a construct or binding domain is alanine scanning, in which each residue analyzed is replaced with alanine, for example, by site-directed mutagenesis (see, e.g., Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7). Alanine is used because it has a non-bulky, chemically inactive methyl functional group that still mimics the secondary structure criteria of many other amino acids. If size preservation of the mutated residue is desired, bulkier amino acids such as valine or leucine may be used.
[0050] The interaction between the binding domain and the epitope of the target antigen implies that the binding domain is recognizable or exhibits significant affinity for the epitope / target antigen (CD3 in this specification), and generally does not exhibit significant affinity for proteins or antigens other than the target antigen, even if there is cross-reactivity with homologous targets from other species, as discussed above. "Significant affinity" is defined as 10 -6 Examples of binding include binding with an affinity (dissociation constant, KD) of M or less. Preferably, the binding affinity is 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 M or less, or 10 more -11 M or less or 10 -12 It is considered specific when M is less than or equal to M. Whether a binding domain (immune) specifically reacts to or binds to a target can be easily tested, for example, by comparing the affinity of the binding domain to the desired target protein or antigen with the affinity of the binding domain to a non-target protein or antigen (here, proteins other than CD3, respectively). Preferably, the construct of the present invention does not significantly bind to proteins or antigens other than CD3 (i.e., the CD3 binding domain does not bind to proteins other than CD3) unless any further binding domains for further targets are intentionally introduced into the construct of the present invention, in which case the binding of the binding domain to its specific target is also provided by the present invention.
[0051] The affinity of the first domain is assumed to be ≤100 nM, ≤90 nM, ≤80 nM, ≤70 nM, ≤60 nM, ≤50 nM, ≤40 nM, ≤30 nM, or ≤20 nM for human CD3ε. These values are preferably measured by cell-based assays such as the scatchard assay. Other affinity determination methods are also well known. These values are preferably measured by surface plasmon resonance assays such as the Biacore assay.
[0052] The terms "not significantly binding" and "not selectively binding" mean that when the construct or binding domain of the present invention is expressed on the surface of a cell, it does not bind to any protein or antigen other than CD3. Therefore, the construct exhibits reactivity with any protein or antigen other than CD3 (when the protein or antigen is expressed on the surface of a cell) of 30% or less, preferably 20% or less, more preferably 10% or less, particularly preferably 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less (where binding to CD3 is considered 100%). "Reactivity" can be expressed, for example, by affinity values (see above).
[0053] The construct of the present invention (more specifically, a domain containing a paratope / binding domain that binds to human CD3ε) is expected not to bind to or not significantly bind to CD3ε analogs, more specifically to human CD3ε analogs and / or macaque / cynomolgus monkey CD3ε analogs. It is also expected that the construct will not bind to or not significantly bind to (human or macaque / cynomolgus monkey) CD3ε paralogs on the surface of target cells.
[0054] The VH region, as part of the binding domain that binds to the extracellular epitope of the human CD3ε chain, includes the CDR-H1, CDR-H2, and CDR-H3 sequences described above. The CDR sequences include placeholders, indicated as "X" for a given amino acid residue that may substitute for a placeholder, as is common practice in the art. The placeholders are sequentially numbered for each given CDR sequence in the form of X1, X2, X3, etc. The amino acid residues that may substitute for placeholders in the enumerated CDR sequences are preferably, for example, in other embodiments, unless otherwise specified, the first listed amino acid is most preferred, the second listed amino acid is second preferred, and so on. If a sequence contains two or more placeholders, the same applies with respect to amino acid preference; i.e., the combination of the first amino acid residues enumerated for each placeholder is most preferred, the combination of the second amino acid residues enumerated for each placeholder is second preferred, and so on. This preferred hierarchy does not exclude combinations of amino acid residues for each of the placeholders independent of the preferred hierarchy, such that different preferred amino acid residues are combined. The same hierarchy applies to all amino acid residues listed below in this specification that substitute for placeholders in the amino acid sequences described below. Accordingly, the above also applies to placeholders indicated as "X" in the VH and VL sequences and any other sequences listed throughout this specification.
[0055] The CDR-H1 sequence contains the amino acid sequence X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I. With respect to placeholder amino acids, according to the hierarchy described above, the amino acids of placeholders X1 and X2 are listed according to their preference, with the first listed amino acid being the most preferred, the second listed amino acid being the second most preferred, and so on. For X1, amino acid K is the most preferred, and for X2, amino acid M is the most preferred. Preferred combinations include X1 and X2 combinations selected from K and M, V and M, S and M, etc., with M of X2 combined with any amino acid residue of X1, and the most preferred combination being K and M. Another preferred combination is K and I of X1 and X2, respectively. Preferred examples of the CDR-H1 sequence are selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, TYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being the most preferred.
[0056] The CDR-H2 sequence comprises the amino acid sequence RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, S, or E. For X1, amino acid S is most preferred, and for X2, amino acid D is most preferred. Preferred combinations include S of X1 combined with any of the amino acid residues of X2, such as combinations for X1 and X2 selected from S and D, S and G, S and K, and S and S, with the most preferred combination being S and D. Preferred examples of the CDR-H2 sequence are selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKE, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD being the most preferred.
[0057] The CDR-H3 sequence comprises the amino acid sequence HX1NFGNSYX2SX3X4AY, where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W, or F; and X4 is W, F, or Y. For X1, amino acid G is most preferred; for X2, amino acid I is most preferred; for X3, amino acid Y is most preferred; and for X4, amino acid W is most preferred. Preferred examples of the CDR-H3 sequence are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0058] The CDR-L1 sequence comprises the amino acid sequence X1SSTGAVTX2X3X4YX5N, where X1 is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y; and X5 is P or A. For X1, amino acid G is most preferred; for X2, amino acid S is most preferred; for X3, amino acid G is most preferred; for X4, amino acid N is most preferred; and for X5, amino acid P is most preferred. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred.
[0059] The CDR-L2 sequence comprises the amino acid sequence X1TX2X3X4X5X6, where X1 is G or A; X2 is K, D, or N; X3 is F, M, or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S. For X1, amino acid G is most preferred; for X2, amino acid K is most preferred; for X3, amino acid F is most preferred; for X4, amino acid L is most preferred; for X5, amino acid A is most preferred; and for X6, amino acid P is most preferred. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred.
[0060] The CDR-L3 sequence comprises the amino acid sequence X1LWYSNX2WV, where X1 is V, A, or T; and X2 is R or L. For X1, amino acid V is most preferred, and for X2, amino acid R is most preferred. Preferred combinations include X1 and X2 combinations selected from V and R, A and R, and T and R, with R of X2 being combined with any amino acid residue of X1, and the most preferred combination being V and R. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0061] In a preferred embodiment, the VH region of i) comprises a CDR-H1 sequence containing or consisting of the amino acid sequence X1YAX2N (where X1 is K, V, S, G, R, or I; X2 is M or I); a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2 (where X1 is S or Q; X2 is D, G, K, S, or E); and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY (where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W, or F; X4 is W, F, or Y); and the VL region of ii) comprises a CDR-L1 sequence of X1SSTGAVTSGX2YPN (where X1 is G, R, or A; X2 is N, or Y); X1T The CDR-L2 sequence X2X3X4X5X6 (where X1 is G or A; X2 is K or D; X3 is F or M; X4 is L or R; X5 is A, P or V; X6 is P or S; and the CDR-L3 sequence X1LWYSNRWV (where X1 is V, A or T); i) the VH region and / or ii) the VL region of the one or more CDR sequences comprising one or more amino acid substitutions selected from X24V or X24F in CDR-H1; D15 (preferably E), X116A in CDR-H2; H1 (preferably A or N), X12E, F4 (preferably I) in CDR-H3 and / or N6 (preferably S or T) in CDR-H3; and W93 (preferably Y) in CDR-L3.
[0062] The CDR-H1 sequence comprises or consists of the amino acid sequence X1YAX2N, where X1 is K, V, S, G, R, or I; and X2 is M or I. For X1, amino acid K is most preferred, and for X2, amino acid M is most preferred. Preferred combinations include X1 and X2 combinations selected from K and M, V and M, S and M, etc., with M of X2 combined with any amino acid residue of X1, and the most preferred combination is K and M. Another preferred combination is K and I of X1 and X2, respectively. Preferred examples of the CDR-H1 sequence are selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being preferred, and KYAMN being the most preferred.
[0063] The CDR-H2 sequence includes or consists of the amino acid sequence RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, S, or E. For X1, amino acid S is most preferred, and for X2, amino acid D is most preferred. Preferred combinations include S of X1 combined with any of the amino acid residues of X2, such as combinations for X1 and X2 selected from S and D, S and G, S and K, and S and S, with the most preferred combination being S and D. Preferred examples of the CDR-H2 sequence are selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKE, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD being the most preferred.
[0064] The CDR-H3 sequence comprises the amino acid sequence HX1NFGNSYX2SX3X4AY, where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W, or F; and X4 is W, F, or Y. For X1, amino acid G is most preferred; for X2, amino acid I is most preferred; for X3, amino acid Y is most preferred; and for X4, amino acid W is most preferred. Preferred examples of the CDR-H3 sequence are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0065] The CDR-L1 sequence comprises the amino acid sequence X1SSTGAVTSGX2YPN, where X1 is G, R, or A; and X2 is N or Y. For X1, amino acid G is most preferred; for X2, amino acid N is preferred. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, and ASSTGAVTSGNYPN, with GSSTGAVTSGNYPN or ASSTGAVTSGNYPN being preferred, and GSSTGAVTSGNYPN being the most preferred.
[0066] The CDR-L2 sequence comprises the amino acid sequence X1TX2X3X4X5X6; X1 is G or A; X2 is K or D; X3 is F or M; X4 is L or R; X5 is A, P, or V; and X6 is P or S. For X1, amino acid G is most preferred; for X2, amino acid K is most preferred; for X3, amino acid F is most preferred; for X4, amino acid L is most preferred; for X5, amino acid A is most preferred; and for X6, amino acid P is most preferred. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, and GTKFLVP, with GTKFLAP or GTKFLVP being preferred, and GTKFLAP being most preferred.
[0067] The CDR-L3 sequence comprises the amino acid sequence X1LWYSNRWV, where X1 is V, A, or T, with amino acid V being the most preferred. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, and TLWYSNRWV, with VLWYSNRWV or TLWYSNRWV being more preferred, and VLWYSNRWV being the most preferred.
[0068] In a more preferred embodiment, the VH region of i) comprises a CDR-H1 sequence containing or consisting of the amino acid sequence X1YAX2N (where X1 is K, V, S, R, or I; X2 is M or I); a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2 (where X1 is S or Q; X2 is D, G, K, or S); and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY (where X1 is G or A; X2 is I, L, V, or T; X3 is Y, W, or F; X4 is W, F, or Y); and the VL region of ii) comprises the CD of X1SSTGAVTSGX2YPN The one or more CDR sequences in the VH region of i) and / or the VL region of ii) include one or more amino acid substitutions selected from X24V or X24F in CDR-H1; D15 (preferably E), X116A in CDR-H2; H1 (preferably A or N), X12E, F4 (preferably I), and / or N6 (preferably S or T) in CDR-H3; and W93 (preferably Y) in CDR-L3.
[0069] The CDR-H1 sequence comprises or consists of the amino acid sequence X1YAX2N, where X1 is K, V, S, R, or I; and X2 is M or I. For X1, amino acid K is most preferred, and for X2, amino acid M is most preferred. Preferred combinations include X1 and X2 combinations selected from K and M, V and M, S and M, etc., with M of X2 combined with any amino acid residue of X1, and the most preferred combination is K and M. Another preferred combination is K and I of X1 and X2, respectively. Preferred examples of the CDR-H1 sequence are selected from KYAMN, VYAMN, SYAMN, RYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being preferred, and KYAMN being the most preferred.
[0070] The CDR-H2 sequence comprises or consists of the amino acid sequence RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, or S. For X1, amino acid S is most preferred, and for X2, amino acid D is most preferred. Preferred combinations include, for example, S of X2 combined with any of the amino acid residues of X1, such as S and D, S and G, S and K, and combinations of S and S for X1 and X2, with the most preferred combination being S and D. Preferred examples of the CDR-H2 sequence are selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADQVKD being preferred, and RIRSKYNNYATYYADSVKD being the most preferred.
[0071] The CDR-H3 sequence comprises or consists of the amino acid sequence HX1NFGNSYX2SX3X4AY, where X1 is G or A; X2 is I, L, V, or T; X3 is Y, W, or F; and X4 is W, F, or Y. For X1, amino acid G is most preferred; for X2, amino acid I is most preferred; for X3, amino acid Y is most preferred; and for X4, amino acid W is most preferred. Preferred examples of the CDR-H3 sequence are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, and HANFGNSYISYWAY, with HGNFGNSYISYWAY or HANFGNSYISYWAY being preferred, and HGNFGNSYISYWAY being most preferred.
[0072] The CDR-L1 sequence comprises or consists of the amino acid sequence X1SSTGAVTSGX2YPN, where X1 is G or A; and X2 is N or Y. For X1, amino acid G is most preferred; for X2, amino acid N is preferred. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, GSSTGAVTSGYYPN, and ASSTGAVTSGNYPN, with GSSTGAVTSGNYPN or ASSTGAVTSGNYPN being preferred, and GSSTGAVTSGNYPN being the most preferred.
[0073] The CDR-L2 sequence comprises or consists of the amino acid sequence of GTKFLX1P; X1 is A or V. Amino acid A is preferred for X1. The CDR-L2 sequence is GTKFLAP or GTKFLVP, with GTKFLAP being preferred.
[0074] The CDR-L3 sequence contains or consists of the amino acid sequence X1LWYSNRWV, where X1 is V, A, or T, with amino acid V being the most preferred. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, and TLWYSNRWV, with VLWYSNRWV or TLWYSNRWV being more preferred, and VLWYSNRWV being the most preferred.
[0075] In a more preferred embodiment, the VH region of i) comprises a CDR-H1 sequence containing or consisting of the amino acid sequence X1YAMN (where X1 is K or S); a CDR-H2 sequence of RIRSKYNNYATYYADSVKX1 (where X1 is D or G); and a CDR-H3 sequence of HGNFGNSYX1SX2WAY (where X1 is I or V; where X2 is Y or W); and the VL region of ii) comprises a CDR-L1 sequence of GSSTGAVTSGX1YPN (where X1 is N or Y); GTK The CDR-L2 sequence of FLAP; and the CDR-L3 sequence of X1LWYSNRWV (where X1 is V or A); the one or more CDR sequences in the VH region of i) and / or the VL region of ii) include one or more amino acid substitutions selected from M4V or M4F in CDR-H1; D15 (preferably E), S16A in CDR-H2; H1 (preferably A or N), G2E, F4 (preferably I) and / or N6 (preferably S or T) in CDR-H3; and W93 (preferably Y) in CDR-L3.
[0076] The CDR-H1 sequence includes or consists of the amino acid sequence X1YAMN, where X1 is K or S, and amino acid K is preferred. The CDR-H1 sequence is KYAMN or SYAMN, with KYAMN being most preferred.
[0077] The CDR-H2 sequence contains or consists of the amino acid sequence RIRSKYNNYATYYADSVKX1, where X1 is D or G. Amino acid D is preferred for X1. The CDR-H2 sequence is RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADSVKG, with RIRSKYNNYATYYADSVKD being preferred.
[0078] The CDR-H3 sequence includes or consists of the amino acid sequence HGNFGNSYX1SX2WAY, where X1 is I or V; and X2 is Y or W. For X1, amino acid I is preferred; for X2, amino acid Y is preferred. The CDR-H3 sequence is HGNFGNSYISYWAY or HGNFGNSYVSWWAY, with HGNFGNSYISYWAY being preferred.
[0079] The CDR-L1 sequence includes or consists of the amino acid sequence GSSTGAVTSGX1YPN, where X1 is N or Y. Amino acid N is preferred for X1. The CDR-L1 sequence is GSSTGAVTSGNYPN or GSSTGAVTSGYYPN, with GSSTGAVTSGNYPN being preferred.
[0080] The CDR-L2 sequence contains or consists of the amino acid sequence of GTKFLAP.
[0081] The CDR-L3 sequence contains or consists of the amino acid sequence X1LWYSNRWV, where X1 is V or A, and V is preferred. The CDR-L3 sequence is VLWYSNRWV or ALWYSNRWV, and VLWYSNRWV is preferred.
[0082] Each of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences can be freely combined in the form of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3 (which is a preferred orientation of the VH and VL regions) or CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, CDR-H3, and exhibits the listed bindings to the extracellular epitopes of the human CD3ε chain.
[0083] Table 1 below lists preferred combinations of CDR-L1 to L3 sequences in the VL region and preferred combinations of CDR-H1 to H3 sequences in the VH region.
[0084] [Table 1]
[0085] Preferably, one of the CDR-L1 to L3 combinations listed above is combined with one of the CDR-H1 to H3 combinations listed above as the extracellular binding domain portion of the human CD3ε chain. In other words, the VL region consists of CDR-L1, CDR-L2, and CDR-L3 sequences in this order. GSSTGAVTSGYYPN, GTKFLAP, ALWYSNRWV; RSSTGAVTSGYYPN, ATDMRPS, ALWYSNRWV; GSSTGAVTSGNYPN, GTKFLAP, VLWYSNRWV; ASSTGAVTSGNYPN, GTKFLVP, TLWYSNRWV; or RSSTGAVTTSNYAN, GTNKRAP, ALWYSNLWV It includes or consists of; and The VL region consists of the CDR-H1, CDR-H2, and CDR-H3 sequences, in that order. IYAMN, RIRSKYNNYATYYADSVKS, HGNFGNSYVSFFAY; KYAMN, RIRSKYNNYATYYADSVKD, HGNFGNSYISYWAY; SYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYLSFWAY; RYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYLSYFAY; VYAMN, RIRSKYNNYATYYADSVKK, HGNFGNSYLSWWAY; KYAMN, RIRSKYNNYATYYADSVKS, HGNFGNSYTSYYAY; GYAMN, RIRSKYNNYATYYADSVKE, HRNFGNSYLSWFAY; VYAMN, RIRSKYNNYATYYADSVKK, HGNFGNSYISWWAY; SYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYVSWWAY; KYAIN, RIRSKYNNYATYYADQVKD, HANFGNSYISYWAY; or TYAMN, RIRSKYNNYATYYADSVKD, HGNFGNSYVSWFAY It includes or consists of.
[0086] According to the present invention, preferred combinations of CDR sequences for the VH and VL regions, listed in the order of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, are defined by sequence numbers 118-123, 166-171, 356-361, 546-551, 724-729, 922-927, 1100-1105, 1290-1295, 1468-1473, 1658-1663, and 1848-1853.
[0087] Most preferably, the VL region consists of CDR-L1, CDR-L2, and CDR-L3 sequences in this order. GSSTGAVTSGNYPN, GTKFLAP, VLWYSNRWV including; and The VL region consists of the CDR-H1, CDR-H2, and CDR-H3 sequences in this order. As shown in Sequence IDs 1848 to 1853, KYAMN, RIRSKYNNYATYYADSVKD, HGNFGNSYISYWAY This includes the following: Preferably, the orientation of the CDR is from VH to VL, i.e., the orientation of the variable region is from VH to VL, from the N-terminus to the C-terminus.
[0088] According to the present invention, the CDR sequence in the VH region and / or VL region comprises one or more amino acid substitutions. As is common in the art, the location and nature of an amino acid substitution are indicated herein by showing the original amino acid residue at the position to be substituted and the amino acid used for the substitution in the form of, for example, F4I, where "F" indicates the original amino acid residue that occurs at position "4" of a given amino acid sequence, and "I" indicates the amino acid residue that replaces "F" at position 4. If the substitution is by any amino acid residue (other than the original amino acid residue), the amino acid residue is not shown, and only the original amino acid residue and its position in a given amino acid sequence are shown, so the previous example is shown only as "F4". Preferably, only naturally occurring amino acids are used for substitution.
[0089] The VH region of i) and / or the VL region of ii) include one or more amino acid substitutions as specified herein in one or more CDR sequences listed above. Thus, at least one of the listed amino acid substitutions of the variable region is included in the binding domain that binds to the extracellular epitope of the human CD3ε chain. The at least one or more amino acid substitutions may be present in the CDR sequence of the VH region or the VL region if only one amino acid substitution is present, or in the CDR of both the VH region and the VL region if two or more amino acid substitutions are present, or may be limited to the CDR sequence of the VH region or the VL region only. In certain embodiments where two or more amino acid substitutions are present, the substitutions are present in the VH region and the VL region, or in only one variable region. Preferably, the substitutions are present in the CDR of the VH region and the VL region.
[0090] If CDR-H1 contains an amino acid substitution at position 4, it is preferably a substitution of the original amino acid at amino acid V. Preferably, the CDR-H1 sequence is KYAIN or KYAMN, i.e., does not contain any of the amino acid substitutions listed above.
[0091] In CDR-H2, the amino acid substitution at position 15 is preferably D15E, or the amino acid substitution at position 16 is amino acid A. Preferably, CDR-H1 includes an amino acid residue substitution at position 16 by amino acid A; in this case, the preferred last amino acid of CDR-H2 is D or G, with D being the most preferred. Therefore, preferred CDR-H2 sequences are RIRSKYNNYATYYADAVKD or RIRSKYNNYATYYADAVKG, with RIRSKYNNYATYYADAVKD being more preferred. If CDR-H2 includes two amino acid substitutions, the combination of amino acid E at position 15 and amino acid A at position 16 is preferred; in this case, the preferred last amino acid of CDR-H2 is G. Therefore, a preferred CDR-H2 sequence with the combination of amino acid E at position 15 and amino acid A at position 16 is RIRSKYNNYATYYAEAVKG.
[0092] In CDR-H3, amino acid substitutions are substitutions at position 1, preferably with amino acid A or N; substitutions at position 2, preferably with amino acid E; substitutions at position 4, preferably with amino acid I; and substitutions at position 6, preferably with amino acid S or T. Preferably, CDR-H3 contains amino acid A or N at position 1 and amino acid S or T at position 6; in this case and when the placeholder is present at the indicated position in the CDR-H3 sequence, the preferred amino acid of X1 is G or A, most preferably G; X2 is I; X3 is Y; and X4 is W or Y. If CDR-H3 contains two amino acid substitutions, preferred combinations are amino acid A at position 1 and amino acid S at position 6; and amino acid N at position 1 and amino acid T at position 6; in this case and when the placeholder is present at the indicated position in the CDR-H3 sequence, the preferred amino acid of X1 is G or A, most preferably G; X2 is I, X3 is Y, and X4 is W and F. If CDR-H3 contains three amino acid substitutions, preferred combinations are amino acid A at position 1, amino acid I at position 4, and amino acid S at position 6; and amino acid N at position 1, amino acid I at position 4, and amino acid T at position 6. In this case, and when placeholders are present at the indicated positions in the CDR-H3 sequence, preferred amino acids X2 are I, X3 is Y, and X4 are W and F. If CDR-H3 contains four amino acid substitutions, preferred combinations are amino acid N at position 1, amino acid E at position 2, amino acid I at position 4, and amino acid T at position 6. In this case, and when placeholders are present at the indicated positions in the CDR-H3 sequence, preferred amino acids X2 are I, X3 is Y, and X4 is W. Therefore, preferred CDR-H3 sequences are selected from AGNFGSSYISYWAY, NENIGTSYISYWAY, AGNFGTSYISYWAY, NANFGTSYISYFAY, and AGNFGSSYISYFAY, with AGNFGSSYIWAY and AGNFGSSYISYFAY being the most preferred.
[0093] In CDR-L3, the amino acid substitution at position 1 is due to amino acid L in the sequence X1LWYSNX2WV, or the amino acid substitution is W93, preferably W93Y (also known as X193Y), where X1 is V, A, or T; and X2 is R or L. Preferably, if CDR-L3 contains only one amino acid substitution, the CDR-L3 sequence is VLYYSNRWV. However, it is preferable that CDR-L3 does not contain the aforementioned X11L and W93 amino acid substitutions, in which case the preferred CDR-L3 sequence is VLYYSNRWV.
[0094] While we do not wish to be bound by any particular scientific theory, each of the amino acid substitutions listed above results in increased thermal stability of the binding domain to the extracellular epitope of the human CD3ε chain, which includes or consists of a VH region linked to a VL region sequence as described herein, compared to the binding domain to the extracellular epitope of the human CD3ε chain, which includes or consists of a VH region linked to an unmodified VL region sequence that does not contain the aforementioned amino acid substitutions. The increased thermal stability is preferably measured by a well-known differential scanning fluorescence (DSF) method, as also described herein. The aforementioned method is described, for example, in Wen et al., “Nano differential scanning fluorimetry for comparability studies of therapeutic proteins”, Analytical Biochemistry, Volume 593, 2020, 113581, ISSN 0003-2697 or Dart, ML, et al. (2018) “Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift”, ACS Medical Chemistry Letters, 9(6), 546-551). As is evident from the Examples section, the amino acid substitutions or combinations thereof as defined herein result in increased thermal stability (see Examples 1, Tables 2 and 3) compared to the unmodified CD3-binding domain ("I2C") as defined herein, while maintaining cytotoxic activity, which is not applicable to prior art methods for improving thermal stability, namely CC44 / 100 cisclamp. Here, further disulfide bonds were manipulated to stabilize the unmodified CD3-binding domain as defined herein by substituting amino acid residues at the cysteine residues at position 44 of the heavy chain variable region and position 100 of the light chain variable region (numbering scheme according to Kabat et al, 1991) (Reiter, Y. et al, 1994) (VH and VL sequence numbers: 1854 and 1855, respectively; see Examples 2, Table 5).Therefore, the combination of VH and VL regions of the CD3ε-binding domain described herein is temperature-stabilized compared to VH and VL region sequences that do not contain a given substitution introduced at the positions defined herein.
[0095] In a preferred embodiment of the polypeptide or polypeptide construct described in claim 1 of the present invention, in addition to the one amino acid substitution or combination thereof as defined in iii), in the CDR-H1 sequence, X2 is I; in the CDR-H2 sequence, X2 is G; in the CDR-H3 sequence, X1 is A and X4 is F; and / or in the CDR-L3 sequence, X1 is A. The one amino acid substitution or combination thereof as defined herein is further combined with a specific amino acid at a specific position in the CDR. Thus, at least one of the amino acid substitutions enumerated in iii) is present, and in the CDR-H2 sequence, at least one of X2 is G; in the CDR-H3 sequence, X1 is A and X4 is F; and / or in the CDR-L3 sequence, X1 is A, and further present in the CDR. In this specification, as previously stated above, when only one additional amino acid is present in the CDR, the preferred amino acid for X2 is I in the CDR-H1 sequence, or most preferably X2 is G in the CDR-H2 sequence and X2 is I in the CDR-H1 sequence. Two preferred combinations of the additional amino acids are that X2 is I in the CDR-H1 sequence and X4 is F in the CDR-H3 sequence; or X2 is G in the CDR-H2 sequence and X4 is F in the CDR-H3 sequence. Three preferred combinations of the additional amino acids are that X2 is I in the CDR-H1 sequence, X1 is A and X4 is F in the CDR-H3 sequence; or X2 is I in the CDR-H1 sequence, X4 is F in the CDR-H3 sequence and X1 is A in the CDR-L3 sequence. Since the latter amino acids would be further present, it is understood that the additional listed amino acids whose positions overlap with the amino acid substitution in iii) cannot replace the overlapping amino acid substitution.For example, if the only amino acid substitution by iii) is either X24V or X24F in CDR-H1, then the amino acid cannot be replaced by amino acid I in the CDR-H1 sequence because there are no amino acid substitutions defined in iii) remaining in the binding domain. In other words, at least one of the amino acid substitutions defined in iii) must always be present in the polypeptide or polypeptide construct of the present invention.
[0096] Depending on the actual sequence of the CDR, one or more of the further amino acids may already be part of the CDR as defined herein above, and if not, it is understood that the CDR may be modified to represent the further amino acids in combination with one or more amino acid substitutions or combinations thereof, as enumerated in iii).
[0097] In other preferred embodiments, the polypeptide or polypeptide construct of the present invention includes or comprises the amino acid substitutions defined in iii), two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or more amino acid substitutions, or a combination of up to two, three, four, five, six, seven, eight, nine, ten, eleven, twelve amino acid substitutions. Preferably, only the substitutions defined herein are introduced into the VH region sequence and the VL region sequence. This applies to all embodiments enumerated herein such that the VH region sequence and the VL region sequence consist of unmodified amino acid sequences having the substitutions defined herein.
[0098] More specifically, i) the single amino acid substitution is selected from a. X24V or X24F in CDR-H1; H1A in CDR-H3; and b. X11L and W3Y in CDR-L3; ii) the combination of two or more amino acid substitutions is selected from X116A in CDR-H2 and N6S in CDR-H3; and X116A in CDR-H2 and N6T in CDR-H3; iii) the combination of three or more amino acid substitutions is CD The following combinations of four or more amino acid substitutions are selected: X116A in R-H2 and H1A and N6S in CDR-H3; X116A in CDR-H2, H1A and N6T in CDR-H3; X116A in CDR-H2, H1N and N6T in CDR-H3; iv) The above combinations of four or more amino acid substitutions are X116A in CDR-H2, H1A and N6S in CDR-H3 and W3Y in CDR-L3; D15E in CDR-H2, X116A, CDR-H 3 is selected from H1A and N6T; D15E, X116A in CDR-H2, H1A and N6S in CDR-H3; X116A in CDR-H2, H1A, F4I and N6S in CDR-H3; v) The above combination of five or six amino acid substitutions is X116A in CDR-H2, H1A, X12E, F4I and N6T in CDR-H3; X116A in CDR-H2, H1N, X12E, F4I and N 6S; Select from D15E, X116A in CDR-H2, H1A, N6S in CDR-H3; and W3Y in CDR-L3; Select from D15E, X116A in CDR-H2, H1N, X12E, F4I, and N6T in CDR-H2; Select from D15E, X116A in CDR-H2, H1A, X12E, F4I, and N6T in CDR-H3; Select from D15E, X116A in CDR-H2, X12E, F4I, and N6T in CDR-H3.
[0099] In accordance with the foregoing, the amino acid substitution H1A of CDR-H3 is a preferred amino acid substitution when there is only one amino acid substitution in the CD3ε-binding domain within the CDR sequence or VH region sequence as defined herein. Further, in the case of the combination of amino acid substitutions defined in iii), preferably H1A of CDR-H3 is one of the amino acid substitutions of the said combination.
[0100] In one embodiment, the invention provides a polypeptide or polypeptide construct comprising a binding domain that binds to an extracellular epitope of the human CD3ε chain, comprising or consisting of a VH region and a VL region. i) the VH region comprises
Chemical formula
Chemical formula
[0101] In this embodiment, preferred VH and VL region sequences that are included in the binding domain and mediate binding to the human CD3ε chain are described. As is evident from the above, the VH and VL region sequences of i) and ii) include various placeholders, and the same hierarchy and nomenclature apply herein to the placeholders listed above in relation to the CDRs included in the VH and VL regions of i) and ii). As is evident from the VH and VL region sequences, the CDRs described herein above are part of the VH and VL region sequences. Therefore, the preferred embodiments of the CDRs of i) and ii) above also apply herein to this preferred embodiment.
[0102] i) The VH region is [ka] X is an array containing or consisting of X1 being Q or K; X2 being V or L; X3 being V or E; X4 being G or K; X5 being K, V, S, G, R, T or I; X6 being M or I; X7 being S or Q; X8 being D, G, K, S or E; X9 being K or Q; X 10 is N or S; X 11 is T or I; X 12 is A or L; X 13 is V or M; X 14 is G, R, or A; X 15 is I, L, V, or T; X 16 is Y, W, or F; X 17 is W, F, or Y; X 18 It is either S or A.
[0103] The CDR sequences within the VH region are as follows: a CDR-H1 sequence containing or consisting of X5YAX6N; a CDR-H2 sequence containing or consisting of RIRSKYNNYATYYADX7VKX8; and HX 14 NFGNSYX 15 SX 16 X17 A CDR-H3 sequence containing or consisting of AY. A preferred example of the CDR-H1 sequence X5YAX6N is selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, TYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being the most preferred. A preferred example of the CDR-H2 sequence RIRSKYNNYATYYADX7VKX8 is selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKE, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD being the most preferred. The CDR-H3 sequence HX 14 NFGNSYX 15 SX 16 X 17 Preferred examples of AY are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0104] For X1, amino acid Q is preferred. For X2, amino acid V is preferred. For X3, amino acid V is preferred. For X4, amino acid G is preferred. For X5, amino acid K is most preferred, and for X6, amino acid M is most preferred. Preferred combinations for X5 and X6 are M of X6 combined with any amino acid residue of X5, such as combinations of X5 and X6 selected from K and M, V and M, and S and M, respectively, with the most preferred combination being K and M. Another preferred combination is K and I of X5 and X6, respectively. Preferred examples of the CDR-H1 sequence X5YAX6N are selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, TYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being most preferred. For X7, amino acid S is most preferred, and for X8, amino acid D is most preferred. Preferred combinations include S and D, S and G, S and K, and S and S, with X7's S being combined with any of the amino acid residues of X8, and the most preferred combination is S and D. Preferred examples of the CDR-H2 sequence RIRSKYNNYATYYADX7VKX8 are selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD being the most preferred. For X9, amino acid K is preferred. 10 Regarding this, amino acid N is preferred. 11 Regarding this, amino acid T is preferred. 12 Regarding this, amino acid A is preferred. 13 Regarding this, amino acid V is preferred. 14 Regarding this, amino acid G is most preferred; X 15 Regarding this, amino acid I is most preferred; X 16 Regarding this, amino acid Y is most preferred; X 17 Regarding this, amino acid W is most preferred. The CDR-H3 sequence HX 14 NFGNSYX 15 SX16 X 17 Preferred examples of AY include HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred. X 18 Regarding, the amino acid sequence S is preferred.
[0105] The VL region of ii) is
Chemical formula
[0106] The CDR sequence within the aforementioned VL region is as follows: X6SSTGAVTX7X8X9YX 10 CDR-L1 sequence containing or consisting of N; X 17 TX 18 X 19 X 20 X 21 X 22 A CDR-L2 sequence containing or consisting of X 32 LWYSNX 33 A CDR-L3 sequence containing or consisting of WV. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0107] For X1, amino acid T is preferred. For X2, amino acid P is preferred. For X3, amino acid S is preferred. For X4, amino acid V is preferred. For X5, amino acid G is preferred. For X6, amino acid G is most preferred. For X7, amino acid S is most preferred. For X8, amino acid G is most preferred. For X9, amino acid N is most preferred. 10 Regarding this, amino acid P is the most preferred. X6~X 10This is a portion of the CDR-L1 sequence within the VL region. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. 11 Regarding this, amino acid Q is preferred. 12 Regarding this, amino acid G is preferred. 13 Regarding this, amino acid Q is preferred. 14 Regarding this, amino acid A is preferred. 15 Regarding this, amino acid P is preferred. 16 Regarding this, amino acid R is preferred. 17 Regarding this, amino acid G is preferred. 18 Regarding this, amino acid K is preferred. 19 Regarding this, amino acid F is preferred. 20 Regarding this, amino acid L is preferred. 21 Regarding this, amino acid A is preferred. 22 Regarding this, amino acid P is preferred. 17 ~X 22 This is a part of the CDR-L2 sequence in the VL region. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred. 23 Regarding this, amino acid T is preferred. 24 Regarding this, amino acid L is preferred. 25 Regarding this, amino acid G is preferred. 26 Regarding this, amino acid L is preferred. 27 Regarding this, amino acid S is preferred. 28 Regarding this, amino acid V is preferred. 29 Regarding this, amino acid P is preferred. 30 Regarding this, amino acid E is preferred. 31 Regarding this, amino acid Y is preferred. 32 Regarding this, amino acid V is preferred. 33 Regarding this, amino acid R is preferred. 32 and X 33This is a part of the CDR-L3 sequence in the VL region. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0108] In a more preferred embodiment, the VH region of i) is [ka] The sequence includes or consists of X1 being V or E; X2 being K, V, S, G, R, or I; X3 being M or I; X4 being S or Q; X5 being D, G, K, S, or E; X6 being G, R, or A; X7 being I, L, V, or T; X8 being Y, W, or F; X9 being W or F; and ii) the VL region is QTVVTQEPSLTVSPGGTVTLTCX1SSTGAVTSGX2YPNWVQQKP The sequence GQAPRGLIGX3TX4X5X6X7X8GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX9LWYSNRWVFGGGTKLTVL contains or consists of the sequence GQAPRGLIGX3TX4X5X6X7X8GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX9LWYSNRWVFGGGTKLTVL, where X1 is G, R, or A; X2 is N or Y; X3 is G or A; X4 is K or D; X5 is F or M; X6 is L or R; X7 is A, P, or V; X8 is P or S; and X9 is V, A, or T.
[0109] i) The VH region is [ka] The sequence includes or consists of X1 being V or E; X2 being K, V, S, G, R, or I; X3 being M or I; X4 being S or Q; X5 being D, G, K, S, or E; X6 being G, R, or A; X7 being I, L, V, or T; X8 being Y, W, or F; and X9 being W or F.
[0110] The CDR sequences within the VH region are as follows: a CDR-H1 sequence containing or consisting of X2YAX3N; a CDR-H2 sequence containing or consisting of RIRSKYNNYATYYADX4VKX5; and a CDR-H3 sequence containing or consisting of HX6NFGNSYX7SX8X9AY. Preferred examples of the CDR-H1 sequence X2YAX3N are selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, TYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being more preferred, and KYAMN being the most preferred. A preferred example of the CDR-H2 sequence RIRSKYNNYATYYADX4VKX5 is selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKE, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADQVKD being more preferred, and RIRSKYNNYATYYADSVKD being the most preferred. Preferred examples of the CDR-H3 sequence HX6NFGNSYX7SX8X9AY are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0111] For X1, amino acid V is preferred. For X2, amino acid K is most preferred, and for X3, amino acid M is most preferred. Preferred combinations for X2 and X3 are M of X3 combined with any amino acid residue of X2, such as combinations of X2 and X3 selected from K and M, V and M, and S and M, respectively, with the most preferred combination being K and M. Another preferred combination is K and I of X2 and X3, respectively. Preferred examples of the CDR-H1 sequence X2YAX3N are selected from KYAMN, VYAMN, SYAMN, GYAMN, RYAMN, TYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being more preferred, and KYAMN being the most preferred. For X4, amino acid S is preferred. For X5, amino acid D is most preferred. Preferred combinations are S of X4 combined with any amino acid residue of X5, such as combinations of X4 and X5 selected from S and D, S and G, S and K, and S and S, respectively, with the most preferred combination being S and D. A preferred example of the CDR-H2 sequence RIRSKYNNYATYYADX4VKX5 is selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADQVKD being preferred, and RIRSKYNNYATYYADSVKD being the most preferred. For X6, amino acid G is most preferred; for X7, amino acid I is most preferred; for X8, amino acid Y is most preferred; and for X9, amino acid W is most preferred. Preferred examples of the CDR-H3 sequence HX6NFGNSYX7SX8X9AY are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0112] ii) The VL region contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCX1SSTGAVTSGX2YPNWVQQKPGQAPRGLIGX3TX4X5X6X7X8GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX9LWYSNRWVFGGGTKLTVL, where X1 is G, R, or A; X2 is N or Y; X3 is G or A; X4 is K or D; X5 is F or M; X6 is L or R; X7 is A, P, or V; X8 is P or S; and X9 is V, A, or T.
[0113] The CDR sequences within the VL region are as follows: a CDR-L1 sequence containing or consisting of X1SSTGAVTSGX2YPN; a CDR-L2 sequence containing or consisting of X3TX4X5X6X7X8; and a CDR-L3 sequence containing or consisting of X9LWYSNRWV. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0114] For X1, amino acid G is most preferred. For X2, amino acid N is preferred. X1 and X2 are part of the CDR-L1 sequence X1SSTGAVTSGX2YPN in the VL region. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. For X3, amino acid G is preferred. For X4, amino acid K is preferred. For X5, amino acid F is preferred. For X6, amino acid L is preferred. For X7, amino acid A is most preferred. For X8, amino acid P is preferred. X3 to X8 are part of the CDR-L2 sequence X3TX4X5X6X7X8 in the VL region. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred. For X9, amino acid V is most preferred. X9 is part of the CDR-L3 sequence X9LWYSNRWV in the VL region. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0115] In another preferred embodiment, the VH region in ii) is [ka] ii) The VL region contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCX1SSTGAVTSGX2YPNWVQQKPGQAPRGLIGGTKFLX3PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX4LWYSNRWVFGGGTKLTVL or the sequence X1 is G or A; X2 is N or Y; X3 is A or V; X4 is V, A or T.
[0116] ii) The VH region is, [ka] The sequence includes or consists of X1 being V or E; X2 being K, V, S, R, or I; X3 being M or I; X4 being S or Q; X5 being D, G, K, or S; X6 being G or A; X7 being I, L, V, or T; X8 being Y, W, or F; and X9 being W or F.
[0117] The CDR sequences within the VH region are as follows: a CDR-H1 sequence containing or consisting of X2YAX3N; a CDR-H2 sequence containing or consisting of RIRSKYNNYATYYADX4VKX5; and a CDR-H3 sequence containing or consisting of HX6NFGNSYX7SX8X9AY. Preferred examples of the CDR-H1 sequence X2YAX3N are selected from KYAMN, VYAMN, SYAMN, RYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being more preferred, and KYAMN being the most preferred. A preferred example of the CDR-H2 sequence RIRSKYNNYATYYADX4VKX5 is selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADQVKD being more preferred, and RIRSKYNNYATYYADSVKD being the most preferred. Preferred examples of the CDR-H3 sequence HX6NFGNSYX7SX8X9AY are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY or HANFGNSYISYWAY being more preferred, and HGNFGNSYISYWAY being the most preferred.
[0118] For X1, amino acid V is preferred. For X2, amino acid K is most preferred, and for X3, amino acid M is most preferred. Preferred combinations for X2 and X3 are M of X3 combined with any amino acid residue of X2, such as combinations of X2 and X3 selected from K and M, V and M, and S and M, respectively, with the most preferred combination being K and M. Another preferred combination is K and I of X2 and X3, respectively. Preferred examples of the CDR-H1 sequence X2YAX3N are selected from KYAMN, VYAMN, SYAMN, RYAMN, IYAMN, and KYAIN, with KYAMN or KYAIN being more preferred, and KYAMN being the most preferred. For X4, amino acid S is preferred. For X5, amino acid D is most preferred. Preferred combinations are S of X4 combined with any amino acid residue of X5, such as combinations of X4 and X5 selected from S and D, S and G, S and K, and S and S, respectively, with the most preferred combination being S and D. A preferred example of the CDR-H2 sequence RIRSKYNNYATYYADX4VKX5 is selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD or RIRSKYNNYATYYADQVKD being more preferred, RIRSKYNNYATYYADSVKD being most preferred, and selected from RIRSKYNNYATYYADSVKD, RIRSKYNNYATYYADSVKK, RIRSKYNNYATYYADSVKS, RIRSKYNNYATYYADSVKE, RIRSKYNNYATYYADSVKG, and RIRSKYNNYATYYADQVKD, with RIRSKYNNYATYYADSVKD being most preferred. For X6, amino acid G is most preferred; for X7, amino acid I is most preferred; for X8, amino acid Y is most preferred; and for X9, amino acid W is most preferred.Preferred examples of the CDR-H3 sequence HX6NFGNSYX7SX8X9AY are selected from HGNFGNSYISYWAY, HGNFGNSYLSWWAY, HGNFGNSYTSYYAY, HRNFGNSYLSWFAY, HGNFGNSYVSFFAY, HGNFGNSYISWWAY, HGNFGNSYVSWWAY, HGNFGNSYLSYFAY, HGNFGNSYLSFWAY, HANFGNSYISYWAY, and HGNFGNSYVSWFAY, with HGNFGNSYISYWAY being the most preferred.
[0119] ii) The VL region contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCX1SSTGAVTSGX2YPNWVQQKPGQAPRGLIGGTKFLX3PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX4LWYSNRWVFGGGTKLTVL, where X1 is G or A; X2 is N or Y; X3 is A or V; and X4 is V, A or T.
[0120] The CDR sequences within the VL region are as follows: a CDR-L1 sequence containing or consisting of X1SSTGAVTSGX2YPN; a CDR-L2 sequence containing or consisting of GTKFLX3P; and a CDR-L3 sequence containing or consisting of X4LWYSNRWV. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. Preferred examples of the CDR-L2 sequence are selected from GTKFLAP, ATDMRPS, GTKFLVP, and GTNKRAP, with GTKFLAP being the most preferred. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, TLWYSNRWV, and ALWYSNLWV, with VLWYSNRWV being the most preferred.
[0121] For X1, amino acid G is preferred. For X2, amino acid N is preferred. X1 and X2 are parts of the CDR-L1 sequence X1SSTGAVTSGX2YPN in the VL region. Preferred examples of the CDR-L1 sequence are selected from GSSTGAVTSGNYPN, RSSTGAVTSGYYPN, GSSTGAVTSGYYPN, ASSTGAVTSGNYPN, and RSSTGAVTTSNYAN, with GSSTGAVTSGNYPN being the most preferred. X3 is part of the CDR-L2 sequence GTKFLX3P in the VL region. The CDR-L2 sequence can be either GTKFLAP or GTKFLVP, with GTKFLAP being preferred. For X3, amino acid A is preferred. X4 is part of the CDR-L3 sequence X4LWYSNRWV in the VL region. Preferred examples of the CDR-L3 sequence are selected from VLWYSNRWV, ALWYSNRWV, and TLWYSNRWV, with VLWYSNRWV being the most preferred. Regarding X4, amino acid V is the most preferred.
[0122] In a more preferred embodiment, the VH region of i) is [ka] The VL region of ii) contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGX1YPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX2LWYSNRWVFGGGTKLTVL, where X1 is N or Y and X2 is V or A.
[0123] i) The VH region is [ka] The sequence includes or consists of, where X1 is K or S, preferably K; X2 is D or G, preferably D; X3 is I or V, preferably I; X4 is Y or W, preferably Y.
[0124] The CDR sequences within the VH region are as follows: a CDR-H1 sequence containing or consisting of X1YAMN; a CDR-H2 sequence containing or consisting of RIRSKYNNYATYYADSVKX2; and a CDR-H3 sequence containing or consisting of HGNFGNSYX3SX4WAY. The CDR-H1 sequence X1YAMN is selected from KYAMN or SYAMN, with KYAMN being preferred. Preferred examples of the CDR-H2 sequence RIRSKYNNYATYYADSVKX2 are selected from RIRSKYNNYATYYADSVKD and RIRSKYNNYATYYADSVKG, with RIRSKYNNYATYYADSVKD being preferred. The CDR-H3 sequence HGNFGNSYX3SX4WAY is HGNFGNSYISYWAY or HGNFGNSYVSWWAY, with HGNFGNSYISYWAY being preferred.
[0125] ii) The VL region contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGX1YPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCX2LWYSNRWVFGGGTKLTVL, where X1 is N or Y, preferably N; and X2 is V or A, preferably V.
[0126] The CDR sequences within the VL region are as follows: a CDR-L1 sequence containing or consisting of GSSTGAVTSGX1YPN; a CDR-L2 sequence containing or consisting of GTKFLAP; and a CDR-L3 sequence containing or consisting of X2LWYSNRWV. The CDR-L1 sequence is GSSTGAVTSGNYPN or GSSTGAVTSGYYPN, with GSSTGAVTSGNYPN being preferred. The CDR-L3 sequence is VLWYSNRWV or ALWYSNRWV, with VLWYSNRWV being preferred.
[0127] In a preferred embodiment, the VH region of i) includes or consists of sequences defined by sequence numbers 124, 172, 362, 552, 730, 928, 1106, 1296, 1474, 1664, or 1854, and the VL region of ii) includes or consists of sequences defined by sequence numbers 125, 173, 363, 553, 731, 929, sequence number 1107, sequence number 1297, sequence number 1475, sequence number 1665, or sequence number 1855. The preferred combinations of the VH and VL regions in i) and ii) are defined as SEQ ID NOs: 124 and 125 (a binder combination called "2B2"), 172 and 173 ("A2J"), 362 and 363 ("E1L"), 552 and 553 ("E2M"), 730 and 731 ("F12Q"), 928 and 929 ("F6A"), 1106 and 1107 ("F7O"), 1296 and 1297 ("G4H"), 1474 and 1475 ("H1E"), 1664 and 1665 ("H2C"), or 1854 and 1855 ("I2C"). Preferably, the CD3ε-binding domain contains or consists of combinations of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 124 and 125, 172 and 173, 362 and 363, 552 and 553, 730 and 731, 928 and 929, 1106 and 1107, 1296 and 1297, 1474 and 1475, 1664 and 1665, and 1854 and 1855. More preferably, the CD3ε-binding domain includes or consists of combinations of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 124 and 125, 362 and 363, 730 and 731, 928 and 929, 1106 and 1107, 1296 and 1297, 1474 and 1475, 1664 and 1665, and 1854 and 1855. Even more preferably, the CD3ε-binding domain includes or consists of combinations of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 124 and 125, 730 and 731, 1664 and 1665, and 1854 and 1855.In a more preferred embodiment, the CD3ε-binding domain includes or comprises a combination of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 730 and 731, 1664 and 1665, and 1854 and 1855.
[0128] In the most preferred embodiment, the VH region of i) is [ka] The VL region of (ii) contains or consists of the sequence QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (sequence number 1855).
[0129] As outlined above herein in relation to amino acid substitutions in the CDR sequence and applicable to this embodiment, the VH region of i) and / or the VL region of ii) contain one or more amino acid substitutions as specified above herein. Thus, at least one of the enumerated amino acid substitutions of the variable region is contained in the binding domain that binds to the extracellular epitope of the human CD3ε chain. The at least one or more amino acid substitutions may be present in the CDR sequence of the VH region or the VL region if only one amino acid substitution is present, or in the CDR of both the VH region and the VL region if two or more amino acid substitutions are present, or may be limited to the CDR sequence of the VH region or the VL region only. In certain embodiments where two or more amino acid substitutions are present, the substitutions are present in the VH region and the VL region, or in only one variable region. Preferably, the substitutions are present in the VH region and the VL region.
[0130] Specifically, the VH region sequence of i) and / or the VL region sequence of ii) are ai) VH region sequence N30 (preferably S), X634V, X634F, Q39 (E, K, R, D, preferably E), L45 (M or V, preferably M), D64 (preferably E), X765A, X 12 81V, X 12 81T, X 12 81I, V99 (A or L, preferably A), H101 (preferably A or N), X 14 102E, F104 (preferably I), N106 (preferably S or T); and b.ii) In the VL region sequence, L20 (preferably I or M), V38 (I, L, M, F or Y, preferably I), X 11 40R, X 11 40K, X 24 69 (S or E, preferably S), X 32 91L, X 33 93 (preferably Y), G102 (preferably S) It includes one or more amino acid substitutions selected from the following.
[0131] In the VH region sequence, the amino acid substitution at position 30 is preferably S (and can therefore be written as N30S; the same applies to subsequent substitutions given according to position number). The amino acid substitution at position 34 is V or F. Preferably, position 34 of the VH region sequence contains I or M, most preferably I. The amino acid substitution at position 39 is E, K, R, D, preferably E. The amino acid substitution at position 45 is preferably M or V, more preferably M. The amino acid substitution at position 64 is preferably E. The amino acid substitution at position 65 is A. The amino acid substitution at position 81 is V, T, or I, preferably V. The amino acid substitution at position 99 is preferably A or L, more preferably A. The amino acid substitution at position 101 is preferably A or N, more preferably A(H1A). The amino acid substitution at position 102 is E. The amino acid substitution at position 104 is preferably I. The amino acid substitution at position 106 is preferably S or T, more preferably S.
[0132] Notwithstanding the foregoing, in the CDR-H2 sequence within the VH region, the amino acid substitution at position 64 is preferably D15E, or the amino acid substitution at position 65 is by amino acid A. Preferably, the CDR-H2 includes an amino acid residue substitution at position 65 by amino acid A; in this case, the preferred last amino acid of the CDR-H2 is D or G, preferably D. Therefore, preferred CDR-H2 sequences are RIRSKYNNYATYYADAVKD or RIRSKYNNYATYYADAVKG, with RIRSKYNNYATYYADAVKD being more preferred. If the CDR-H2 includes two amino acid substitutions, the combination of amino acid E at position 64 and amino acid A at position 64 is preferred; in this case, the preferred last amino acid of the CDR-H2 is G. Therefore, a preferred CDR-H2 sequence with the combination of amino acid E at position 64 and amino acid A at position 65 is RIRSKYNNYATYYAEAVKG.
[0133] In the CDR-H3 sequence of the VH sequence, amino acid substitutions are preferably substitutions of amino acid A or N at position 101, substitutions of amino acid E at position 102, substitutions of amino acid I at position 104, and substitutions of amino acid S or T at position 106. Preferably, CDR-H3 includes amino acid A or N at position 101 and amino acid S or T at position 106; in this case and when a placeholder is present at the indicated position in the CDR-H3 sequence, X 14 The preferred amino acid is G or A, with G being the most preferred; X 15 is I; X 16 is Y; X 17 is W or Y. If CDR-H3 contains two amino acid substitutions, preferred combinations are amino acid A at position 101 and amino acid S at position 106; and amino acid N at position 101 and amino acid T at position 106; in this case and when the placeholder is present at the indicated position of the CDR-H3 sequence, X 14 The preferred amino acid is G or A, with G being the most preferred; X 15 is I, X 16 Y is X 17These are W and F. When CDR-H3 contains three amino acid substitutions, preferred combinations are amino acid A at position 101, amino acid I at position 104 and amino acid S at position 106; and amino acid N at position 101, amino acid I at position 104 and amino acid T at position 106, in which case and when a placeholder is present at the indicated position of the CDR-H3 sequence, X 15 The preferred amino acid is I, and X 16 Y is X 17 These are W and F. If CDR-H3 contains four amino acid substitutions, the preferred combination is amino acid N at position 101, amino acid E at position 102, amino acid I at position 104 and amino acid T at position 106; in this case and if a placeholder is present at the indicated position of CDR-H3, X 15 The preferred amino acid is I, and X 16 Y is X 17 is W. Therefore, preferred CDR-H3 sequences are selected from AGNFGSSYISYWAY, NENIGTSYISYWAY, AGNFGTSYISYWAY, NANFGTSYISYFAY, and AGNFGSSYISYFAY, with AGNFGSSYISYWAY and AGNFGSSYISYFAY being the most preferred.
[0134] In the VL region sequence, the amino acid substitution at position 20 is preferably I or M, more preferably I. The amino acid substitution at position 38 is preferably I, L, M, F, or Y, more preferably I. The amino acid substitution at position 40 is preferably K or R, more preferably K. The amino acid substitution at position 69 is preferably S or E, more preferably S. The amino acid substitution at position 91 is L. The amino acid substitution at position 93 is preferably Y. The amino acid substitution at position 102 is preferably S.
[0135] Notwithstanding the foregoing, in the CDR-L3 sequence within the VL region sequence, the amino acid substitution at position 1 is either by amino acid L, or the amino acid substitution is W93, preferably W93Y. Preferably, the CDR-L3 sequence is VLYYSNRWV if CDR-L3 contains an amino acid substitution. However, it is preferable that CDR-L3 does not contain the X11L and W93 amino acid substitutions, in which case the preferred CDR-L3 sequence is VLYYSNRWV.
[0136] As described above, if there is only one amino acid substitution in the CD3ε-binding domain within the VH region sequence and / or VL region sequence as defined herein, it is preferable that the amino acid substitution H101A in the VH region (part of CDR-H3) is that amino acid substitution. Furthermore, in the case of a combination of amino acid substitutions as defined in iii), it is preferable that H101A in the VH region sequence is one of the amino acid substitutions in the combination.
[0137] In preferred embodiments of the polypeptide or polypeptide construct of the present invention, in addition to the one amino acid substitution or combination thereof as defined in iii), X6 is I; X8 is G; and in the VH region sequence, X 12 L is X 14 A is X 17 is F; and / or X 32 is A in the VL region sequence. In a preferred embodiment of the polypeptide or polypeptide construct according to claim 1 of the present invention, in addition to the one amino acid substitution or combination thereof as defined in iii), X6 is I; X8 is G; and in the VH region sequence, X 14 A is X 17 is F; and / or in the VL region array, X 32 is A. One amino acid substitution or combination thereof as defined herein is further combined with a specific amino acid at a specific position in the CDR. Thus, there is at least one of the amino acid substitutions enumerated by iii), and at least one of X8 is G; in the VH region sequence, X 14 A is X17 is F; and / or in the VL region array, X 32 is A, and is further present in the CDR. In this specification, as previously stated above, if only one further amino acid is present in the CDR, the preferred amino acid of X6 in the VH region sequence is I, or X8 is G, and it is most preferable that X5 is I in the VH region sequence. Two preferred combinations of the further amino acids are that X6 is I and X 17 is F; or in the VH region array, X8 is G, X 17 The condition is that is F. The three further preferred combinations of amino acids are that in the VH region sequence, X6 is I, and X 14 A is X 17 is F; or in the VH region array, X6 is I, and X 17 is F, and in the VL region array, X 32 The condition is that A. Since the latter amino acids will be present in addition, it is understood that any additional listed amino acids whose positions overlap with the amino acid substitution in iii) cannot replace the overlapping amino acid substitution. For example, if the only amino acid substitution by iii) is either X634V or X634F in CDR-H1, then the amino acid cannot be replaced by amino acid I in the CDR-H1 sequence because there is no amino acid substitution defined in iii) remaining in the binding domain. In other words, at least one of the amino acid substitutions defined in iii) must always be present in the polypeptide or polypeptide construct of the present invention.
[0138] Depending on the actual sequences of the VH region sequence and / or VL region sequence, one or more of the further amino acids may be part of a given variable sequence as already defined herein, or, if not, the given variable region may be modified to represent the further amino acids in combination with one or more amino acid substitutions or combinations thereof as enumerated in iii).
[0139] A preferred embodiment of the polypeptide or polypeptide construct of the present invention includes a combination of two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or more amino acid substitutions as defined in iii).
[0140] In preferred embodiments of the polypeptide or polypeptide construct of the present invention, i) the one amino acid substitution is a. X634V, Q39E, Q39K, Q39R, Q39D, L45M, L45V, X in the VH region. 12 81V, X 12 81T, X 12 81I, V99A, V99L, H101A, H101N; and b. V38I, V38L, V38M, V38F, V38Y, X 11 40R, X 11 40K, X 24 69S, X 24 69E, X 32 91L, X 33 ii) A combination of two or more amino acid substitutions is X634F and A81V(X) in the VH region. 12 It can also be called 81V); Q39E in the VH region and X in the VL region 11 40K; Q39E in the VH region and X in the VL region 11 40R; Q39D in the VH region and X in the VL region 11 40K; Q39D in the VH region and X in the VL region 11 40R; L45V in the VH region and V38F in the VL region; L45V in the VH region and V38Y in the VL region; L45M in the VH region and X in the VL region 11 40K; L20I in the VL region and G102S; A81V in the VH region and X in the VL region 11 Selected from 40K; iii) The above combination of three or more amino acid substitutions is Q39E in the VH region, X in the VL region. 11 40K and G102S; Q39E in the VH region, X in the VL region 11 40R and G102S; Q39D in the VH region, X in the VL region11 40K and G102S; Q39D in the VH region, X in the VL region 11 40R and G102S; L45M in the VH region, X in the VL region 11 40K and G102S; X765A, H101A and N106S in the VH region; L20I, X in the VL region 11 Selected from 40K and G102S; iv) The above combination of four or more amino acid substitutions is Q39E in the VH region, L20I in the VL region, X 11 40K and G102S; Q39E in the VH region, L20I and X in the VL region 11 40R and G102S; Q39D in the VH region, L20I and X in the VL region 11 40K and G102S; Q39D in the VH region, L20I and X in the VL region 11 40R and G102S; L45M in the VH region, L20I and X in the VL region 11 L20I, X in the 40K and G102S;VL regions 11 40K, X 24 69S and G102S; A81V in the VH region, L20I and X in the VL region 11 Selected from 40K and G102S; and / or v) the above combination of 5, 6, 7, 8, 9, 10 or more amino acid substitutions, X765A, A81V, V99A, N106S in the VH region, L20I, X in the VL region 11 40K, X 24 69S and G102S; D64E, X765A, A81V, X in the VH region 14 102E, F104I, N106T, L20I in the VL region, X 24 69S and G102S; L45M, X765A, N106T in the VH region, L20I, X in the VL region 11 40K, X 24 69S and G102S; X765A, A81V, V99A, H101A, F104I, N106S in the VH region, L20I, X in the VL region 11 40K, X 2469S, G102S; X765A, A81V, V99A, H101A, N106S in the VH region; A81V, V99A in the VH region, L20I, X in the VL region 11 40K, X 24 69S, G102S; Q39E, A81V in the VH region, L20I, X in the VL region 11 40K, G102S; L45V in the VH region, L20I, V38F, X in the VL region 11 The choice is between 40K and G102S.
[0141] In a more preferred embodiment of the polypeptide or polypeptide construct of the present invention, the above combination of amino acid substitutions is: i) In the VH region, a.X765A, A81V, V99A, H101A and N106S; b.D64E, X765A, A81V, H101N, X 14 102E, F104I, and N106S; c.L45M, X765A, H101A and N106T; d.L45M, X765A, H101A and N106S; e.Q39E, X765A, H101N and N106T; f.D64E, X765A, V99A, H101A, and N106T; g.X765A, A81V, V99A, H101A, X 14 102E, F104I, and N106T; h.X765A, A81V, H101N, X 14 102E, F104I, and N106S; i.D64E, X765A, A81V, H101A and N106S; j.D64E, X765A, H101A and N106T; k.X765A, V99A, H101A, and N106T; l.D64E, X765A, H101A and N106S; m.D64E, X765A, A81V, V99A, H101A and N106S; n.X765A, H101A, and N106S; o.N30S, Q39E, D64E, X765A, A81V, H101A, X 14 102E, F104I, and N106T; p.L45M, D64E, X765A, H101A and N106T; q.N30S, L45M, X765A, A81V, H101A and N106T; r.N30S, L45M, D64E, X765A, A81V, H101A and N106S; ii) In the VL region, a. L20I, X 11 40K, X 24 69S and G102S; b.L20I, X 24 69S and G102S; c.L20I, V38I, X 11 40K, X 24 69E, G102S, and W93Y; dX 11 40K and G102S; e.L20I, X 11 40K, X 24 69S, G102S, and W93Y; f.L20M, X 11 40K and X 24 69E; g.L20I, V38I, X 11 40K, X 24 69E and G102S; hX 11 40K, X 24 69S and W93Y; iX 11 40K and X 24 69S; and iii) A combination of one amino acid substitution from i) and ii) Selected from.
[0142] In yet another preferred embodiment of the polypeptide or polypeptide construct of the present invention, the combination of amino acid substitutions of iii) is: a. X765A, A81V, V99A, H101A, N106S in the VH region, and L20I, X in the VL region.11 40K, X 24 69S and G102S; b. D64E, X765A, A81V, H101N, X in the VH region 14 102E, F104I, N106S, L20I in the VL region, X 24 69S and G102S; c. L45M, X765A, H101A, N106T in the VH region, and L20I, X in the VL region. 11 40K, X 24 69S and G102S; d. L45M, X765A, H101A, N106S in the VH region, and L20I, V38I, X in the VL region. 11 40K, X 24 69E, G102S, and W93Y; e. Q39E, X765A, H101N, N106T in the VH region, X in the VL region 11 40K and G102S; f. D64E, X765A, V99A, H101A, N106T in the VH region, X in the VL region 11 40K and G102S; g. X765A, A81V, V99A, H101A, X in the VH region 14 102E, F104I, N106T, L20I in the VL region, X 11 40K, X 24 69S and G102S; X765A, A81V, H101N, X in the h.VH region 14 102E, F104I, N106S, L20I in the VL region, X 24 69S and G102S; i. D64E, X765A, A81V, H101A, N106S in the VH region, and L20I, X in the VL region. 24 69S and G102S; j. D64E, X765A, H101A, N106T in the VH region, and X in the VL region 11 40K and G102S; X765A, V99A, H101A, N106T in the k.VH region, and X in the VL region.11 40K and G102S; l. D64E, X765A, H101A, N106S in the VH region, X in the VL region 11 40K and G102S; m. D64E, X765A, A81V, V99A, H101A, N106S in the VH region, L20I, X in the VL region 11 40K, X 24 69S, G102S and W93Y; n. X765A, H101A, N106S in the VH region, X in the VL region 11 40K and G102S; o. N30S, Q39E, D64E, X765A, A81V, H101A, X in the VH region 14 102E, F104I, N106T, L20M, X in the VL region 11 40K and X 24 69E; p. L45M, D64E, X765A, H101A, N106T in the VH region, L20I, V38I, X in the VL region 11 40K, X 24 69E and G102S; q. N30S, L45M, X765A, A81V, H101A, N106T in the VH region, X in the VL region 11 40K and X 24 69S; and r. N30S, L45M, D64E, X765A, A81V, H101A, N106S in the VH region, X in the VL region 11 40K and X 24 69S selected from.
[0143] In other preferred embodiments of the polypeptide or polypeptide construct of the present invention, in said combination of defined amino acid substitutions, a. and m., X6 is I in the VH region sequence; b. and r., X8 is G in the VH region sequence; c., X 12 is L in the VH region; d. In the VH region, X 12 is L, and X 17 is F; e. In the VH region sequence, X6 is I, and X 14 is A, and X 17 is F; f. In the VH region sequence, X6 is I; and in the VL region sequence, X 32 is A; g. In the VH region sequence, X6 is I; h. And in i. the VH region sequence, X8 is G; j., l and n. In the VH region sequence, X6 is I, and X 17 is F; and in the VL region sequence, X 32 is A; k. In the VH region sequence, X6 is I; and in the VL region sequence, X 32 is A; p. In the VH region, X 12 is L; or q. In the VH region sequence, X8 is G, and X 17 is F.
[0144] Examples of VH region sequences and VL region sequences as defined in this embodiment are defined by SEQ ID NOs: 2012 and 2013; 2020 and 2021; 2028 and 2029; 2036 and 2037; 2044 and 2045; 26 and 27; 34 and 35; 42 and 43; 50 and 51; 58 and 59; 66 and 67; 74 and 75; 82 and 83; 90 and 91; 98 and 99; 100 and 101; 108 and 109; 116 and 117. Table 2 demonstrates an increase in the thermal stability of the combinations of the aforementioned VH and VL region sequences of CD3ε-binding domains that exceed the CD3ε-binding domain defined as "I2C" (SEQ ID NOs: 1854 and 1855, respectively).
[0145] According to the present invention, the binding domain of a polypeptide or polypeptide construct of the present invention that binds to an extracellular epitope of a human CD3ε chain and comprises or consists of a VH region and a VL region as defined herein comprises at least one of the following CDR sequences or combinations thereof as defined in SEQ ID NOs: 1878, 1908, 1989, and 2003. The sequence comprises one amino acid substitution or combination thereof as defined in iii), and in some examples also comprises the further amino acids as defined herein above. Preferred combinations of the CDR sequences are listed below in the order of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3: 1878-1883; 1908-1913; 1984-1989; 1998-2003.
[0146] The combination of CDR sequences in the order of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, as defined by sequence numbers 126-131; 134-139; 142-147; 150-155; and 158-163, also conforms to the present invention.
[0147] According to the present invention, combinations of CDR sequences defined by the sequence numbers (listed in the order of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3): 2006~2011; 2014~2019; 2022~2027; 2030~2035; 2038~2043; 20~25; 36~41; 44~49; 52~57; 60~65; 68~73; 76~81; 84~89; 92~97; 102~107; 110~115 are also more preferred. Further examples include sequence numbers 282~287;290~295;298~303;306~311;314~319;472~477;480~485;488~493;496~501;504~509;650~655;658~663;666~671;674~679;682~687;840~845;848~853;856~861;864~869;872~877;1026~1031;1034~1039;1042~1047;1050~1055;1 The ranges are 058~1063;1216~1221;1224~1229;1232~1237;1240~1245;1248~1253;1394~1399;1402~1407;1410~1415;1418~1423;1426~1431;1584~1589;1592~1597;1600~1605;1608~1613;1616~1621;1774~1779;1782~1787;1790~1795;1798~1803;1806~1811.
[0148] According to the present invention, the binding domain of the polypeptide or polypeptide construct of the present invention that binds to the extracellular epitope of the human CD3ε chain includes or comprises a VH region sequence as defined by the following SEQ ID NOs: 1856, 1860, 1862, 1864, 1872, 1884, 1894, 1896, 1898, 1900, 1902, 1904, 1906, 1914, 1916, 1918, 1920, 1922, 1924, 1926, 1928, 1930, 1932, 1934, 1936, 1938, 1940, 1942, 1944, 1946, 1948, 1950. The sequence includes one amino acid substitution or combination thereof as defined above herein, and in some examples also includes the further amino acids as defined above herein. This also applies to the following embodiments, which feature a sequence ID number CD3ε-binding domain resulting from the amino acid residue exchanges identified herein.
[0149] According to the present invention, the binding domain of the polypeptide or polypeptide construct of the present invention that binds to the extracellular epitope of the human CD3ε chain includes or consists of a VL region sequence as defined by the following SEQ ID NOs: 1867, 1869, 1871, 1875, 1877, 1899, 1901, 1903, 1905, 1907, 1919, 1921, 1923, 1925, 1927, 1929, 1931, 1933, 1935, 1937, 1939, 1941, 1943, 1961, 1963, 1965, 1967, 1969, 1971, 1975, 1991, 1993, 1995, 1997, or 2005.
[0150] Preferred combinations of VH and VL region sequences of the binding domain of the polypeptide or polypeptide construct of the present invention that binds to the extracellular epitope of the human CD3ε chain are the following sequence numbers: 1856 and 1857; 1860 and 1861; 1862 and 1863; 1864 and 1865; 1866 and 1867; 1868 and 1869; 1870 and 1871 ;1872 and 1873;1874 and 1875;1876 and 1877;1884 and 1885;1894 and 1895;1896 and 1897;1898 and 1899;1900 and 1901;1902 and 1903;1904 and 1905;1906 and 1907;1914 and 1915;1916 and 1917;1918 and 1919;19 20 and 1921; 1922 and 1923; 1924 and 1925; 1926 and 1927; 1928 and 1929; 1930 and 1931; 1932 and 1933; 1934 and 1935; 1936 and 1937; 1938 and 1939; 1940 and 1941; 1942 and 1943; 1944 and 1945; 1946 and 1947; 1948 and As defined in 1949; 1950 and 1951; 1960 and 1961; 1962 and 1963; 1964 and 1965; 1966 and 1967; 1968 and 1969; 1970 and 1971; 1974 and 1975; 1990 and 1991; 1992 and 1993; 1994 and 1995; 1996 and 1997; or 2004 and 2005.
[0151] The VH region sequences defined in sequence numbers 132, 140, 148, 156, and 164 also conform to the present invention.
[0152] The VL region sequences defined in sequence numbers 133, 141, 149, 157, and 165 also conform to the present invention.
[0153] Any combination of the particularly preferred VH and VL region sequences described above is also in accordance with the present invention. The following VH and VL combinations, defined by the following sequence numbers, are preferred: sequence numbers 132 and 133; 140 and 141; 148 and 149; 156 and 157; and 164 and 165.
[0154] The VH region sequences defined by sequence numbers 2012, 2020, 2028, 2036, 2044, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 100, 108, and 116 also conform to the present invention and are more preferred. Further examples include sequence numbers 288, 296, 304, 312, 320, 478, 486, 494, 502, 510, 656, 664, 672, 680, 688, 846, 854, 862, 870, 878, 1032, 1040, 1048, 1056, 1064, 1222, 1230, 1238, 1246, 1254, 1400, 1408, 1416, 1424, 1432, 1590, 1598, 1606, 1614, 1622, 1780, 1788, 1796, 1804, and 1812.
[0155] The VL region sequences defined by sequence numbers 2013, 2021, 2029, 2037, 2045, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 101, 109, and 117 also conform to the present invention and are more preferred. Further examples include sequence numbers 289, 297, 305, 313, 321, 479, 487, 495, 503, 511, 657, 665, 673, 681, 689, 847, 855, 863, 871, 879, 1033, 1041, 1049, 1057, 1065, 1223, 1231, 1239, 1247, 1255, 1401, 1409, 1417, 1425, 1433, 1591, 1599, 1607, 1615, 1623, 1781, 1789, 1797, 1805, and 1813.
[0156] Any combination of the particularly preferred VH and VL region sequences described above is also in accordance with the present invention and is preferred. The following VH and VL combinations, defined by the following sequence numbers, are preferred: 2012 and 2013; 2020 and 2021; 2028 and 2029; 2036 and 2037; 2044 and 2045; 26 and 27; 34 and 35; 42 and 43; 50 and 51; 58 and 59; 66 and 67; 74 and 75; 82 and 83; 90 and 91; 98 and 99; 100 and 101; 108 and 109; and 116 and 117. Further examples include: Sequence IDs 288 and 289; 296 and 297; 304 and 305; 312 and 313; 320 and 321; 478 and 479; 486 and 487; 494 and 495; 502 and 503; 510 and 511; 656 and 657; 664 and 665; 672 and 673; 680 and 681; 688 and 689; 846 and 847; 854:855; 862 and 863; 870 and 871; 878 and 879; 1032 and 1033; 1040 and 1041; 1048 and 1049; 1056 and 1057; 1 These are 064 and 1065; 1222 and 1223; 1230 and 1231; 1238 and 1239; 1246 and 1247; 1254 and 1255; 1400 and 1401; 1408 and 1409; 1416 and 1417; 1424 and 1425; 1432 and 1433; 1590 and 1591; 1598 and 1599; 1606 and 1607; 1614 and 1615; 1622 and 1623; 1780 and 1781; 1788 and 1789; 1796 and 1797; 1804 and 1805; and 1812 and 1813.
[0157] According to the present invention, the binding domain of the polypeptide or polypeptide construct of the present invention that binds to the extracellular epitope of the human CD3ε chain is SEQ ID NOs: 2012, 2020, 2028, 2036, 2044, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 100, 108, 116, 288, 296, 304, 312, 320, 478, 486, 494, 502, 510, 656, 664, 672, 680, 688, 846, 854, 862, 870, 878, 1032, 1040, 1048, 1056, 1064, 1222, 1230, 1238, 1246, 1254, 140 0, 1408, 1416, 1424, 1432, 1590, 1598, 1606, 1614, 1622, 1780, 1788, 1796, 1804, 1812, 1856, 1860, 1862, 1864, 1872, 1884, 1894, 1896, 1898, 1900, 1902, 1904, 1 VH region array selected from 906, 1914, 1916, 1918, 1920, 1922, 1924, 1926, 1928, 1930, 1932, 1934, 1936, 1938, 1940, 1942, 1944, 1946, 1948, 1950, 132, 140, 148, 156, and 164;and / or Sequence IDs 2013, 2021, 2029, 2037, 2045, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 101, 109 and 117, 289, 297, 305, 313, 321, 479, 487, 495, 503, 511, 657, 665, 673, 681, 689, 847, 855, 863, 871, 879, 1033, 1041, 1049, 1057, 1065, 1223, 1231, 1239, 1247, 1255, 1401, 1409, 1417, 1425, 1433, 1591, 1599, 1607, 1615 It includes or consists of a VL region sequence selected from 1623, 1781, 1789, 1797, 1805, 1813, 1867, 1869, 1871, 1875, 1877, 1899, 1901, 1903, 1905, 1907, 1919, 1921, 1923, 1925, 1927, 1929, 1931, 1933, 1935, 1937, 1939, 1941, 1943, 1961, 1963, 1965, 1967, 1969, 1971, 1975, 1991, 1993, 1995, 1997, 2005, 133, 141, 149, 157, and 165.
[0158] According to the present invention, preferably, a polypeptide or polypeptide construct comprises a binding domain that binds to an extracellular epitope of the human CD3ε chain, i) comprising a VH region and ii) a VL region, wherein the VH and VL regions of i) and ii) are selected from combinations of VH and VL regions defined by SEQ ID NOs: 124 and 125, 172 and 173, 362 and 363, 552 and 553, 730 and 731, 928 and 929, 1106 and 1107, 1296 and 1297, 1474 and 1475, 1664 and 1665 and 1854 and 1855, wherein the one amino acid substitution or combination thereof in the VH and / or VL region sequence results in a VH and / or VL region sequence having the following amino acid residues: i. I at position 34, A at position 65, V at position 81, A at position 99, A at position 101, S at position 106 in the VH region sequence; I at position 20, K at position 40, S at position 69, and S at position 102 in the VL region sequence; M at position 45, A at position 65, L at position 81, A at position 101, T at position 106 in the VH region sequence, I at position 20, K at position 40, S at position 69 and S at position 102 in the VL region sequence; M at position 45, A at position 65, L at position 81, A at position 101, S at position 106, F at position 112 in the VH region sequence, I at position 20, I at position 38, K at position 40, E at position 69, S at position 102 and Y at position 93 in the VL region sequence; I at position 34, E at position 39, A at position 65, N at position 101, A at position 102, T at position 106, F at position 112 in the VH region sequence, K at position 40 and S at position 102 in the VL region sequence; I at position 34, E at position 64, A at position 65, A at position 99, A at position 101, T at position 106 in the VH region sequence, K at position 40, A at position 91 and S at position 102 in the VL region sequence; I at position 34, A at position 65, V at position 81, A at position 99, A at position 101, E at position 102, I at position 104, T at position 106 in the VH region sequence, I at position 20, K at position 40, S at position 69 and S at position 102 in the VL region sequence; E at position 64, A at position 65, G at position 68, V at position 81, A at position 101, S at position 106 in the VH region sequence, I at position 20, S at position 69 and S at position 102 in the VL region sequence; I at position 34, E at position 64, A at position 65, A at position 101, T at position 106, F at position 112 in the VH region sequence, K at position 40, A at position 9I and S at position 102 in the VL region sequence; I at position 34, E at position 64, A at position 65, A at position 101, S at position 106, F at position 112 in the VH region sequence, K at position 40, A at position 91 and S at position 102 in the VL region sequence; I at position 34, E at position 64, A at position 65, V at position 81, A at position 99, A at position 101, S at position 106 in the VH region sequence, I at position 20, K at position 40, S at position 69, S at position 102 and Y at position 93 in the VL region sequence; I at position 34, A at position 65, A at position 101, S at position 106, F at position 112 in the VH region sequence, K at position 40, A at position 91 and S at position 102 in the VL region sequence; M at position 45, E at position 64, A at position 65, L at position 81, A at position 101, T at position 106 in the VH region sequence; I at position 20, I at position 38, K at position 40, E at position 69, and S at position 102 in the VL region sequence; S at position 30, M at position 45, A at position 65, G at position 68, V at position 81, A at position 101, T at position 106, F at position 112, K at position 40, S at position 69 and Y at position 93 in the VL region sequence; and S at position 30, M at position 45, E at position 64, A at position 65, G at position 68, V at position 81, A at position 101, S at position 106, K at position 40 and S at position 69 in the VL region sequence; ii. E at position 64, A at position 65, G at position 68, V at position 81, N at position 101, E at position 102, I at position 104, T at position 106, I at position 20, S at position 69, and S at position 102 in the VL region sequence; A at position 65, G at position 68, V at position 81, N at position 101, E at position 102, I at position 104, S at position 106 in the VH region sequence; I at position 20, S at position 69, and S at position 102 in the VL region sequence; I at position 34, A at position 65, A at position 99, A at position 101, T at position 106 in the VH region sequence; K at position 40, A at position 91 and S at position 102 in the VL region sequence; and S at position 30, E at position 39, E at position 64, A at position 65, V at position 81, A at position 101, E at position 102, I at position 104, T at position 106; M at position 20, K at position 40, and E at position 69 in the VL region sequence; iii. A at position 101 in the VH region sequence; iv. V at position 81 and A at position 99 in the VH region sequence; I at position 20, K at position 40, S at position 69 and S at position 102 in the VL region sequence; I at position 34 and V at position 81 in the VH region sequence; I at position 20, K at position 40 and S at position 102 in the VL region sequence; I at position 34 in the VH region sequence, I at position 20, K at position 40, and S at position 102 in the VL region sequence; I at position 34, E at position 39, V at position 81 in the VH region sequence; I at position 20, K at position 40, and S at position 102 in the VL region sequence; v. I at position 34 in the VH region sequence, V at position 81, and K at position 40 in the VL region sequence; M at position 45, I at position 20, K at position 40, and S at position 102 in the VH region sequence; I at position 34, A at position 65, A at position 101, and S at position 106 in the VH region sequence; I at position 20, K at position 40, S at position 69, and S at position 102 in the VL region sequence; F at position 34 and V at position 81 in the VH region sequence; M at position 45 in the VH region sequence, and K at position 40 and S at position 102 in the VL region sequence; D at position 39 in the VH region sequence, I at position 20, K at position 40, and S at position 102 in the VL region sequence; I at position 34 and V at position 81 in the VH region sequence; E at position 39 in the VH region sequence, I at position 20, K at position 40, and S at position 102 in the VL region sequence; M at position 45 in the VH region sequence and K at position 40 in the VL region sequence; I at position 34, A at position 65, V at position 81, A at position 99, A at position 101 and S at position 106 in the VH region sequence; or vi. D at position 39 in the VH region sequence, I at position 20, R at position 40, and S at position 102 in the VL region sequence; I at position 34 in the VH region sequence; K at position 40 in the VL region sequence; D at position 39 in the VH region sequence, and K at position 40 and S at position 102 in the VL region sequence; I at position 20 and S at position 102 in the VH region sequence; K at position 39 in the VH region sequence; E at position 39 in the VH region sequence, and K at position 40 and S at position 102 in the VL region sequence; E at position 39 in the VH region sequence, I at position 20, R at position 40, and S at position 102 in the VL region sequence; D at position 39 in the VH region sequence, R at position 40 and S at position 102 in the VL region sequence; V at position 81 in the VH region sequence; D at position 39 in the VH region sequence and K at position 40 in the VL region sequence; F at position 112 in the VH region sequence; F at position 112 in the VH region sequence and I at position 38 in the VL region sequence; E at position 39 in the VH region sequence and K at position 40 in the VL region sequence; V at position 34 in the VH region sequence.
[0159] The above amino acid residues are located at a given position in the CD3ε-binding domain according to the present invention. If one of the VH region of the VH and / or VL region sequence (i) and the VL region of (ii) that will be modified, i.e., the base VH and / or VL region sequence, already contains one of the above amino acid residues at a given position, then these cannot be modified because the respective amino acid residues are already present in the VH region and / or VL region of (i) and / or ii).
[0160] More preferably, the CD3ε-binding domain includes or consists of combinations of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 124 and 125, 362 and 363, 730 and 731, 928 and 929, 1106 and 1107, 1296 and 1297, 1474 and 1475, 1664 and 1665, and 1854 and 1855. Even more preferably, the CD3ε-binding domain includes or consists of combinations of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 124 and 125, 730 and 731, 1664 and 1665, and 1854 and 1855. In a more preferred embodiment, the CD3ε-binding domain includes or comprises a combination of VH and VL regions i) and ii) selected from the group consisting of SEQ ID NOs: 730 and 731, 1664 and 1665, and 1854 and 1855. Most preferred is that the CD3ε-binding domain includes or comprises a combination of VH and VL regions i) and ii) of SEQ ID NOs: 1854 and 1855, respectively.
[0161] As is evident from the Examples section, the amino acid residues listed above at a given position have a favorable effect on increasing the temperature stability measured by the well-known differential scanning fluorescence (DSF) method described herein; for example, when introduced into the VH and VL sequences listed above in i) and ii), see Wen et al., “Nano differential scanning fluorimetry for comparability studies of therapeutic proteins”, Analytical Biochemistry, Volume 593, 2020, 113581, ISSN 0003-2697; Dart, M Let al. (2018) “Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift”, ACS medical chemistry letters, 9(6), 546-551). More specifically, the amino acid residues at the given positions listed in sections i and iv show an increase in temperature stability of 6°C or more compared to the values measured for the unmodified sequences, i.e., each basic VH and VL sequence. Sections ii. and v. show an increase in temperature stability of 3°C or more compared to the values measured for the unmodified sequences, i.e., the respective basic VH and VL sequences, while sections iii. and vi. show an increase in temperature stability of 1°C or more compared to the values measured for the unmodified sequences, i.e., the respective basic VH and VL sequences.
[0162] Preferably, amino acid residues at given positions in sections i, ii, iv, and / or v are present in the CD3ε-binding domain according to this embodiment. More preferably, amino acid residues at given positions in sections i and / or iv are present in the CD3ε-binding domain according to the present invention. This preference also applies to the preferred embodiments listed below. As outlined herein, the VH and VL regions are also preferably linked by a linker, preferably a peptide linker, most preferably a G4S or G4Q linker, wherein the G4S or G4Q linker is repeated three times, i.e., a (G4S)3 or (G4Q)3 linker.
[0163] According to the present invention, the present invention comprises a polypeptide or polypeptide construct comprising a binding domain that binds to an extracellular epitope of a human CD3ε chain, which includes or consists of a VH region and a VL region. a) The VH region contains or consists of the sequence defined by sequence number 1854, and the VL region contains or consists of the sequence defined by sequence number 1855; the VH and / or VL region sequences are i. M34I, S65A, A81V, V99A, H101A, N106S in the VH region sequence (the VH sequence obtained as defined by sequence number 2012), and L20I, Q40K, L69S, and G102S in the VL region sequence (the VL sequence obtained as defined by sequence number 2013); L45M, S65A, A81L, H101A, N106T in the VH region sequence (sequence number 2036), and L20I, Q40K, L69S, and G102S in the VL region sequence (sequence number 2037); L45M, S65A, A81L, H101A, N106S, W112F in the VH region sequence (sequence number 2028), and L20I, V38I, Q40K, L69E, G102S, and W93Y in the VL region sequence (sequence number 2029); M34I, Q39E, S65A, H101N, G102A, N106T, W112F in the VH region sequence (sequence number 2044), and Q40K and G102S in the VL region sequence (sequence number 2045); M34I, D64E, S65A, V99A, H101A, N106T in the VH region sequence (sequence number 34), and Q40K, V91A, and G102S in the VL region sequence (sequence number 35); M34I, S65A, A81V, V99A, H101A, G102E, F104I, N106T in the VH region sequence (sequence number 90), and L20I, Q40K, L69S, and G102S in the VL region sequence (sequence number 91); D64E, S65A, D68G, A81V, H101A, N106S in the VH region sequence (sequence number 100), and L20I, L69S, G102S in the VL region sequence (sequence number 101); M34I, D64E, S65A, H101A, N106T, W112F in the VH region sequence (sequence number 58), and Q40K, V91A, and G102S in the VL region sequence (sequence number 59); M34I, D64E, S65A, H101A, N106S, W112F in the VH region sequence (sequence number 50), and Q40K, V91A, and G102S in the VL region sequence (sequence number 51); M34I, D64E, S65A, A81V, V99A, H101A, N106S in the VH region sequence (sequence number 98), and L20I, Q40K, L69S, G102S, and W93Y in the VL region sequence (sequence number 99); M34I, S65A, H101A, N106S, W112F in the VH region sequence (sequence number 42), and Q40K, V91A, and G102S in the VL region sequence (sequence number 43); L45M, D64E, S65A, A81L, H101A, N106T in the VH region sequence (sequence number 116), and L20I, V38I, Q40K, L69E, and G102S in the VL region sequence (sequence number 117); N30S, L45M, S65A, D68G, A81V, H101A, N106T, W112F in the VH region sequence (sequence number 82), Q40K, L69S and W93Y in the VL region sequence (sequence number 83); and N30S, L45M, D64E, S65A, D68G, A81V, H101A, N106S in the VH region sequence (sequence number 74), and Q40K and L69S in the VL region sequence (sequence number 75); ii. D64E, S65A, D68G, A81V, H101N, G102E, F104I, N106T in the VH region sequence (sequence number 2020), and L20I, L69S, and G102S in the VL region sequence (sequence number 2021); S65A, D68G, A81V, H101N, G102E, F104I, N106S in the VH region sequence (sequence number 108), and L20I, L69S, and G102S in the VL region sequence (sequence number 109); M34I, S65A, V99A, H101A, N106T in the VH region sequence (sequence number 26), Q40K, V91A and G102S in the VL region sequence (sequence number 27); and N30S, Q39E, D64E, S65A, A81V, H101A, G102E, F104I, N106T in the VH region sequence (sequence number 66), and L20M, Q40K, and L69E in the VL region sequence (sequence number 67); iii. H101A in the VH region sequence (sequence number 2560); iv. A81V, V99A in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; M34I, A81V in the VH region sequence (sequence number 1898), and L20I, Q40K, and G102S in the VL region sequence (sequence number 1899); M34I in the VH region sequence (sequence number 1904), L20I, Q40K, and G102S in the VL region sequence (1905); M34I, Q39E, A81V in the VH region sequence (sequence number 1906), and L20I, Q40K, and G102S in the VL region sequence (sequence number 1907); v. M34I and A81V in the VH region sequence (sequence number 1900) and Q40K in the VL region sequence (sequence number 1901); L45M in the VH region sequence (sequence number 1866), L20I, Q40K, and G102S in the VH region sequence (sequence number 1867); M34I, S65A, H101A, and N106S in the VH region sequence; L20I, Q40K, L69S, and G102S in the VL region sequence; M34F and A81V in the VH region sequence (sequence number 1884); L45M in the VH region sequence (sequence number 1870), Q40K and G102S in the VL region sequence (sequence number 1871); Q39D in the VH region sequence (sequence number 1918), L20I, Q40K, and G102S in the VL region sequence (sequence number 1919); M34I and A81V in the VH region sequence (sequence number 1869); Q39E in the VH region sequence (sequence number 1932), L20I, Q40K, and G102S in the VL region sequence (sequence number 1933); L45M in the VH region sequence (sequence number 1868) and Q40K in the Vl region sequence (sequence number 1869); M34I, S65A, A81V, V99A, H101A and N106S in the VH region sequence; or vi. Q39D in the VH region sequence (sequence number 1928), L20I, Q40R, and G102S in the VL region sequence (sequence number 1929); M34I in the VH region sequence (sequence number 1892); Q40K in the VL region sequence (sequence number 1974); Q39D in the VH region sequence (sequence number 1922), and Q40K and G102S in the VL region sequence (sequence number 1923); L20I and G102S in the VH region sequence; Q39K in the VH region sequence (sequence number 1944); Q39E in the VH region sequence (sequence number 1938), and Q40K and G102S in the VL region sequence (sequence number 1939); Q39E in the VH region sequence (sequence number 1934), and L20I, Q40R, and G102S in the VL region sequence (sequence number 1935); Q39D in the VH region sequence (sequence number 1926), and Q40R and G102S in the VL region sequence (sequence number 1926); A81V in the VH region sequence (sequence number 1862); Q39D in the VH region sequence (sequence number 1920) and Q40K in the VL region sequence (sequence number 1921); W112F in the VH region sequence (sequence number 1958); W112F in the VH region sequence (sequence number 1960) and V38I in the VL region sequence (sequence number 1961); Q39E in the VH region sequence (sequence number 1936) and Q40K in the VL region sequence (sequence number 1937); M34V in the VH region sequence (sequence number 1914) Includes amino acid substitutions selected from; b) The VH region contains or consists of the sequence defined by sequence number 730, and the VL region contains or consists of the sequence defined by sequence number 731; the VH and / or VL region sequences are i. M34I, S65A, A81V, V99A, H101A, N106S in the VH region sequence (the resulting VH sequence defined by sequence number 846), and L20I, Q40K, L69S, and G102S in the VL region sequence (the resulting VL sequence defined by sequence number 847); L45M, S65A, A81L, H101A, N106T in the VH region sequence (sequence number 870), and L20I, Q40K, L69S, and G102S in the VL region sequence (sequence number 871); L45M, S65A, A81L, H101A, N106S, W112F in the VH region sequence (sequence number 862), and L20I, V38I, Q40K, L69E, G102S, and W93Y in the VL region sequence (sequence number 863); M34I, Q39E, S65A, H101N, G102A, N106T, W112F in the VH region sequence (sequence number 878), and Q40K and G102S in the VL region sequence (sequence number 879); M34I, D64E, S65A, V99A, H101A, N106T in the VH region sequence, and Q40K, V91A, and G102S in the VL region sequence; M34I, S65A, A81V, V99A, H101A, G102E, F104I, N106T in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; D64E, S65A, A81V, H101A, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; M34I, D64E, S65A, H101A, N106T, W112F in the VH region sequence, and Q40K, V91A, and G102S in the VL region sequence; M34I, D64E, S65A, H101A, N106S, W112F in the VH region sequence, and Q40K, V91A, and G102S in the VL region sequence; M34I, D64E, S65A, A81V, V99A, H101A, N106S in the VH region sequence, and L20I, Q40K, L69S, G102S, and W93Y in the VL region sequence; M34I, S65A, H101A, N106S, W112F in the VH region sequence, and Q40K, V91A, and G102S in the VL region sequence; L45M, D64E, S65A, A81L, H101A, N106T in the VH region sequence, and L20I, V38I, Q40K, L69E, and G102S in the VL region sequence; N30S, L45M, S65A, A81V, H101A, N106T, W112F in the VH region sequence, and Q40K, L69S, and W93Y in the VL region sequence; and N30S, L45M, D64E, S65A, A81V, H101A, N106S in the VH region sequence, and Q40K and L69S in the VL region sequence; ii. D64E, S65A, A81V, H101N, G102E, F104I, N106T in the VH region sequence (sequence number 854), and L20I, L69S, and G102S in the VL region sequence (sequence number 855); S65A, A81V, H101N, G102E, F104I, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; M34I, S65A, V99A, H101A, N106T in the VH region sequence, and Q40K, V91A, and G102S in the VL region sequence; and N30S, Q39E, D64E, S65A, A81V, H101A, G102E, F104I, N106T in the VH region sequence, and L20M, Q40K, and L69E in the VL region sequence; iii. H101A in the VH region sequence; iv. A81V, V99A in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; M34I, A81V in the VH region sequence (sequence number 774), and L20I, Q40K, and G102S in the VL region sequence (sequence number 775); M34I in the VH region sequence (sequence number 780), L20I, Q40K, and G102S in the VL region sequence (781); M34I, Q39E, A81V in the VH region sequence (sequence number 782), and L20I, Q40K, and G102S in the VL region sequence (sequence number 783); v. M34I and A81V in the VH region sequence (sequence number 776) and Q40K in the VL region sequence (sequence number 777); L45M in the VH region sequence (sequence number 742), L20I, Q40K, and G102S in the VH region sequence (sequence number 743); M34I, S65A, H101A, and N106S in the VH region sequence; L20I, Q40K, L69S, and G102S in the VL region sequence; M34F and A81V in the VH region sequence (sequence number 760); L45M in the VH region sequence (sequence number 746), and Q40K and G102S in the VL region sequence (sequence number 747); Q39D in the VH region sequence (sequence number 794), and L20I, Q40K, and G102S in the VL region sequence (sequence number 795); M34I and A81V in the VH region sequence (sequence number 772); Q39E in the VH region sequence (sequence number 808), and L20I, Q40K, and G102S in the VL region sequence (sequence number 809); L45M in the VH region sequence (sequence number 744) and Q40K in the Vl region sequence (sequence number 745); M34I, S65A, A81V, V99A, H101A and N106S in the VH region sequence; or vi. Q39D in the VH region sequence (sequence number 796), and L20I, Q40R, and G102S in the VL region sequence (sequence number 797); M34I in the VH region sequence (sequence number 768); Q40K in the VL region sequence (sequence number 891); Q39D in the VH region sequence (sequence number 800), and Q40K and G102S in the VL region sequence (sequence number 801); L20I and G102S in the VH region sequence; Q39K in the VH region sequence (sequence number 820); Q39E in the VH region sequence (sequence number 814), and Q40K and G102S in the VL region sequence (sequence number 815); Q39E in the VH region sequence (sequence number 810), and L20I, Q40R, and G102S in the VL region sequence (sequence number 811); Q39D in the VH region sequence (sequence number 804), and Q40R and G102S in the VL region sequence (sequence number 805); A81V in the VH region sequence (sequence number 738); Q39D in the VH region sequence (sequence number 798) and Q40K in the VL region sequence (sequence number 799); W112F in the VH region sequence (sequence number 834); W112F in the VH region sequence (sequence number 836) and V38I in the VL region sequence (sequence number 837); Q39E in the VH region sequence (sequence number 812) and Q40K in the VL region sequence (sequence number 813); M34V in the VH region array (sequence number 790) Includes amino acid substitutions selected from; The VH region contains or consists of the sequence defined by sequence number 1664, and the VL region contains or consists of the sequence defined by sequence number 1665; the VH and / or VL region sequences are i. M34I, S65A, A81V, V99A, H101A, N106S in the VH region sequence (the resulting VH sequence defined by sequence number 1780), and L20I, Q40K, L69S, and G102S in the VL region sequence (the resulting VL sequence defined by sequence number 1781); L45M, S65A, A81L, H101A, N106T in the VH region sequence (sequence number 1804), and L20I, Q40K, L69S, and G102S in the VL region sequence (sequence number 1805); L45M, S65A, A81L, H101A, N106S, W112F in the VH region sequence (sequence number 1796), and L20I, V38I, Q40K, L69E, G102S, and W93Y in the VL region sequence (sequence number 1797); M34I, Q39E, S65A, H101N, G102A, N106T, W112F in the VH region sequence (sequence number 1812), and Q40K and G102S in the VL region sequence (sequence number 1813); M34I, D64E, S65A, V99A, H101A, N106T in the VH region sequence, and Q40K and G102S in the VL region sequence; M34I, S65A, A81V, V99A, H101A, G102E, F104I, N106T in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; D64E, S65A, D68G, A81V, H101A, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; M34I, D64E, S65A, H101A, N106T, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; M34I, D64E, S65A, H101A, N106S, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; M34I, D64E, S65A, A81V, V99A, H101A, N106S in the VH region sequence, and L20I, Q40K, L69S, G102S, and W93Y in the VL region sequence; M34I, S65A, H101A, N106S, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; L45M, D64E, S65A, A81L, H101A, N106T in the VH region sequence, and L20I, V38I, Q40K, L69E, and G102S in the VL region sequence; N30S, L45M, S65A, D68G, A81V, H101A, N106T, W112F in the VH region sequence, and Q40K, L69S, and W93Y in the VL region sequence; and N30S, L45M, D64E, S65A, D68G, A81V, H101A, N106S in the VH region sequence, and Q40K and L69S in the VL region sequence; ii. D64E, S65A, D68G, A81V, H101N, G102E, F104I, N106T in the VH region sequence (sequence number 1788), and L20I, L69S, and G102S in the VL region sequence (sequence number 1789); S65A, D68G, A81V, H101N, G102E, F104I, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; M34I, S65A, V99A, H101A, N106T in the VH region sequence, and Q40K and G102S in the VL region sequence; and N30S, Q39E, D64E, S65A, A81V, H101A, G102E, F104I, N106T in the VH region sequence, and L20M, Q40K, and L69E in the VL region sequence; iii. H101A in the VH region sequence; iv. A81V, V99A in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; M34I, A81V in the VH region sequence (sequence number 1708), and L20I, Q40K, and G102S in the VL region sequence (sequence number 1709); M34I in the VH region sequence (sequence number 1714), L20I, Q40K, and G102S in the VL region sequence (1715); M34I, Q39E, A81V in the VH region sequence (sequence number 1716), and L20I, Q40K, and G102S in the VL region sequence (sequence number 1717); v. M34I and A81V in the VH region sequence (sequence number 1710) and Q40K in the VL region sequence (sequence number 1711); L45M in the VH region sequence (sequence number 1676), L20I, Q40K, and G102S in the VH region sequence (sequence number 1677); M34I, S65A, H101A, and N106S in the VH region sequence; L20I, Q40K, L69S, and G102S in the VL region sequence; M34F and A81V in the VH region sequence (sequence number 1694); L45M in the VH region sequence (sequence number 1680), Q40K and G102S in the VL region sequence (sequence number 1681); Q39D in the VH region sequence (sequence number 1728), L20I, Q40K, and G102S in the VL region sequence (sequence number 1729); M34I and A81V in the VH region sequence (sequence number 1706); Q39E in the VH region sequence (sequence number 1742), and L20I, Q40K, and G102S in the VL region sequence (sequence number 1743); L45M in the VH region sequence (sequence number 1678) and Q40K in the Vl region sequence (sequence number 1679); M34I, S65A, A81V, V99A, H101A and N106S in the VH region sequence; or vi. Q39D in the VH region sequence (sequence number 1730), and L20I, Q40R, and G102S in the VL region sequence (sequence number 1731); M34I in the VH region sequence (sequence number 1702); Q40K in the VL region sequence (sequence number 1755); Q39D in the VH region sequence (sequence number 1734), and Q40K and G102S in the VL region sequence (sequence number 1735); L20I and G102S in the VH region sequence; Q39K in the VH region sequence (sequence number 1754); Q39E in the VH region sequence (sequence number 1748), and Q40K and G102S in the VL region sequence (sequence number 1749); Q39E in the VH region sequence (sequence number 1744), and L20I, Q40R, and G102S in the VL region sequence (sequence number 1745); Q39D in the VH region sequence (sequence number 1738), and Q40R and G102S in the VL region sequence (sequence number 1739); A81V in the VH region sequence (sequence number 1672); Q39D in the VH region sequence (sequence number 1732) and Q40K in the VL region sequence (sequence number 1733); W112F in the VH region sequence (sequence number 1768); W112F in the VH region sequence (sequence number 1770) and V38I in the VL region sequence (sequence number 1771); Q39E in the VH region sequence (sequence number 1746) and Q40K in the VL region sequence (sequence number 1747); M34V in the VH region sequence (sequence number 1724) Includes amino acid substitutions selected from; or d) The VH region contains or consists of the sequence defined by sequence number 124, and the VL region contains or consists of the sequence defined by sequence number 125; the VH and / or VL region sequences are i. Q65A, A81V, V99A, H101A, N106S in the VH region sequence (the resulting VH sequence defined by sequence number 132), and L20I, Q40K, L69S, and G102S in the VL region sequence (the resulting VL sequence defined by sequence number 133); L45M, Q65A, A81L, H101A, N106T in the VH region sequence (sequence number 156), and L20I, Q40K, L69S, and G102S in the VL region sequence (sequence number 157); L45M, Q65A, A81L, H101A, N106S, W112F in the VH region sequence (sequence number 148), and L20I, V38I, Q40K, L69E, G102S, and W93Y in the VL region sequence (sequence number 149); Q39E, Q65A, H101N, N106T, W112F in the VH region sequence (sequence number 164), and Q40K and G102S in the VL region sequence (sequence number 165); D64E, Q65A, V99A, H101A, N106T in the VH region sequence, and Q40K, T91A, and G102S in the VL region sequence; Q65A, A81V, V99A, H101A, A102E, F104I, N106T in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; D64E, Q65A, D68G, A81V, H101A, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; D64E, Q65A, H101A, N106T, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; D64E, Q65A, H101A, N106S, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; D64E, Q65A, A81V, V99A, H101A, N106S in the VH region sequence, and L20I, Q40K, L69S, G102S, and W93Y in the VL region sequence; Q65A, H101A, N106S, W112F in the VH region sequence, and Q40K and G102S in the VL region sequence; L45M, D64E, Q65A, A81L, H101A, N106T in the VH region sequence, and L20I, V38I, Q40K, L69E, and G102S in the VL region sequence; N30S, L45M, Q65A, D68G, A81V, H101A, N106T, W112F in the VH region sequence, and Q40K, L69S, and W93Y in the VL region sequence; and N30S, L45M, D64E, Q65A, D68G, A81V, H101A, N106S in the VH region sequence, and Q40K and L69S in the VL region sequence; ii. D64E, Q65A, D68G, A81V, H101N, A102E, F104I, N106T in the VH region sequence (sequence number 140), and L20I, L69S, and G102S in the VL region sequence (sequence number 141); Q65A, D68G, A81V, H101N, A102E, F104I, N106S in the VH region sequence, and L20I, L69S, G102S in the VL region sequence; Q65A, V99A, H101A, N106T in the VH region sequence, and Q40K and G102S in the VL region sequence; and N30S, Q39E, D64E, Q65A, A81V, H101A, A102E, F104I, N106T in the VH region sequence, and L20M, Q40K, and L69E in the VL region sequence; iii. H101A in the VH region sequence; iv. A81V, V99A in the VH region sequence, and L20I, Q40K, L69S, and G102S in the VL region sequence; A81V in the VH region sequence, and L20I, Q40K, and G102S in the VL region sequence; L20I, Q40K, and G102S in the VL region sequence; Q39E, A81V in the VH region sequence, and L20I, Q40K, and G102S in the VL region sequence; v. A81V in the VH region sequence and Q40K in the VL region sequence; L45M, L20I, Q40K, and G102S in the VH region sequence; Q65A, H101A, and N106S in the VH region sequence; L20I, Q40K, L69S, and G102S in the VL region sequence; I34F and A81V in the VH region sequence; L45M in the VH region sequence, and Q40K and G102S in the VL region sequence; Q39D in the VH region sequence, and L20I, Q40K, and G102S in the VL region sequence; Q39E in the VH region sequence, and L20I, Q40K, and G102S in the VL region sequence; L45M in the VH region sequence and Q40K in the VL region sequence; Q65A, A81V, V99A, H101A and N106S in the VH region sequence; or vi. Q39D in the VH region sequence, L20I, Q40R, and G102S in the VL region sequence; Q40K in the VL region sequence; Q39D in the VH region sequence, and Q40K and G102S in the VL region sequence; L20I and G102S in the VH region sequence; Q39K in the VH region sequence; Q39E in the VH region sequence, and Q40K and G102S in the VL region sequence; Q39E in the VH region sequence, and L20I, Q40R, and G102S in the VL region sequence; Q39D in the VH region sequence, and Q40R and G102S in the VL region sequence; A81V in the VH region array; Q39D in the VH region sequence and Q40K in the VL region sequence; W112F in the VH region sequence; W112F in the VH region sequence and V38I in the VL region sequence; Q39E in the VH region sequence and Q40K in the VL region sequence; M34V in the VH region array The present invention relates to polypeptides or polypeptide constructs comprising amino acid substitutions selected from the following.
[0164] The CD3ε-binding domains of the polypeptide or polypeptide construct of the present invention are preferably the options a) to c) listed above, with option a) being more preferred. The preferred linkers mentioned above, namely (G4S)3 or G4Q)3, are also preferred in this embodiment.
[0165] According to the present invention, the polypeptide or polypeptide construct of the present invention may have linkers, half-life extension peptides and other structural parts disclosed in SEQ ID NOs: 1-19 and 2551. Details regarding the properties and functions of these structures can be found in the sequence listing disclosed herein.
[0166] The present invention provides embodiments in which the polypeptide construct is in a form selected from the group consisting of scFv, (scFv)2 (inso that a further binding domain is present), a diabody, and any oligomer of the above forms. The term “is in a form” does not preclude that the construct may be further modified by binding or fusion to other parts, for example, as described herein. According to one embodiment of the polypeptide construct of the present invention, the domain containing the paratope described herein is in the form of scFv. In scFv, the VH region and the VL region are arranged in the order VH-VL or VL-VH (from N-terminus to C-terminus). The VH region and the VL region of the domain are assumed to be connected via a linker, preferably a peptide linker. In a preferred embodiment, the peptide linker is a G4S or G4Q linker or a repeat thereof, for example, preferably (G4S)3 (i.e., three repeats of G4S) or (G4Q)3 (i.e., three repeats of G4Q). According to one embodiment of a binding domain containing VH and VL regions as described herein, the VH region is located at the N-terminus of the linker and the VL region is located at the C-terminus of the linker. In other words, in one embodiment of a paratope-containing domain as described herein, scFv contains VH-linker-VL from the N-terminus to the C-terminus. If the polypeptide or polypeptide construct contains at least one further binding domain in addition to the CD3ε binding domain, it is further assumed that the binding domain of the construct (including the paratope as described herein) is linked via a linker, preferably a peptide linker. The construct may contain, for example, domains in the order of CD3 binding domain-linker-further binding domain (from the N-terminus to the C-terminus). The reverse order (further binding domain-linker-CD3 binding domain) is also possible and preferred orientation.
[0167] The linker is preferably a peptide linker, and more preferably a short-chain peptide linker. According to the present invention, a “peptide linker” includes an amino acid sequence that links the amino acid sequence of one domain of the construct to the other (variable and / or binding) domain (e.g., the variable domain or the binding domain). An essential technical feature of such peptide linkers is that they are free from polymerization activity. Suitable peptide linkers are those described in U.S. Patent Nos. 4,751,180 and 4,935,233 or International Publication No. 88 / 09344. Peptide linkers can also be used to link other domains, modules, or regions (such as half-life extension domains) to the construct of the present invention. Examples of useful peptide linkers are shown in Sequence IDs 1-11 and 2551. In this regard, a “short” linker has 2-50 amino acids, preferably 3-35, 4-30, 5-25, 6-20, or 6-17 amino acids. The linker between two variable regions of a single binding domain may have a different length (e.g., longer) than the linker between two binding domains. For example, the linker between two variable regions of a single binding domain may have a length of 7 to 15 amino acids, preferably 9 to 13, while the linker between two binding domains may have a length of 3 to 10 amino acids, preferably 4 to 8. Furthermore, the peptide linker is assumed to be a glycine / serine linker, such as those shown in SEQ ID NOs: 1 to 11 and 2551. Most of the amino acids in the glycine / serine linker are selected from glycine and serine.
[0168] When a linker is used, it is preferable that the linker has a length and sequence that ensures each of the first and second domains independently maintains its different binding specificity. For peptide linkers that connect at least two binding domains (or two variable regions forming one binding domain) in a construct, peptide linkers containing only a small number of amino acid residues, for example, 12 amino acid residues or less, are envisioned. Therefore, peptide linkers with 12, 11, 10, 9, 8, 7, 6, or 5 amino acid residues are preferred. For peptide linkers envisioned to have fewer than 5 amino acids, 4, 3, 2, or 1 amino acid are preferred, and glycy-rich linkers are preferred. In relation to the "peptide linker," a "single amino acid" linker is glycy. Another embodiment of the peptide linker is characterized by the amino acid sequence Gly-Gly-Gly-Gly-Ser, i.e., Gly4Ser (SEQ ID NO: 15), or a polymer thereof, i.e., (Gly4Ser)x, where x is an integer of 1 or more (e.g., 2 or 3), e.g., SEQ ID NOs: 1 and 2. Preferred linkers are shown in SEQ ID NOs: 2, 4, 5, 6, 8, 10, 11, and 2551. Other preferred linkers include or consist of (Gly4Ser)6. The characteristics of the peptide linkers are known in the art and are described, for example, in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273), Cheadle et al. (Mol Immunol (1992) 29, 21-30), and Raag and Whitlow (FASEB (1995) 9(1), 73-80). Peptide linkers that do not promote secondary structure are preferred. The linkage of the aforementioned domains can be provided, for example, by genetic engineering.Methods for preparing fused and operably linked bispecific single-stranded constructs and expressing them in mammalian cells or bacteria are known in the art (e.g., International Publication No. 99 / 54440 or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). More preferably, the peptide linker is a G4S or G4Q linker or a repeat thereof, for example, (G4S)3 or (G4Q)3.
[0169] According to one embodiment of the present invention, the polypeptide construct of the present invention is a “single-chain construct” or “single-chain polypeptide.” In the case of a further binding domain, it is also conceivable that either or both of the CD3 binding domain or the further binding domain (also called “second”) may be in the form of a “single-chain Fv” (scFv). The two domains of the Fv fragment, VL and VH, are encoded by separate genes, but they can be linked by an artificial linker (as described above herein) which allows them to be constructed using recombination so that the VL and VH regions pair up to form a monovalent molecule (see, for example, Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883). These antibody fragments are obtained using prior art known to those skilled in the art, and the fragments are evaluated for function in the same manner as full-length antibodies or IgG. Therefore, a single-chain variable fragment (scFv) is a fusion protein of the variable region (VH) of the heavy chain and the variable region (VL) of the light chain of an immunoglobulin, usually linked by a short linker peptide. The linker is typically rich in glycine for flexibility and rich in serine or even threonine for solubility, and can ligate the N-terminus of VH to the C-terminus of VL or vice versa. This protein retains the specificity of the original immunoglobulin despite the removal of the constant region and the introduction of a linker.
[0170] Bispecific single-chain molecules are known in the art and are described in International Publication No. 99 / 54440, Mack, J. Immunol. (1997), 158, 3965-3970, Mack, PNAS, (1995), 92, 7021-7025, Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197, Loeffler, Blood, (2000), 95, 6, 2098-2103, Bruehl, Immunol., (2001), 166, 2420-2426, and Kipriyanov, J. Mol. Biol., (1999), 293, 41-56. The techniques described for producing single-chain constructs (see, in particular, U.S. Patent No. 4,946,778, Kontermann and Duebel (2010), cited above, and Little (2009), cited above) can be adapted to produce single-chain constructs that selectively, preferably specifically, recognize a selected target.
[0171] Bivalent (also called divalent) or bispecific single-stranded variable fragments (bi-scFv or di-scFv) having the (scFv)2 form can be modified by linking two scFv molecules (e.g., by a linker as described above). Linking can be done by creating a single polypeptide chain having two VH regions and two VL regions to produce a tandem scFv (see, for example, Kufer, P. et al., (2004) Trends in Biotechnology 22(5):238-244). Another possibility is to create an scFv molecule with a linker peptide (e.g., about 5 amino acids) that is too short for the two variable regions to fold together, thereby forcing the scFv to dimerize. In this case, the VH and VL of the binding domain (which binds to either CD3ε or a further target antigen) are not directly linked via a peptide linker. Therefore, the VH of the CD3 antigen-binding domain can, for example, fuse to the VL of a further target antigen-binding domain via a peptide linker, and the VH of the further target antigen-binding domain is fused to the VL of the CD3-binding domain via such a peptide linker. This type is known as a diabody (see, for example, Hollinger, Philipp et al., (July 1993) Proceedings of the National Academy of Sciences of the United States of America 90(14):6444-8).
[0172] In accordance with the present invention, the polypeptide or polypeptide construct of the present invention comprises at least one further binding domain. In other words, the polypeptide or polypeptide construct comprises a CD3ε binding domain as defined herein and at least one further binding domain. The further binding domain may be a further CD3 binding domain, preferably as defined herein. Thus, the polypeptide may contain two of the same CD3 binding domains as defined herein. Alternatively or additionally (in a construct comprising at least three binding domains), at least one further binding domain binds to a different target, such as a cell surface antigen.
[0173] Preferably, the at least one additional binding domain binds to a cell surface antigen. As used herein, the term “cell surface antigen” refers to a molecule presented on the surface of a cell. In most cases, the molecule is located inside or on the cell’s plasma membrane such that at least a portion of it remains accessible from outside the cell in its tertiary form. A non-limiting example of a cell surface molecule located inside the plasma membrane is a transmembrane protein that contains hydrophilic and hydrophobic regions in its tertiary conformation. Here, at least one hydrophobic region allows the cell surface molecule to be embedded in or inserted into the cell’s hydrophobic plasma membrane, while the hydrophilic region extends into the cytoplasm and extracellular space on either side of the plasma membrane, respectively. It will be understood that an extracellular epitope refers to an epitope composed of a portion of a protein located in extracellular space, for example, a portion of a cell surface molecule extending into extracellular space if the cell surface molecule is a native configuration located, embedded in, or inserted into the plasma membrane. Non-exclusive examples of cell surface molecules located on the plasma membrane include proteins modified with cysteine residues to have a palmitoyl group, proteins modified with C-terminal cysteine residues to have a farnesyl group, or proteins modified at the C-terminus to have a glycosylphosphatidylinositol ("GPI") anchor.
[0174] The cell surface antigens are preferably tumor antigens. As used herein, the term “tumor antigen” may be understood as those antigens presented on tumor cells. These antigens may be presented on the cell surface along with their extracellular components, often comprising both transmembrane and cytoplasmic portions of the molecule. These antigens may, in some cases, be presented only by tumor cells and never by normal cells. Tumor antigens may be expressed exclusively on tumor cells or may exhibit tumor-specific mutations compared to normal cells. In this case, they are called tumor-specific antigens. More general antigens are those presented by both tumor cells and normal cells, and these are called tumor-associated antigens. These tumor-associated antigens may be overexpressed compared to normal cells or, due to the less compact structure of tumor tissue compared to normal tissue, may be accessible to tumor cells for antibody binding.
[0175] In preferred embodiments, the tumor antigens include BCMA (B cell maturation antigen), CD123 (interleukin-3 receptor alpha chain (IL-3R)), CD19 (B lymphocyte antigen CD19), CD20 (B lymphocyte antigen CD20), CD22 (differentiation cluster-22), CD33 (Siglec-3), CD70 (differentiation cluster 70), CDH19 (cadherin 19), CDH3 (cadherin 3), CLL1 (C-type lectin domain family 12 member A), and CS1 (CCND3 subset 1). The group selected consists of ), CLDN6 (Claudin-6), CLDN18.2 (Claudin-18.2), DLL3 (Delta-like ligand 3), EGFRvIII (Epidermal growth factor receptor vIII), FLT3 (fms-like kinase 3), MAGEB2 (Melanoma-associated antigen B2), MART1 (Melanoma antigen 1 recognized by T cells), MSLN (Mesothelin), MUC17 (Mucin-17), PSMA (Prostate-specific membrane antigen), and STEAP1 (Metalloreductase STEAP1). These tumor antigens are well known in the art due to their expression on tumor cells.
[0176] Preferred CDR sequences and VH / VL region sequences for the BCMA binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as the bispecific single-stranded molecular sequences (with and without the half-life extension domain) of the polypeptide or polypeptide construct of the present invention having the BCMA binding domain as a further binding domain, are defined in Sequence IDs 02072 to 02095.
[0177] Preferred CDR sequences and VH / VL region sequences for the CD123 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD123 binding domain as a further binding domain, are defined in Sequence IDs 2096 to 2110.
[0178] Preferred CDR sequences and VH / VL region sequences for the CD19 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD19 binding domain as a further binding domain, are defined in Sequence IDs 2111 to 2125.
[0179] Preferred CDR sequences and VH / VL region sequences for the CD20 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD20 binding domain as a further binding domain, are defined in Sequence IDs 2126 to 2140.
[0180] Preferred CDR sequences and VH / VL region sequences for the CD22 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD22 binding domain as a further binding domain, are defined in Sequence IDs 2141 to 2154.
[0181] Preferred CDR sequences and VH / VL region sequences for the CD33 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD33 binding domain as a further binding domain, are defined in SEQ ID NOs: 2155-2178.
[0182] Preferred CDR sequences and VH / VL region sequences for the CD70 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CD70 binding domain as a further binding domain, are defined in Sequence IDs 2179 to 2192.
[0183] Preferred CDR sequences and VH / VL region sequences for the CDH19 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CDH19 binding domain as a further binding domain, are defined in Sequence IDs 2193 to 2212.
[0184] Preferred CDR sequences and VH / VL region sequences for the CDH3 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as the bispecific single-stranded molecular sequences (with and without the half-life extension domain) of the polypeptide or polypeptide construct of the present invention having the CDH3 binding domain as a further binding domain, are defined in Sequence IDs 2213 to 2256.
[0185] Preferred CDR sequences and VH / VL region sequences for the CLL1 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CLL1 binding domain as a further binding domain, are defined in Sequence IDs 2257 to 2271.
[0186] Preferred CDR sequences and VH / VL region sequences for the CS1 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CS1 binding domain as a further binding domain, are defined in Sequence IDs 2272 to 2285.
[0187] Preferred CDR sequences and VH / VL region sequences for the CLDN6 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the CLDN6 binding domain as a further binding domain, are defined in Sequence IDs 2286 to 2299.
[0188] Preferred CDR sequences and VH / VL region sequences for the CLDN18.2 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct according to the present invention having the CLDN18.2 binding domain as a further binding domain, are defined in SEQ ID NOs: 2300-2314.
[0189] Preferred CDR sequences and VH / VL region sequences for the DLL3 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-chain molecular sequences (with and without half-life extension domains) of polypeptides or polypeptide constructs according to the present invention having the DLL3 binding domain as a further binding domain, are defined by SEQ ID NOs: 2315-2328.
[0190] Preferred CDR sequences and VH / VL region sequences for the EGFRvIII binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-chain molecular sequences (with and without half-life extension domains) of polypeptides or polypeptide constructs according to the present invention having the EGFRvIII binding domain as a further binding domain, are defined by Sequence IDs 2329 to 2342.
[0191] Preferred CDR sequences and VH / VL region sequences for the FLT3 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-chain molecular sequences (with and without half-life extension domains) of polypeptides or polypeptide constructs according to the present invention having the FLT3 binding domain as a further binding domain, are defined by SEQ ID NOs: 2343 to 2357.
[0192] Preferred CDR sequences and VH / VL region sequences for the MAGEB2 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the MAGEB2 binding domain as a further binding domain, are defined in Sequence IDs 2358 to 2378.
[0193] Preferred CDR sequences and VH / VL region sequences for the MART1 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention are defined in SEQ ID NOs: 2379-2387.
[0194] Preferred CDR sequences and VH / VL region sequences for the MSLN-binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-chain molecular sequences (with and without half-life extension domains) of polypeptides or polypeptide constructs according to the present invention having an MSLN-binding domain as a further binding domain, are defined by SEQ ID NOs: 2388-2431.
[0195] Preferred CDR sequences and VH / VL region sequences for the MUC17 binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, as well as bispecific single-chain molecular sequences (with and without half-life extension domains) of polypeptides or polypeptide constructs according to the present invention having the MUC17 binding domain as a further binding domain, are defined by SEQ ID NOs: 2432-2445.
[0196] Preferred CDR sequences and VH / VL region sequences for the PSMA-binding domain as a further binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-stranded molecular sequences (with and without half-life extension domains) of the polypeptide or polypeptide construct of the present invention having the PSMA-binding domain as a further binding domain, are defined by SEQ ID NOs: 2446-2475.
[0197] Preferred bispecific single-stranded molecular sequences of polypeptides or polypeptide constructs according to the present invention having CD20 and CD22 binding domains (with and without further CD3 binding domains as defined herein) and half-life extension domains are defined by SEQ ID NOs: 2505-2516.
[0198] Preferred bispecific single-stranded molecular sequences of the polypeptide or polypeptide construct according to the present invention, having CS1 and BCMA binding domains as further binding domains and a half-life extension domain, are defined by Sequence IDs 2517 to 2522.
[0199] Preferred bispecific single-stranded molecular sequences of the polypeptide or polypeptide construct according to the present invention, having MSLN and CDH3 binding domains as further binding domains and a half-life extension domain, are defined by SEQ ID NOs: 2529-2536.
[0200] As described herein, the polypeptide constructs of the present invention include a binding domain that binds to CD3 on the surface of T cells. "CD3" (differentiation cluster 3) is a T cell coreceptor composed of four chains. In mammals, the CD3 protein complex contains a CD3γ (gamma) chain, a CD3δ (delta) chain, and two CD3ε (epsilon) chains. These four chains associate with the T cell receptor (TCR) and the so-called ζ (zeta) chain to form the "T cell receptor complex," which generates an activation signal in T lymphocytes. The CD3γ (gamma), CD3δ (delta), and CD3ε (epsilon) chains are highly related cell surface proteins of the immunoglobulin superfamily, each containing a single extracellular immunoglobulin domain. The intracellular tail of the CD3 molecule contains a single conserved motif known as the immunoreceptor tyrosine activation motif (ITAM), which is essential for the signaling ability of the TCR. The CD3ε molecule is a polypeptide encoded by the CD3ε gene located on human chromosome 11. In relation to the present invention, CD3 is understood as a protein complex and T cell coreceptor involved in the activation of both cytotoxic T cells (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). CD3 is typically composed of four distinct chains. In mammals in particular, this complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T cell receptor (TCR) and the ζ chain (zeta chain) to produce an activation signal in T lymphocytes. The TCR, ζ chain, and CD3 molecules together constitute the TCR complex.
[0201] Lysis of target cells redirected via T cell recruitment by constructs that bind CD3 on T cells and target proteins on target cells generally involves cytolytic synapse formation and delivery of perforins and granzymes. The associated T cells possess a range of target cell lytic capabilities and are unaffected by immune escape mechanisms that prevent peptide antigen processing and presentation or clonal T cell differentiation; see, for example, International Publication No. 2007 / 042261.
[0202] Cytotoxicity mediated by a given tumor antigen × CD3 construct can be measured in various ways. The "maximum half-volume effective concentration" (EC50) is commonly used as a measure of the potency of biologically active molecules, such as the constructs of the present invention. This can be expressed in molar units. In this case, when measuring cytotoxicity, the EC50 value refers to the concentration of the construct that induces an intermediate cytotoxic response (lysation of target cells) between baseline and maximum. Effector cells in a cytotoxicity assay may be, for example, stimulated enriched (human) CD8-positive T cells or unstimulated (human) peripheral blood mononuclear cells (PBMCs). Typically, the EC50 value can be expected to be lower when stimulated / enriched CD8+ T cells are used as effector cells compared to unstimulated PBMCs. If the target cells are of macaque origin or transfected with a given macaque tumor antigen, the effector cells may also be of macaque origin, such as a macaque T cell line, e.g., 4119LnPx. The target cells express the tumor antigen on their cell surface. The target cells may be cell lines (such as CHOs) that have been stably or transiently transfected with the tumor antigen. Alternatively, the target cells may be tumor antigen-positive naturally expressing cell lines, such as human cancer cells. Typically, the EC50 value is expected to be lower when using target cells that express higher levels of the tumor antigen on their cell surface compared to target cells with lower target expression rates.
[0203] The effector-to-target cell (E:T) ratio in cytotoxic assays is typically around 10:1, but can vary. The cytotoxic activity of tumor antigen × CD3 constructs can be measured using a 51-chromium release assay (e.g., using an incubation time of approximately 18 hours) or a FACS-based cytotoxic assay (e.g., using an incubation time of approximately 48 hours). Modification of incubation time (cytotoxic response) is also possible. Other well-known methods for measuring cytotoxicity include MTT or MTS assays, ATP-based assays including bioluminescence assays, sulforhodamine B (SRB) assays, WST assays, clonality assays, and ECIS technology.
[0204] According to one embodiment, the cytotoxic activity mediated by the tumor antigen × CD3 construct of the present invention is measured in a cell-based cytotoxic assay. This can also be measured in a 51-chromium release assay. The EC50 values of the construct of the present invention are expected to be ≤300 pM, ≤280 pM, ≤260 pM, ≤250 pM, ≤240 pM, ≤220 pM, ≤200 pM, ≤180 pM, ≤160 pM, ≤150 pM, ≤140 pM, ≤120 pM, ≤100 pM, ≤90 pM, ≤80 pM, ≤70 pM, ≤60 pM, ≤50 pM, ≤40 pM, ≤30 pM, ≤20 pM, ≤15 pM, ≤10 pM, or ≤5 pM.
[0205] The given EC50 values described above can be measured under different conditions in different assays. For example, when human PBMCs are used as effector cells and tumor antigen transfected cells such as CHO cells are used as target cells, the EC50 values of the tumor antigen × CD3 construct are expected to be ≤500 pM, ≤400 pM, ≤300 pM, ≤280 pM, ≤260 pM, ≤250 pM, ≤240 pM, ≤220 pM, ≤200 pM, ≤180 pM, ≤160 pM, ≤150 pM, ≤140 pM, ≤120 pM, ≤100 pM, ≤90 pM, ≤80 pM, ≤70 pM, ≤60 pM, ≤50 pM, ≤40 pM, ≤30 pM, ≤20 pM, ≤15 pM, ≤10 pM, or ≤5 pM. When human PBMCs are used as effector cells, and therefore the target cells are CLDN6-positive cell lines, the EC50 values of the CLDN6×CD3 construct are expected to be ≤300 pM, ≤280 pM, ≤260 pM, ≤250 pM, ≤240 pM, ≤220 pM, ≤200 pM, ≤180 pM, ≤160 pM, ≤150 pM, ≤140 pM, ≤120 pM, ≤100 pM, ≤90 pM, ≤80 pM, ≤70 pM, ≤60 pM, ≤50 pM, ≤40 pM, ≤30 pM, ≤20 pM, ≤15 pM, ≤10 pM, or ≤5 pM.
[0206] According to one embodiment, the tumor antigen × CD3 polypeptide / polypeptide construct of the present invention does not induce / intervene in lysis, or essentially does not induce / intervene in the lysis of cells that do not express the given tumor antigen on the surface of cells such as CHO cells (tumor antigen-negative cells). The terms “does not induce lysis,” “essentially does not induce lysis,” “does not intervene in lysis,” or “essentially does not intervene in lysis” mean that the construct of the present invention does not induce or intervene in the lysis of more than 30%, preferably 20% or less, more preferably 10% or less, particularly preferably 9%, 8%, 7%, 6%, or 5% or less of tumor antigen-negative cells, thereby setting the lysis of tumor antigen-expressing target cells (cells transformed or transfected with the tumor antigen or naturally expressing cell lines such as human cancer lines) to 100%. This typically applies to construct concentrations up to 500 nM. Cell lysis measurement is a routine technique. Furthermore, this specification provides specific instructions for methods of measuring cell lysis.
[0207] The difference in cytotoxic activity between the monomeric and dimeric isoforms of individual tumor antigen × CD3 polypeptide / polypeptide constructs is referred to as the "potency gap." This potency gap can be calculated, for example, as the ratio between the EC50 value of the monomeric form of the molecule and the EC50 value of the dimeric form. One method for determining this gap is to perform an 18-hour 51-chromium release assay or a 48-hour FACS-based cytotoxicity assay using the monomeric and dimeric forms of the purified construct, as described later. Effector cells are stimulated enriched human CD8+ T cells or unstimulated human PBMCs. Target cells are CHO cells transfected with human tumor antigens. The effector-to-target cell (E:T) ratio is 10:1. The potency gap of the tumor antigen × CD3 constructs of the present invention is preferably 5 or less, more preferably 4 or less, even more preferably 3 or less, even more preferably 2 or less, and most preferably 1 or less.
[0208] The binding domain of the polypeptide construct of the present invention is preferably cross-species specific to members of the order Mammalia, such as macaques. According to one embodiment, in addition to binding to human tumor antigens, a further binding domain would also bind to the aforementioned tumor antigens of primates, including (but not limited to) New World primates (such as common marmosets (Callithrix jacchus), cotton-top tamarins (Saguinus Oedipus), or squirrel monkeys (Saimiri sciureus)), Old World primates (such as baboons and macaques), gibbons, orangutans, and non-human Hominidae. The domain of the present invention that binds to human CD3 on the surface of T cells is expected to bind to at least macaque CD3. A preferred macaque is the cynomolgus macaque (Macaca fascicularis). Rhesus macaques (Macaca mulatta) are also considered. The polypeptide or polypeptide construct of the present invention comprises a domain that binds to human CD3 epsilon and at least macaque CD3 on the surface of T cells.
[0209] In one embodiment, the affinity gap of the construct according to the present invention for binding human CD3 to macaque CD3 (as determined, for example, by BiaCore or scatchard analysis) [KD ma CD3:KD hu CD3] is 0.01 to 100, preferably 0.1 to 10, more preferably 0.2 to 5, more preferably 0.3 to 4, even more preferably 0.5 to 3 or 0.5 to 2.5, and most preferably 0.5 to 1.
[0210] As previously detailed herein, the binding domain of the polypeptide or polypeptide construct of the present invention binds to human CD3 epsilon (or human CD3 epsilon on the surface of T cells), preferably to CD3 epsilon of marmoset (Callithrix jacchus) or squirrel monkey (Saimiri sciureus). More specifically, the domain binds to the extracellular epitope of human CD3ε. It is also conceivable that the domain binds to the extracellular epitope of human and the macaque CD3ε chain. The extracellular epitope of CD3 epsilon is contained within amino acid residues 1-27 of the extracellular domain of human CD3 epsilon (see amino acid residues 1-27 of SEQ ID NO: 2552; SEQ ID NO: 2553). More specifically, the epitope contains at least the amino acid sequence Gln-Asp-Gly-Asn-Glu. The marmoset (Callithrix jacchus) is a New World primate belonging to the family Callitrichidae, while the squirrel monkey (Saimiri sciureus) is a New World primate belonging to the family Cebidae.
[0211] In preferred embodiments, the polypeptide or polypeptide construct of the present invention is a single-stranded polypeptide that is at least bispecific. In these embodiments, the CD3-binding domain according to the present invention is preferably present as an scFv in the polypeptide or polypeptide construct.
[0212] In addition to its function of binding to CD3, the polypeptide constructs of the present invention are also envisioned to have, in certain embodiments, further functions of binding to at least a further binding domain. In this form, the constructs may be triplicate or multifunctional constructs by providing further functions such as targeting target cells, preferably through tumor antigen binding, mediating cytotoxic T cell activity through CD3 binding and enhancing or prolonging serum half-life, fully functional or modified Fc constant domains that mediate cytotoxicity through effector cell recruitment, therapeutic agents such as labels (fluorescence, etc.), toxins, or radionuclides.
[0213] Examples of means or domains for extending the serum half-life of polypeptide / polypeptide constructs of the present invention include peptide, protein, or protein domains that fused to or otherwise attached to the polypeptide / polypeptide construct. The group of peptide, protein, or protein domains includes peptides that bind to other proteins having a favorable pharmacokinetic profile in the human body, such as serum albumin (see International Publication No. 2009 / 127691). An alternative concept for such half-life-extending peptides includes peptides that bind to the neonatal Fc receptor (FcRn, see International Publication No. 2007 / 098420), which can also be used in constructs of the present invention. The concept of attaching larger domains or complete proteins to proteins includes the fusion of human serum albumin, human serum albumin (see International Publication Nos. 2011 / 051489, 2012 / 059486, 2012 / 150319, 2013 / 135896, 2014 / 072481, and 2013 / 075066) or variants or mutants of its domain, as well as the fusion of immunoglobulin constant regions (Fc domains) and their variants. Such variants of the Fc domain are called Fc-based domains and may be optimized / modified, for example, to disable Fc receptor binding (e.g., to evade ADCC or CDC) or for other reasons, to enable desired pairing of dimers or multimers. A further concept known in the art for extending the half-life of substances or molecules in the human body is the pegylation of those molecules (such as the constructs of the present invention).
[0214] In one embodiment, the polypeptide / polypeptide construct according to the present invention is linked (e.g., via a peptide bond) to a fusion partner (e.g., a protein, polypeptide, or peptide) to extend the serum half-life of the construct. These fusion partners can be selected from constructs containing human serum albumin ("HSA" or "HALB") and its sequence variants, peptides that bind to HSA, peptides that bind to FcRn ("FcRn BP"), or (antibody-derived) Fc regions. Exemplary sequences of these fusion partners are shown in SEQ ID NOs: 16, 18, and 19. Generally, the fusion partner can be linked either directly (e.g., via a peptide bond) to the N-terminus or C-terminus of the construct according to the present invention, or through a peptide linker such as (GGGGS)n or (GGGGQ)n (wherein "n" is an integer of 2 or more, e.g., 2, 3, or 4). Suitable peptide linkers are discussed above and shown in SEQ ID NOs: 2 and 2551.
[0215] The polypeptide construct according to the present invention comprises at least a bispecific single-chain polypeptide, wherein the polypeptide is arranged in the following order from the N-terminus to the C-terminus: a) VL (containing part of the cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (containing part of the cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the CD3ε-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope); b) VH(containing cell surface antigen-binding domain / part of paratope)-(G4S)3 or (G4Q)3-VL(containing cell surface antigen-binding domain / part of paratope)-peptide linker(SG4S) or (SG4Q)-VH(containing CD3ε-binding domain / part of paratope)-(G4S)3 or (G4Q)3-VL(containing CD3 epsilon-binding domain / part of paratope); c) VL (including part of the cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (including part of the cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (including part of the CD3 epsilon-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6-Fc monomer (part of the HLE domain); d) VH (including part of the cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (including part of the CD3 epsilon-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6-Fc monomer (part of the HLE domain); e) VH (including part of the first cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VL (including part of the second cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (including part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (including part of the CD3 epsilon-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6 or-Fc monomer (part of the HLE domain), f) VH (containing part of the first cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the second cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the CD3ε-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6 or-Fc monomer (part of the HLE domain); g) VL (containing part of the first cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VL (containing part of the second cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6 or-Fc monomer (part of the HLE domain) h) VL (containing part of the first cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VH (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the second cell surface antigen-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4S) or (SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4S)3 or (G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 or (G4Q)6 or-Fc monomer (part of the HLE domain); or i) Binding domain 1 ((VL (including part of the first cell surface antigen binding domain / paratope)-(G4S)3 or (G4Q)3-VH (including part of the first cell surface antigen binding domain / paratope)) or (VH (including part of the first cell surface antigen binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the first cell surface antigen binding domain / paratope)))-peptide linker (G4S) or (G4Q)-CD3 binding domain 1 (VH (including part of the first CD3 epsilon binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the first CD3 epsilon binding domain / paratope))-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4S)6 Or (G4Q)6-Fc monomer (part of the HLE domain)-peptide linker (G4)-binding domain 2 ((VL (including part of the second cell surface antigen binding domain / paratope)-(G4S)3 or (G4Q)3-VH (including part of the first cell surface antigen binding domain / paratope)) or (VH (including part of the second cell surface antigen binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the second cell surface antigen binding domain / paratope)))-peptide linker (G4S) or (G4Q)-CD3-binding domain 2 (VH (including part of the second CD3 epsilon binding domain / paratope)-(G4S)3 or (G4Q)3-VL (including part of the second CD3 epsilon binding domain / paratope)) It includes or consists of.
[0216] As is clear from the above, the orientation of the sequences of the VH and VL regions of the cell surface antigen binding domain can be VH-VL or VL-VH. Preferably, the cell surface antigen is a tumor antigen as detailed above herein. More specifically, the HLE domain sequence, which consists of the Fc monomer and the linking linker, is preferably selected from the sequences defined in SEQ ID NOs. 18 and 19. The two CD3 binding domains of the polypeptide construct in item i) are preferably the same CD3 binding domain, for example, preferably the CD3 binding domain having the VH region sequence and the VL region sequence of SEQ ID NOs. 2028 and 2029. The peptide linker (SG4S) or (SG4Q) is preferred at the indicated position, but can also be replaced with a (G4S) or (G4Q) linker.
[0217] Covalent modifications of polypeptides / polypeptide constructs are also within the scope of the present invention, generally occurring post-translation, but not necessarily. For example, several types of covalent modifications of a construct are introduced intramolecularly by reacting specific amino acid residues of the construct with organic derivatization factors that can react with selected side chains or N-terminal or C-terminal residues. Derivatization with bifunctional factors is useful for crosslinking the constructs of the present invention to water-insoluble support matrices or surfaces for use in various ways. Glutaminyl and asparaginyl residues are often deamidated to their corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under weakly acidic conditions. Any form of these residues falls within the scope of the present invention. Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of ceryl or threonyl residues, methylation of α-amino groups of lysine, arginine, and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, 1983, pp. 79-86), acetylation of the N-terminal amine, and amidation of any of the C-terminal carboxyl groups.
[0218] Another type of covalent modification of constructs that falls within the scope of the present invention involves altering the glycosylation pattern of a protein. As is known in the art, the glycosylation pattern can depend on both the sequence of the protein (e.g., the presence or absence of certain glycosylated amino acid residues, which will be discussed later) or on the host cell or organism in which the protein is produced. Specific expression systems will be discussed later. Polypeptide glycosylation is typically either N-linked or O-linked. N-linking refers to the binding of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (wherein X is any amino acid other than proline) are recognition sequences for enzymatic binding of the carbohydrate moiety to the asparagine side chain. Therefore, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the binding of one of the sugars, N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[0219] The addition of glycosylation sites to the construct is conveniently achieved by altering the amino acid sequence (for N-linked glycosylation sites) to contain one or more of the aforementioned tripeptide sequences. The alteration may also be carried out by the addition or substitution of one or more serine or threonine residues to the starting sequence (for O-linked glycosylation sites). For ease of use, the amino acid sequence of the construct may be altered through DNA-level changes, particularly by mutating the polypeptide-encoding DNA with pre-selected bases to produce codons that will be translated into the desired amino acids.
[0220] Another means of increasing the number of carbohydrate moieties on a construct is by chemical or enzymatic coupling of glycosides to proteins. These procedures are advantageous in that they do not require the production of proteins in host cells that have the glycosylation capacity for N and O-linked glycosylation. Depending on the coupling method used, sugars can be coupled to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) amide groups of glutamine. These methods are described in International Publication No. 87 / 05330 and in Aplin and Wriston, 1981, CRC Crit. Rev. Biochem., pp. 259-306.
[0221] The removal of carbohydrate moieties present on the starting construct can be achieved chemically or enzymatically. Chemical deglycosylation requires exposure of the protein to the compound trifluoromethanesulfonic acid or an equivalent compound. This process results in the cleavage of almost all sugars except the linked sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., 1987, Arch. Biochem. Biophys. 259:52 and Edge et al., 1981, Anal. Biochem. 118:131. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved using various endoglycosidases and exoglycosidases as described by Thotakura et al., 1987, Meth. Enzymol. 138:350. Glycosylation at potential glycosylation sites can be prevented by using the compound tunicamycin, as described by Duskin et al., 1982, J. Biol. Chem. 257:3105. Tunicamycin blocks the formation of protein-N-glycosidic bonds.
[0222] Other modifications of the constructs are also contemplated herein. For example, another type of covalent modification of the constructs includes linking the construct to various non-proteinaceous polymers, including polyols, in the manner shown in U.S. Patent Nos. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192, or 4,179,337. In addition, as is known in the art, amino acid substitutions may be made at various positions within the construct to facilitate the addition of polymers such as polyethylene glycol (PEG).
[0223] In some embodiments, the covalent modification of the construct of the present invention involves the addition of one or more labels. To reduce potential steric hindrance, label groups may be ligated to the construct via spacer arms of varying lengths. Various methods for labeling proteins are known in the art and can be used when carrying out the present invention. The terms “label” or “labeling group” refer to any detectable label. Generally, labels are divided into various classes depending on the assay in which they will be detected, and include, but are not limited to, the following: a) Radioactive isotopes or radionuclides (for example, 3 H, 14 C, 15 N, 35 S, 89 Zr, 90 Y, 99 Tc, 111 In, 125 I, 131 I) Radioactive or heavy isotope-like isotope labels b) Magnetic labeling (e.g., magnetic particles) c) Redox-active moiety d) Optical dyes such as fluorescent labels or phosphors that may be fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), chemiluminescent groups, or "small molecule" phosphors or protein phosphors (but not limited to chromophores, phosphors, and phosphors). e) Enzyme groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase) f) Biotinylation group g) A predetermined polypeptide epitope recognized by a secondary reporter (e.g., a leucine zipper pair sequence, a binding site for a secondary antibody, a metal-binding domain, an epitope tag, etc.).
[0224] "Fluorescent labeling" refers to any molecule that can be detected through its inherent fluorescent properties. Suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malasite green, stilbene, Lucifer yellow, Cascade Blue J, Texas red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and R-phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, rhodamine, and Texas This includes, but is not limited to, Red (Pierce, Rockford, IL), Cy5, Cy5.5, and Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes, including phosphors, are described in Richard P. Haugland's Molecular Probes Handbook.
[0225] Suitable protein-based fluorescent labels include green fluorescent protein, e.g., GFP from Renilla, Ptilosarcus, or Aequorea species (Chalfie et al., 1994, Science 263:802-805), EGFP (Clontech Laboratories, Inc., Genbank® accession number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc., 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H 1J9, Stauber, 1998, Biotechniques 24:462-471, Heim et al., 1996, Curr. Biol. 6:178-182), enhanced yellow fluorescent protein (EYFP, Clontech Laboratories, Inc.), and luciferase (Ichiki et al. al., 1993, J.Immunol. 150:5408-5417), β-galactosidase (Nolan et al.) Other examples include, but are not limited to, al., 1988, Proc. Natl. Acad. Sci. USA 85:2603-2607, and Renilla (International Publication No. 92 / 15673, International Publication No. 95 / 07463, International Publication No. 98 / 14605, International Publication No. 98 / 26277, International Publication No. 99 / 49019, U.S. Patent Nos. 5,292,658; 5,418,155; 5,683,888; 5,741,668; 5,777,079; 5,804,387; 5,874,304; 5,876,995; and 5,925,558).
[0226] Leucine zipper domains are peptides that promote the oligomerization of the proteins in which they are found. Leucine zippers were originally discovered in various different proteins and have since been identified in several DNA-binding proteins (Landschulz et al., 1988, Science 240:1759). Known leucine zippers include naturally occurring peptides and dimerizing or trimerizing derivatives. Examples of leucine zipper domains suitable for producing soluble oligomeric proteins are described in the PCT application's international publication 94 / 10308 brochure, and a leucine zipper derived from lung surfactant protein D (SPD) is described in Hoppe et al., 1994, FEBS Letters 344:191. The use of modified leucine zippers enabling stable trimerization of heterologous proteins fused to them is described in Fanslow et al., 1994, Semin.Immunol.6:267-78.
[0227] The polypeptide constructs of the present invention may also include additional domains that, for example, aid in the isolation of molecules or relate to the adapted pharmacokinetic properties of the molecules. Domains that aid in the isolation of constructs may be selected from peptide motifs or secondary introduction portions that can be captured in an isolation method, such as an isolation column. Non-limiting embodiments of such additional domains include peptide motifs known as Myc-tags, HAT-tags, HA-tags, TAP-tags, GST-tags, chitin-binding domains (CBD-tags), maltose-binding protein (MBP-tags), Flag-tags, Strep-tags and their variants (e.g., StrepII-tags), and His-tags. All constructs disclosed herein that feature identified CDRs may include His-tag domains, which are generally known as consecutive His residues in the amino acid sequence of the molecule, for example, repeats of five His residues or six His residues (hexa-histidine). The His tag may be located, for example, at the N-terminus or C-terminus of the construct. In one embodiment, a hexahistidine tag (HHHHHH) is linked to the C-terminus of the construct according to the present invention via a peptide bond. A histidine tag, particularly a 6×Hi tag, is preferred.
[0228] The present invention also relates to polynucleotides encoding polypeptides or polypeptide constructs of the present invention. A nucleic acid molecule is a biopolymer composed of nucleotides. A polynucleotide is a biopolymer composed of 13 or more nucleotide monomers covalently linked in a chain. DNA (e.g., cDNA) and RNA (e.g., mRNA) are examples of polynucleotide / nucleic acid molecules with different biological functions. A nucleotide is an organic molecule that functions as a monomer or subunit of a nucleic acid molecule such as DNA or RNA. The nucleic acid molecule or polynucleotide of the present invention may be double-stranded or single-stranded, linear or cyclic. It is envisioned that the nucleic acid molecule or polynucleotide may be contained in a vector. Furthermore, it is envisioned that such a vector may be contained in a host cell. The host cell may, for example, express a construct after transformation or transfection with the vector or polynucleotide / nucleic acid molecule of the present invention. For this purpose, the polynucleotide or nucleic acid molecule is operably linked to a control sequence.
[0229] The genetic code is a set of rules by which information encoded within genetic material (nucleic acids) is translated into proteins. Biological decoding in living cells is achieved by ribosomes, which ligate amino acids in the order specified by mRNA, using tRNA molecules that carry amino acids and read three nucleotides from mRNA at once. This code defines how a sequence of three nucleotides, called a codon, specifies the next amino acid to be added during protein synthesis. With a few exceptions, a three-nucleotide codon in a nucleic acid sequence specifies one amino acid. Because most genes are coded with the exact same code, this particular code is often referred to as the reference genetic code or standard genetic code.
[0230] Codon degeneracy is the redundancy of the genetic code, expressed as multiple combinations of 3-base pair codons that specify amino acids. Degeneracy arises because there are far more codons than amino acids that can be coded. Codons coding for a single amino acid can differ in any of their three positions, but often this difference lies in the second or third position. For example, codons GAA and GAG both specify glutamic acid and exhibit redundancy, but neither specifies any other amino acid and therefore does not exhibit ambiguity. The genetic code of different organisms may be biased towards using one of several codons that code for the same amino acid more than others, i.e., the frequency of one codon is higher than would be expected by chance. For example, leucine is specified by six distinct codons, some of which are rarely used. Codon usage tables detailing genomic codon usage frequencies for most organisms are available. In recombinant gene technology, this effect is often utilized by employing a technique called codon optimization, for example, to design polynucleotides using codons preferred by each host cell (e.g., human, hamster-derived cells, Escherichia coli cells, or Saccharomyces cerevisiae cells) in order to increase protein expression. Therefore, it is assumed that the polynucleotide / nucleic acid molecules of this disclosure are codon-optimized. Nevertheless, polynucleotide / nucleic acid molecules encoding the constructs of the present invention may be designed using any codon encoding a desired amino acid.
[0231] According to one embodiment, the polynucleotide / nucleic acid molecule of the present invention encoding the polypeptide construct of the present invention is in the form of a single molecule or two or more distinct molecules. If the construct of the present invention is a single-stranded construct, the polynucleotide / nucleic acid molecule encoding such a construct is most likely to also be in the form of a single molecule. However, it is also conceivable that different components of the polypeptide construct (e.g., different domains, such as a paratope-containing domain that binds to a cell surface antigen, a paratope-containing domain that binds to CD3, and / or an antibody constant domain) are located on separate polypeptide chains, in which case the polynucleotide / nucleic acid molecule is most likely to be in the form of two or more distinct molecules.
[0232] The same applies to vectors containing the polynucleotide / nucleic acid molecule of the present invention. If the construct of the present invention is a single-stranded construct, one vector may contain the polynucleotide encoding the construct in one location (as a single open reading frame, ORF). A single vector may also contain two or more polynucleotide / nucleic acid molecules at separate locations (each having its own ORF), each of which encodes a different component of the construct of the present invention. A vector containing the polynucleotide / nucleic acid molecule of the present invention is envisioned to be in the form of a single vector or two or more separate vectors. In one embodiment, for the purpose of expressing the construct in a host cell, the host cell of the present invention should contain the polynucleotide / nucleic acid molecule encoding the construct or a vector containing such polynucleotide / nucleic acid molecule as a whole, meaning that all components of the construct (whether encoded as a single molecule or encoded as separate molecules / locations) assemble post-translation to form a biologically active construct of the present invention.
[0233] Furthermore, the present invention relates to vectors comprising the polynucleotide / nucleic acid molecule of the present invention. A vector is a nucleic acid molecule typically used as a vehicle for transferring (exogenous) genetic material into a cell in order to ensure the replication and / or expression of the genetic material. The term “vector” includes, but is not limited to, plasmids, viruses, cosmids, and artificial chromosomes. Some vectors are specifically designed for cloning (cloning vectors), while others are designed for protein expression (expression vectors). So-called transcription vectors are primarily used to amplify their inserts. DNA manipulation is typically performed on E. coli vectors, which contain elements necessary for their maintenance within E. coli. However, vectors may also contain elements that allow them to be maintained in other organisms such as yeast, plants, or mammalian cells; these vectors are called shuttle vectors. Insertion of a vector into a target or host cell is typically called transformation for bacterial cells and transfection for eukaryotic cells, while insertion of a viral vector is often called transduction.
[0234] Generally, a manipulated vector contains an origin of replication, multiple cloning sites, and selectable markers. The vector itself is typically a nucleotide sequence, usually a DNA sequence, containing an insert (transgene) and a larger sequence that acts as the vector's "backbone." The genetic code determines the polypeptide sequence of a given coding region, but other genomic regions can influence when and where these polypeptides are produced. Therefore, modern vectors may include additional features besides the transgene insert and backbone, such as: promoters, genetic markers, antibiotic resistance, reporter genes, targeting sequences, and protein purification tags. A vector called an expression vector (or expression construct) is specifically for the expression of a transgene in target cells and generally contains a regulatory sequence.
[0235] The term "regulatory sequence" refers to a DNA sequence necessary for the expression of an operablely linked coding sequence in a particular host organism. Examples of regulatory sequences suitable for prokaryotes include promoters, sometimes operator sequences, and ribosome binding sites. Eukaryotic cells are known to utilize promoters, polyadenylation signals, Kozak sequences, and enhancers.
[0236] Nucleic acids are "operably linked" if they are placed in a functionally related position with another nucleic acid sequence. For example, a pre-sequence or secretion leader DNA is operably linked to the polypeptide DNA if this DNA is expressed as a preprotein involved in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if this affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if this ribosome binding site is positioned to facilitate translation. Generally, "operably linked" means that the linked nucleotide sequences are contiguous, and in the case of a secretion leader, contiguous and in the reading phase. Enhancers, however, do not need to be contiguous. Linking is achieved by ligation at a convenient restriction site. If such a site does not exist, synthetic oligonucleotide adapters or linkers are used, following conventional practice.
[0237] "Transfection" is the process of intentionally introducing nucleic acid molecules or polynucleotides (including vectors) into target cells. This term is primarily used for non-viral methods in eukaryotic cells. Transfection is often used to describe the viral transfer of nucleic acid molecules or polynucleotides. Transfection of animal cells typically involves creating transient pores or "holes" in the cell membrane to allow material uptake. Transfection can be performed using biological particles (e.g., viral transfection, also called viral transfection), chemical-based methods (e.g., using calcium phosphate, lipofection, Fugene, cationic polymers, nanoparticles, etc.), or physical treatments (e.g., electroporation, microinjection, gene gun, cell squeezing, magnetofection, hydrostatic pressure, impale infection, ultrasonic treatment, optical transfection, heat shock).
[0238] The term "transformation" is used to describe the nonviral transfer of nucleic acid molecules or polynucleotides (including vectors) into non-animal eukaryotic cells, including bacterial and plant cells. Therefore, transformation is a genetic modification of a bacterial or non-animal eukaryotic cell resulting from the direct uptake from its periphery across the cell membrane and subsequent integration of exogenous genetic material (nucleic acid molecules). Transformation can be achieved by artificial means. For transformation to occur, the cell or bacterium must be in a state of competence, which can occur as a time-limited response to environmental conditions such as starvation and cell density, and can also be artificially induced.
[0239] Furthermore, the present invention provides host cells transformed or transfected with the polynucleotide / nucleic acid molecule or vector of the present invention.
[0240] As used herein, the terms “host cell” or “recipient cell” are intended to include any individual cell or cell culture that may or may have been a recipient of a vector, exogenous nucleic acid molecule and / or polynucleotide encoding a construct of the present invention, and / or recipients of the construct itself. The introduction of individual materials into cells is carried out by transformation, transfection and the like (see above). The term “host cell” is also intended to include single-cell passages or potential passages. Such passages may not be exactly identical to the parent cell (in morphological properties or in genomic DNA or total DNA supplementation factors) because certain modifications may occur in subsequent generations due to spontaneous, accidental, or intentional mutations or environmental influences, but are still included within the scope of the terms as used herein. Suitable host cells include prokaryotic or eukaryotic cells, and are not limited to, bacteria (e.g., Escherichia coli (E. coli)), yeast cells, fungal cells, plant cells and animal cells (e.g., insect cells and mammalian cells, e.g., hamster, mouse, rat, macaque or human).
[0241] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeasts are suitable cloning or expression hosts for the constructs of the present invention. Saccharomyces cerevisiae or common baker's yeast are the most commonly used lower eukaryotic host microorganisms. However, several other genera, species, and strains are generally available and useful in the present invention, for example, Schizosaccharomyces pombe, K. lactis, K. fragilis (ATCC 12424), K. bulgaricus (ATCC 16045), K. wickeramii (ATCC 24178), K. waltii (ATCC 56500), and K. drosophilarum (ATCC 16045). Hosts of the genus Kluyveromyces, such as K. thermotolerans and K. marxianus (36906); yarrowia (European Patent No. 402226); Pichia pastoris (European Patent No. 183070); Candida; Trichoderma reesia (European Patent No. 244234); Neurospora crassa; Schwanniomyces occidentalis Hosts include the genus Schwanniomyces (such as Schwanniomyces occidentalis), as well as filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus, such as A. nidulans and A. niger.
[0242] Host cells suitable for the expression of glycosylated constructs originate from multicellular organisms. Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains and variants, as well as corresponding acceptable insect host cells derived from hosts such as the armyworm (Spodoptera frugiperda), Aedes aegypti (Aedes aegypti), Aedes albopictus (Aedes albopictus), Drosophila melanogaster (Drosophila melanogaster), and silkworm (Bombyx mori), have been identified. Various virus strains for transfection (e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV) are publicly available, and such viruses may be used herein as viruses according to the present invention, and in particular may be used for transfection of armyworm (Spodoptera frugiperda) cells.
[0243] Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, Arabidopsis thaliana, and tobacco can also be used as hosts. Cloning and expression vectors useful for protein production in plant cell cultures are known to those skilled in the art. See, for example, Hiatt et al., Nature (1989) 342:76-78, Owen et al. (1992) Bio / Technology 10:790-794, Artsaenko et al. (1995) The Plant J 8:745-750, and Fecker et al. (1996) Plant Mol Biol 32:979-986.
[0244] However, the greatest interest has been in vertebrate cells, and the proliferation of vertebrate cells in culture (cell culture) has become a routine procedure. Examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 cell line (COS-7, ATCC CRL 1651, etc.), human embryonic kidney cell line (293 cells or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)), baby hamster kidney cells (BHK, ATCC CCL 10, etc.), Chinese hamster ovary cells / -DHFR (CHO, etc., Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), mouse Sertoli cells (TM4, etc., Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVI ATCC CCL 70, etc.); African green monkey kidney cells (VERO-76, ATCC These include CRL1587, human cervical cancer cells (HELA, ATCC CCL 2, etc.), canine kidney cells (MDCK, ATCC CCL 34, etc.), buffalo rat hepatocytes (BRL 3A, ATCC CRL 1442, etc.), human lung cells (W138, ATCC CCL 75, etc.), human hepatocytes (Hep G2, 1413 8065, etc.), mouse mammary tumor cells (MMT 060562, ATCC CCL-51, etc.), TRI cells (Mather et al., Annals NY Acad.Sci. (1982) 383:44-68), MRC 5 cells, FS4 cells, and human hepatocellular carcinoma cells (Hep G2, etc.).
[0245] In further embodiments, the present invention provides a process for producing a polypeptide or polypeptide construct of the present invention, comprising culturing host cells of the present invention under conditions that enable the expression of the construct of the present invention, and recovering the produced construct from the culture.
[0246] As used herein, the term “culturing” refers to the in vitro maintenance, differentiation, growth, proliferation, and / or propagation of cells under appropriate conditions in a culture medium. Cells are grown and maintained in cell growth medium at appropriate temperatures and gas mixtures. Culture conditions vary widely for each cell type. Typical growth conditions are a temperature of approximately 37°C, a CO2 concentration of approximately 5%, and a humidity of approximately 95%. Recipes for growth media may differ, for example, in pH, the concentration of carbon sources (e.g., glucose), the nature and concentration of growth factors, and the presence of other nutrients (e.g., amino acids or vitamins). Growth factors used in supplemental media are often derived from animal blood serum (e.g., fetal bovine serum (FBS), calf serum (FCS), horse serum, and porcine serum). Cells can be grown either in suspension culture or as adherent cultures. Some cell lines are modified to be viable in suspension culture and can grow to higher densities than under adherent conditions.
[0247] The term “expression” includes, but is not limited to, any of the steps involved in the production of the construct of the present invention, including transcription, post-transcriptional modification, translation, folding, post-translational modification, targeting to specific intracellular or extracellular locations, and secretion. The term “recover” refers to a series of processes intended to isolate a construct from a cell culture. The “recovery” or “purification” process can separate the protein and non-protein portions of a cell culture, ultimately separating the desired construct from all other polypeptides and proteins. The separation process typically utilizes differences in protein size, physicochemical properties, binding affinity, and biological activity. Preparative purification aims to produce relatively large quantities of purified protein for subsequent use, while analytical purification produces relatively small quantities of protein for various research or analytical purposes.
[0248] When recombinant technology is used, the construct can be produced intracellularly in the pericellular lumen or secreted directly into the culture medium. If the construct is produced intracellularly, the first step is to remove host cells or particulate fragments of the lysed fragment, for example, by centrifugation or ultrafiltration. The construct of the present invention can be produced in bacteria such as Escherichia coli (E. coli). After expression, the construct can be isolated from the bacterial cell paste in a soluble fraction and purified, for example, by affinity chromatography and / or size exclusion. Final purification can be carried out in the same way as the process for purifying constructs expressed in mammalian cells and secreted into the culture medium. Carter et al. (Biotechnology (NY) 1992 Feb;10(2):163-7) describe a procedure for isolating antibodies secreted into the pericellular lumen of Escherichia coli (E. coli).
[0249] When antibodies are secreted into a culture medium, the supernatant from such an expression system is typically first concentrated using a commercially available protein concentration filter, such as an ultrafiltration unit.
[0250] Constructions of the present invention prepared from host cells can be recovered or purified using, for example, hydroxyl apatite chromatography, gel electrophoresis, dialysis, and affinity chromatography. Other techniques for protein purification, such as fractionation with ion exchange columns, mixed-mode ion exchange, HIC, ethanol precipitation, size exclusion chromatography, reverse-phase HPLC, chromatography with silica, chromatography with heparin Sepharose, chromatography with anion or cation exchange resins (e.g., polyaspartate columns), immunoaffinity chromatography (e.g., protein A / G / L), chromatographic focusing, SDS-PAGE, ultracentrifugation, and ammonium sulfate precipitation, are also available depending on the construct to be recovered.
[0251] Any of the above processes may include protease inhibitors to inhibit protein degradation and antibiotics to prevent the growth of contaminants.
[0252] Furthermore, the present invention provides a pharmaceutical composition or formulation comprising a polypeptide or polypeptide construct of the present invention or a polypeptide or polypeptide construct produced by the process of the present invention.
[0253] As used herein, the term “pharmaceutical composition” refers to a composition suitable for administration to a patient, preferably a human patient. Particularly preferred pharmaceutical compositions of the present invention preferably comprise one or more constructs of the present invention in therapeutically effective amounts. Preferably, the pharmaceutical composition further comprises one or more suitable formulations of pharmaceutically effective carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives and / or adjuvants. The acceptable components of the composition are preferably nontoxic to the recipient at the doses and concentrations used. Pharmaceutical compositions of the present invention include, but are not limited to, liquid, freeze-dried, and lyophilized compositions.
[0254] The composition may contain a pharmaceutically acceptable carrier. Generally, as used herein, “pharmaceutically acceptable carrier” means all aqueous and non-aqueous solutions, sterile solutions, solvents, buffers, e.g., phosphate-buffered salt (PBS) solutions, water, suspensions, emulsions such as oil / water emulsions, various types of wetting agents, liposomes, dispersion media, and coatings suitable for the administration of a pharmacopoeia, particularly parenteral administration. The use of such media and activators in pharmaceutical compositions is well known in the art, and compositions containing such carriers can be formulated by well-known conventional methods.
[0255] Certain embodiments provide pharmaceutical compositions comprising the constructs of the present invention and one or more excipients, such as those described exemplary in this section and elsewhere in this specification. Excipients can be used for a variety of purposes (e.g., to adjust the physical, chemical, or biological properties of a formulation, e.g., viscosity), and / or to improve efficacy, and / or to stabilize such formulations and processes against degradation and deterioration caused by stress during, for example, manufacturing, shipping, storage, pre-preparation, administration, and thereafter. Excipients are generally used at the lowest effective concentration.
[0256] In certain embodiments, the pharmaceutical composition may contain formulation materials for modifying, maintaining, or preserving specific properties of the composition, such as pH, molar osmotic pressure, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution rate or release rate, adsorption or osmosis (see Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Company). In such embodiments, suitable formulation materials may include, but are not limited to, the following: ·amino acid • Antimicrobial agents such as antibacterial and antifungal drugs • Antioxidant Buffers, buffer systems, and buffering agents used to maintain a composition at or slightly below physiological pH, typically within a pH range of about 5 to about 8 or 9. • Non-aqueous solvents, vegetable oils, and organic esters for injection • Aqueous carriers such as water, alcoholic / aqueous solutions, emulsions or suspensions, such as physiological saline solutions and buffer media. • Biodegradable polymers such as polyester • Volume expander Chelatives • Isotonic agents and absorption retarders • Complexing agent • Filler ·carbohydrates Preferably, a human-derived (low molecular weight) protein, polypeptide, or protein carrier. • Colorants and flavorings • Sulfur-containing reducing agent • Diluent ·emulsifier • Hydrophilic polymer • Salt-forming counterions • Preservatives • Metal complex • Solvents and co-solvents • Sugars and sugar alcohols • Suspension • Surfactants or bluing agents • Stabilizer • Isotonic enhancers • Parenteral delivery media • Intravenous delivery medium.
[0257] It is common knowledge that various components of a pharmaceutical composition can have different effects. For example, amino acids can act as buffers, stabilizers, and / or antioxidants; mannitol can act as a volume extender and / or isotonic enhancer; and sodium chloride can act as a delivery medium and / or isotonic enhancer.
[0258] In relation to the present invention, the pharmaceutical composition is (a) polypeptides or polypeptide constructs as described herein, (b) at least one buffer, (c) at least one sugar, and (d) at least one surfactant It may contain [the specified substance], and the pH of the pharmaceutical composition is in the range of 3.5 to 6.
[0259] In the above-described composition, the first domain preferably has an isoelectric point (pI) in the range of 4 to 9.5, the second domain has a pI in the range of 8 to 10, preferably 8.5 to 9.0, and the construct optionally includes a third domain comprising two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, the two polypeptide monomers being fused to each other via a peptide linker.
[0260] In the above-described composition, it is further assumed that at least one buffer is present in a concentration range of 5 to 200 mM, more preferably in a concentration range of 10 to 50 mM. It is also assumed that at least one sugar is selected from the group consisting of monosaccharides, disaccharides, cyclic polysaccharides, sugar alcohols, linear branched dextran, or linear unbranched dextran. The disaccharide is also assumed to be selected from the group consisting of sucrose, trehalose, mannitol, sorbitol, and combinations thereof. It is further assumed that the sugar alcohol is sorbitol. It is also assumed that at least one sugar is present in a concentration range of 1 to 15% (m / V), preferably in a concentration range of 9 to 12% (m / V). It is further assumed that the construct is present in a concentration range of 0.1 to 8 mg / ml, preferably 0.2 to 2.5 mg / ml, more preferably 0.25 to 1.0 mg / ml.
[0261] According to one embodiment of the composition described above, at least one surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, Pluronic F68, Triton X-100, polyoxyethylene, PEG 3350, PEG 4000, and combinations thereof. Furthermore, it is assumed that at least one surfactant is present at a concentration in the range of 0.004 to 0.5% (m / V), preferably in the range of 0.001 to 0.01% (m / V). The pH of the composition is assumed to be in the range of 4.0 to 5.0, preferably in the range of 4.2. The pharmaceutical composition is also assumed to have an osmolality in the range of 150 to 500 mOsm. Furthermore, it is assumed that the pharmaceutical composition further comprises excipients selected from the group consisting of one or more polyols and one or more amino acids. In relation to the present invention, it is assumed that the one or more excipients are present at a concentration in the range of 0.1 to 15% (w / V).
[0262] The present invention also provides a pharmaceutical composition comprising (a) a construct described herein in a concentration range of preferably 0.1 to 8 mg / ml, preferably 0.2 to 2.5 mg / ml, more preferably 0.25 to 1.0 mg / ml, (b) 10 mM glutamate or acetate, (c) 9% (m / V) sucrose or 6% (m / V) sucrose and 6% (m / V) hydroxypropyl-β-cyclodextrin, and (d) 0.01% (m / V) polysorbate 80, wherein the pH of the liquid pharmaceutical composition is 4.2.
[0263] The compositions of the present invention may, in addition to the constructs of the present invention as defined herein, contain further biologically active agents depending on the intended use of the composition. Such agents may include drugs that act on the gastrointestinal system, drugs that act as cell proliferation inhibitors, drugs that prevent hyperuricemia, drugs that suppress immune responses, drugs that modulate inflammatory responses, drugs that act on the circulatory system, and / or cytokines known in the art. The polypeptide constructs of the present invention may also be used in combination therapy, i.e., in combination with other anticancer drugs.
[0264] In this regard, the pharmaceutical composition of the present invention (including a construct comprising a CD3-binding domain and at least one further binding domain that binds to a cell surface target antigen, preferably a tumor antigen on the surface of a target cell, as described in more detail herein) is envisioned to further comprise an activator, preferably an antibody or construct, that binds to a protein of the immune checkpoint pathway (such as PD-1 or CTLA-4) or a co-stimulatory immune checkpoint receptor (such as 4-1BB). The present invention also refers to a combination of the polypeptide construct according to the present invention (including a construct comprising a CD3-binding domain and at least one further binding domain that binds to a cell surface target antigen, preferably a tumor antigen on the surface of a target cell, as described in more detail herein) and an activator, preferably an antibody or polypeptide construct, that binds to a protein of the immune checkpoint pathway (such as PD-1 or CTLA-4) or a co-stimulatory immune checkpoint receptor (such as 4-1BB). Due to the properties of at least two components of the combination, i.e., their pharmaceutically active properties, the combination may also be referred to as a therapeutic combination. In some embodiments, the combination may be in the form of a pharmaceutical composition or a kit. According to one embodiment, a pharmaceutical composition or combination comprises a construct of the present invention and an antibody or construct that binds to PD-1. Anti-PD-1 binding proteins useful for this purpose are described in detail, for example, in PCT / U.S. Patent Application Publication No. 2019 / 013205, which is incorporated herein by reference.
[0265] In certain embodiments, the optimal pharmaceutical composition is determined, for example, by the intended route of administration, the mode of delivery, and the desired dosage. See, for example, Remington's Pharmaceutical Sciences cited above. In certain embodiments, such a composition may affect the physical state, stability, in vivo release rate, and in vivo clearance rate of the construct of the present invention. In certain embodiments, the main vehicle or carrier in the pharmaceutical composition may actually be either aqueous or non-aqueous. For example, a suitable vehicle or carrier may be water for injection or a saline solution supplemented with other materials commonly found in parenteral administration compositions. In certain embodiments, a composition containing the construct of the present invention may be prepared for storage in the form of a lyophilized cake or aqueous solution by mixing selected components having a desired degree of purity with an optional formulation agent (Remington's Pharmaceutical Sciences, cited above). Furthermore, in certain embodiments, the construct of the present invention may be formulated as a lyophilized product using appropriate excipients.
[0266] When parenteral administration is intended, the therapeutic composition for use in the present invention may be provided in the form of a pyrogen-free, parenterally acceptable aqueous solution containing the desired construct of the present invention in a pharmaceutically acceptable vehicle. A vehicle particularly suitable for parenteral injection is sterile distilled water, in which the construct of the present invention is formulated as a well-preserved sterile isotonic solution. In certain embodiments, this preparation may involve formulating the desired molecule with a drug or activator that can result in controlled or sustained release of the formulation, or that can promote the duration of effectiveness in circulation, which can be delivered by depot injection. In certain embodiments, the desired construct may be introduced using an implantable drug delivery device.
[0267] Further pharmaceutical compositions, including formulations containing the constructs of the present invention in sustained delivery or controlled delivery formulations, will be apparent to those skilled in the art. Techniques for formulating various sustained delivery or controlled delivery means are known to those skilled in the art. The constructs can also be encapsulated in microcapsules prepared in colloidal drug delivery systems or in macroemulsions, for example, by coacervate technology or interfacial polymerization. Such techniques are disclosed in the aforementioned Remington's Pharmaceutical Sciences.
[0268] Pharmaceutical compositions used for in vivo administration are typically supplied as sterile preparations. Sterilization can be achieved by filtration through a sterile filtration membrane. When the composition is freeze-dried, sterilization using this method may be performed before or after freeze-drying and reconstitution. Parenteral compositions can be stored in freeze-dried form or in solution. Parenteral compositions are generally placed in containers with a sterile access port, such as intravenous solution bags or vials with a stopper that can be punctured with a subcutaneous needle.
[0269] Another aspect of the present invention includes a self-buffering formulation comprising the construct of the present invention, which can be used as a pharmaceutical composition, as described in International Publication No. 2006 / 138181. Various publications are available for protein stabilization and useful formulation materials and methods therein, such as Arawaka T. et al., Pharm Res. 1991 Mar;8(3):285-91, Kendrick et al. “Physical stabilization of proteins in aqueous solution” in: Rational Design of Stable Protein Formulations: Theory and Practice, Carpenter and Manning, eds. Pharmaceutical Biotechnology. 13:61-84 (2002), and Randolph and Jones, Pharm Biotechnol. 2002;13:159-75, in particular the sections relating to excipients and processes for self-buffering protein formulations, especially protein pharmaceuticals and processes for use in veterinary medicine and / or human medicine.
[0270] Salts may be used, according to specific embodiments of the present invention, for example, to adjust the ionic strength and / or isotonicity of a composition or formulation, and / or to improve the solubility and / or physical stability of a construct or other component of a composition according to the present invention. Ions can stabilize native proteins by binding to charged residues on the surface of proteins and shielding the charged and polar groups of proteins, thereby reducing the intensity of their electrostatic, attractive, and repulsive interactions. Ions can also stabilize denatured proteins, particularly by binding to denatured peptide bonds (--CONH) of proteins. Furthermore, ionic interactions with charged and polar groups in proteins can also reduce intermolecular electrostatic interactions, thereby preventing or reducing protein aggregation and insolubilization.
[0271] Ionic species exhibit remarkably different effects on proteins. Several categorical rankings of ions and their effects on proteins have been developed for use in formulating pharmaceutical compositions according to the present invention. One example is the Hofmeister series, which ranks ionic and polar nonionic solutes according to their effect on the conformational stability of proteins in solution. Stabilizing solutes are referred to as "cosmotropic." Destabilizing solutes are referred to as "chaotropic." Cosmotropes are generally used at high concentrations to precipitate proteins from solution ("salting out"). Chaotropes are generally used to denature and / or solubilize proteins ("salting out"). The relative effectiveness of ions for "salting out" and "salting out" defines the position of ions in the Hofmeister series.
[0272] Free amino acids can be used in formulations or compositions containing constructs of the present invention according to various embodiments of the present invention for bulking agents, stabilizers, antioxidants, and other standard uses. Certain amino acids can be used to stabilize proteins in formulations, while others are useful during lyophilization to ensure the correct cake structure and properties of the active ingredients. Some amino acids may be useful in inhibiting protein aggregation in both liquid and lyophilized formulations, while others are useful as antioxidants.
[0273] Polyols are cosmotropic and useful as stabilizers in both liquid and lyophilized formulations to protect proteins from physical and chemical degradation processes. Polyols are also useful for adjusting the tonicity of formulations and protecting them from freeze-thaw stress during transport, or for bulk preparation during manufacturing. Polyols can also function as cryoprotective substances in connection with the present invention.
[0274] Certain embodiments of formulations or compositions containing the constructs of the present invention may include surfactants. Proteins readily adsorb to surfaces, are easily denatured, and consequently tend to aggregate at gas-liquid, solid-liquid, and liquid-liquid interfaces. These harmful interactions generally increase or decrease in magnitude inversely proportional to protein concentration and are typically aggravated by physical disturbances, such as those occurring during product delivery and handling. Surfactants are routinely used to prevent, minimize, or reduce surface adsorption. Surfactants are also commonly used to control the conformational stability of proteins. In this regard, the use of surfactants is protein-specific, as one particular surfactant will typically stabilize some proteins and destabilize others.
[0275] Certain embodiments of formulations or compositions containing the constructs of the present invention may include one or more antioxidants. Harmful oxidation of proteins in pharmaceutical formulations can be prevented to some extent by maintaining appropriate levels of ambient oxygen and ambient temperature and avoiding exposure to light. Antioxidant excipients can also be used to prevent oxidative degradation of proteins. Antioxidants for use in therapeutic protein formulations according to the present invention are expected to be water-soluble and to maintain their activity throughout the shelf life of the product (composition containing the constructs). Antioxidants can damage proteins, and therefore should also be selected in a manner that eliminates or significantly reduces the possibility, in particular, that antioxidants may damage the constructs or other proteins in the formulation.
[0276] Certain embodiments of formulations or compositions containing the constructs of the present invention may include one or more preservatives. Preservatives are necessary, for example, when developing multi-dose parenteral formulations that involve dispensing from the same container more than once. Their primary function is to inhibit microbial growth over the shelf life or shelf life of the formulation, thereby ensuring the sterility of the product. While preservatives have a long history of use with small molecule parenteral substances, developing protein formulations containing preservatives can be challenging. Preservatives very often cause instability (aggregation) in proteins, which is a major reason why their use in multi-dose protein formulations is limited. To date, most protein drugs have been formulated for single use only. However, the possibility of multi-dose formulations offers the added advantages of patient convenience and high marketability. Human growth hormone (hGH), for example, is a good example of this, as the development of a preservative formulation led to the commercialization of a more convenient multi-dose injectable pen. Several aspects should be considered during the formulation and development of preservative formulations. The effective preservative concentration in a drug product must be optimized. This requires testing a given preservative in a dosage form for a concentration range that provides antimicrobial efficacy without compromising protein stability.
[0277] As expected, developing liquid formulations containing preservatives is more difficult than developing lyophilized formulations. Lyophilized products can be lyophilized without preservatives and reconstituted with a preservative-containing diluent at the time of use. This reduces the time the preservative is in contact with the construct, significantly reducing the associated stability risks. In liquid formulations, the efficacy and stability of the preservative should be maintained throughout the entire shelf life of the product. It is important to note that the efficacy of the preservative must be demonstrated in the final formulation containing the active drug and all excipient components. After formulation, a pharmaceutical composition can be stored in sterile vials as a liquid, suspension, gel, emulsion, solid, crystalline, or as an aqueous or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form that is reconstituted (e.g., lyophilized) before administration.
[0278] The biological activity of the pharmaceutical compositions as defined herein can be determined, for example, by in vitro cytotoxicity assays, as described in the following examples, in International Publication No. 99 / 54440, or by Schlereth et al. (Cancer Immunol.Immunother.20(2005),1-12). As used herein, “efficacy” or “in vivo efficacy” refers to the response to therapy with the pharmaceutical compositions of the present invention, for example, using standardized NCI response criteria. The success of therapy or in vivo efficacy with the pharmaceutical compositions of the present invention refers to the efficacy of the composition with respect to its intended purpose, i.e., the composition’s ability to cause its desired effect, i.e., a drastic reduction in diseased cells, such as tumor cells. In vivo efficacy can be monitored by established standard methods for each disease entity, including, but not limited to, leukocyte count, differentiation, fluorescence cell analysis isolation, and bone marrow aspiration. Furthermore, various disease-specific clinical chemistry parameters and other established standard methods can be used. Furthermore, computed tomography, X-ray, magnetic resonance imaging, positron emission tomography scanning, lymph node biopsy / histological methods, and other established standard methods can be used.
[0279] Another major challenge in the development of drugs, such as the pharmaceutical compositions of the present invention, is the predictable regulation of pharmacokinetic properties. To this end, it is possible to establish a pharmacokinetic profile of a candidate drug, i.e., a profile of pharmacokinetic parameters that influence the ability of a particular drug to treat a given condition. Pharmacokinetic parameters of a drug that influence the ability of a drug to treat a specific disease include, but are not limited to, half-life, volume of distribution, first-pass metabolism in the liver, and degree of serum binding. The efficacy of a given drug may be influenced by each of the above parameters.
[0280] "Half-life" is the time required for a substance or drug to decrease to half of its initial value. In medical science, it refers to the half-life of a substance or drug in the human body. In medical context, half-life can refer to the time it takes for a substance / drug to lose half of its activity, e.g., pharmacological, physiological, or radioactive activity. Half-life can also represent the time it takes for the concentration of a drug or substance (e.g., the construct of this invention) in plasma / serum to reach half of its steady-state value ("serum half-life"). Typically, the elimination or removal of an administered substance / drug refers to the cleansing of the body through biological processes such as metabolism and excretion, including the functions of the kidneys and liver. "First-pass metabolism" is the drug metabolism phenomenon in which the concentration of a drug is reduced before it reaches the circulation. This is the proportion of the drug lost during the absorption process. Therefore, "hepatic first-pass metabolism" means the tendency for a drug to be metabolized when it first comes into contact with the liver, i.e., while it is first passing through the liver. "Volume of distribution" (VD) refers to the extent to which a drug is distributed in body tissues rather than in plasma, with a higher VD indicating a greater amount distributed in tissues. Drug retention can occur in various compartments of the body, including intracellular and extracellular spaces, tissues, and organs. "Serum binding degree" refers to the tendency for a drug to interact with and bind to serum proteins such as albumin, which can lead to a decrease or loss of the drug's biological activity.
[0281] Pharmacokinetic parameters also include the bioavailability, delay time (T lag), Tmax, absorption rate, and / or Cmax of a given amount of drug administered. "Bioavailability" refers to the percentage of the administered dose of the drug / substance that reaches the systemic circulation (blood compartments). When a drug is administered intravenously, its bioavailability is considered to be 100%. However, when a drug is administered via other routes (e.g., orally), its bioavailability is generally reduced. "Delay time" refers to the time delay between the administration of a drug and its detectability and measurability in the blood or plasma. Cmax is the maximum plasma concentration a drug achieves after its administration (and before the administration of a second dose). Tmax is the time to reach Cmax. The time it takes to reach the blood or tissue concentration of the drug necessary for its biological effect is influenced by all of these parameters. For pharmacokinetic parameters of constructs exhibiting interspecies specificity that can be determined in preclinical animal studies in primates other than chimpanzees, as outlined above, please refer, for example, to Schlereth et al. (cited above).
[0282] One embodiment provides a construct of the present invention (or a construct produced by a process of the present invention) for use as a pharmaceutical, particularly for use in the prevention, treatment, or improvement (preferably treatment) of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors. Another embodiment provides the use of a construct of the present invention (or a construct produced by a process of the present invention) in the manufacture of a pharmaceutical for the prevention, treatment, or improvement of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors. It is also conceivable to provide a method for the prevention, treatment, or improvement of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors, comprising the step of administering a construct of the present invention (or a construct produced according to a process of the present invention) to a subject in need thereof. The terms “subject in need,” “patient,” or “subject in need of treatment” include persons who are already afflicted and persons for whom the disease should be prevented. The terms also include human subjects and other mammalian subjects receiving either prophylactic or therapeutic treatment.
[0283] The polypeptides / polypeptide constructs of the present invention and the formulations / pharmaceutical compositions described herein are useful in treating, improving and / or preventing the medical conditions described herein in patients who require them. The term “treatment” includes both therapeutic treatment and prophylactic or preventative measures. Treatment includes the application or administration of polypeptides / polypeptide constructs / pharmaceutical compositions to the body, isolated tissues or cells from a patient or subject having the disease / disorder described herein, the symptoms of such disease / disorder, or a predisposition to such disease / disorder, for the purpose of curing, healing, alleviating, reducing, altering, correcting, mitigating, improving or influencing the disease, the symptoms of the disease, or a predisposition to the disease. The term “improvement” as used herein refers to any improvement in the patient’s condition by administering the polypeptide constructs according to the present invention to such patient or subject who requires them. Such improvement may be a delay or cessation of disease progression and / or a decrease in the severity of disease symptoms, an increase in the frequency or duration of disease-free periods, or a prevention of functional impairment or disability due to the disease. As used herein, the term “prevention” means avoidance of the occurrence or recurrence of any disease specified herein by administration of the construct according to the present invention to any subject in need thereof.
[0284] The term “disease” refers to any condition that would benefit from treatment with the constructs or pharmaceutical compositions described herein. This includes chronic and acute disorders or diseases, including pathological conditions that make mammals susceptible to the disease in question. Diseases are preferably neoplastic diseases, more preferably neoplasms, cancers, or tumors. Diseases, neoplasms, cancers, or tumors are preferably positive for tumor antigens, preferably those defined herein above, i.e., characterized by the expression or overexpression of tumor antigens, preferably those defined herein above. Overexpression of tumor antigens means an increase of at least 10%, particularly at least 25%, at least 50%, at least 100%, at least 250%, at least 500%, at least 750%, at least 1000%, or more. The expression is preferably found only in diseased tissue, but the expression in the corresponding healthy tissue is undetectable or not significantly detectable. According to the present invention, diseases associated with cells expressing tumor antigens, preferably those defined herein above, include cancerous diseases. Furthermore, according to the present invention, cancerous diseases are preferably those in which cancer cells express tumor antigens. In accordance with the present invention, diseases, preferably neoplastic diseases, more preferably neoplasms, tumors, or cancers, are preferably characterized by the presence of BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive cells.In other words, neoplastic diseases, more preferably neoplasms, tumors, or cancers are preferably associated with the presence of BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive cells. Therefore, neoplastic diseases, more preferably neoplasms, tumors, or cancers may be referred to as BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive neoplasms, tumors, or cancers. It is understood herein that each of the tumor antigen-positive neoplasms, tumors, or cancers may be prevented, treated, or improved using polypeptides or polypeptide constructs according to the present invention that include a binding domain to a tumor antigen expressed by the cells in which the neoplasm, tumor, or cancer is associated.Neoplasms, tumors, or cancers that are BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive are BCMA-positive (for BCMA-positive neoplasms, tumors, or cancers), CD12 3 (for CD123-positive neoplasms, tumors, or cancers), CD19 (for CD19-positive neoplasms, tumors, or cancers), CD20 (for CD20-positive neoplasms, tumors, or cancers), CD22 (for CD22-positive neoplasms, tumors, or cancers), CD33 (for CD33-positive neoplasms, tumors, or cancers), CD70 (for CD70-positive neoplasms, tumors, or cancers), CDH19 (for CDH19-positive neoplasms, tumors, or cancers), CDH3 (for CDH3-positive neoplasms, tumors, or cancers), CLL1 ( Polypeptides or polypeptide constructs according to the present invention, each containing a binding domain to CLL1-positive neoplasms, tumors, or cancers, CS1 (for CS1-positive neoplasms, tumors, or cancers), CLDN6 (for CLDN6-positive neoplasms, tumors, or cancers), CLDN18.2 (for CLDN18.2-positive neoplasms, tumors, or cancers), DLL3 (for DLL3-positive neoplasms, tumors, or cancers), EGFRvIII (for EGFRvIII-positive neoplasms, tumors, or cancers), FLT3 (for FLT3-positive neoplasms, tumors, or cancers), MAGEB2 (for MAGEB2-positive neoplasms, tumors, or cancers), MART1 (for MART1-positive neoplasms, tumors, or cancers), MSLN (for MSLN-positive neoplasms, tumors, or cancers), MUC17 (for MUC17-positive neoplasms, tumors, or cancers), PSMA (for PSMA-positive neoplasms, tumors, or cancers), and STEAP1 (for STEAP1-positive neoplasms, tumors, or cancers), can be used to prevent, treat, or improve these conditions.
[0285] A "neoplasm" is an abnormal growth of tissue that usually, though not always, forms a mass. When it forms a mass, it is usually also called a "tumor." Neoplasms or tumors can be benign, potentially malignant (precancerous), or malignant (cancerous). Malignant neoplasms / tumors are commonly referred to as cancer. They usually invade and destroy surrounding tissues and may form metastases, that is, they spread to other parts, tissues, or organs of the body. A "primary tumor" is a tumor that grows in an anatomical site where the tumor's progression began and progressed to form a cancerous mass. Most cancers originate in their primary site but then progress and metastasize or spread to other parts of the body (e.g., tissues and organs). These further tumors are "secondary tumors." Most cancers continue to be referred to by their primary site even after they have spread to other parts of the body.
[0286] Lymphoma and leukemia are lymphoid neoplasms. For the purposes of this invention, they are also encompassed by the terms “tumor” and “cancer.” For the purposes of this invention, the terms “neoplasm,” “tumor,” and “cancer” may be used interchangeably, and they include both primary tumors / cancers and secondary tumors / cancers (or “metastases”), as well as mass-forming neoplasms (tumors) and lymphoid neoplasms (such as lymphoma and leukemia), and minimal residual disease (MRD).
[0287] The term “minimum residual disease” (MRD) refers to evidence of the presence of a small number of residual cancer cells remaining in a patient after cancer treatment, for example, when the patient is in remission (no symptoms or signs of the disease). Standard tests used to assess or detect cancer are not sensitive enough to detect MRD, so very small numbers of residual cancer cells are usually undetectable by routine means. Recently, highly sensitive molecular biological tests for MRD, such as flow cytometry, PCR, and next-generation sequencing, have become available. These tests can measure the minimum level of cancer cells in a tissue sample, sometimes as low as one cancer cell in a million normal cells. In connection with this invention, the terms “prevention,” “treatment,” or “improvement” of cancer are assumed to also encompass “prevention, treatment, or improvement of MRD,” regardless of whether MRD is detected or not.
[0288] The constructs of the present invention will generally be designed to suit specific routes and methods of administration, specific dosages and frequencies of administration, and specific treatments for specific diseases, particularly in terms of bioavailability and persistence. The materials of the composition will preferably be formulated at concentrations acceptable at the administration site. Thus, formulations and compositions can be designed in accordance with the present invention to suit delivery by any suitable route of administration. In relation to the present invention, routes of administration include, but are not limited to, local, enteral, and parenteral routes.
[0289] If the pharmaceutical composition is lyophilized, the lyophilized material is first reconstituted with a suitable liquid before administration. The lyophilized material can be reconstituted with, for example, bacteriostatic water for injection (BWFI), physiological saline, phosphate-buffered saline (PBS), or the same formulation in which the protein was present before lyophilization. The pharmaceutical compositions and constructs of the present invention are particularly useful for parenteral administration, such as intravenous delivery, such as injection or infusion. The pharmaceutical compositions may be administered using medical devices. Examples of medical devices for administering pharmaceutical compositions are described in U.S. Patent Nos. 4,475,196; 4,439,196; 4,447,224; 4,447,233; 4,486,194; 4,487,603; 4,596,556; 4,790,824; 4,941,880; 5,064,413; 5,312,335; 5,312,335; 5,383,851; and 5,399,163.
[0290] The compositions of the present invention can be administered to subjects at appropriate doses, for example, determined by dose-escalation studies. Constructs of the present invention exhibiting heterospecificity as described herein, as indicated above, can also be advantageously used in preclinical studies in non-chimpanzee primates. The administration plan will be determined by the attending physician based on clinical factors. As is well known in the medical field, the drug dose for any one patient depends on many factors, including the patient's size, body surface area, age, the specific compound administered, sex, time and route of administration, overall health status, and other drugs administered concurrently.
[0291] The “effective dose” is the amount of therapeutic agent sufficient to achieve, or at least partially achieve, the desired effect. The “therapeutic effective dose” is the amount sufficient to cure, or at least partially suppress, the disease and its complications, signs, and symptoms in a patient suffering from the disease. The effective dose or amount for this use will depend on the disease being treated (target disease), the construct being delivered, the circumstances and objectives of the treatment, the severity of the disease, previous therapy, the patient’s medical history and respo...
Claims
1. A polypeptide or polypeptide construct comprising a binding domain that binds to an extracellular epitope of the human CD3 epsilon chain, comprising or consisting of a VH region and a VL region linked by a peptide linker, said peptide linker comprising or consisting of a G 4 S or G 4 Q linker or repeats thereof, i) the VH region is EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYY ADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS Contains an array of ii) the VL region QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL Contains an array of iii) the VH and VL region sequences are an I at position 34, an A at position 65, a V at position 81, an A at position 99, an A at position 101, and an S at position 106 in said VH domain sequence; an I at position 20, a K at position 40, an S at position 69, and an S at position 102 in said VL domain sequence; M at position 45, A at position 65, L at position 81, A at position 101, T at position 106 in the VH region sequence, I at position 20, K at position 40, S at position 69, and S at position 102 in the VL region sequence; M at position 45, A at position 65, L at position 81, A at position 101, S at position 106, F at position 112 in the VH region sequence, I at position 20, I at position 38, K at position 40, E at position 69, S at position 102, and Y at position 93 in the VL region sequence; an I at position 34, an E at position 39, an A at position 65, an N at position 101, an A at position 102, a T at position 106, an F at position 112 in the VH domain sequence, a K at position 40, and an S at position 102 in the VL domain sequence; an I at position 34, an E at position 64, an A at position 65, an A at position 99, an A at position 101, and a T at position 106 in said VH domain sequence, a K at position 40, an A at position 91, and an S at position 102 in said VL domain sequence; in said VH domain sequence, an I at position 34, an A at position 65, a V at position 81, an A at position 99, an A at position 101, an E at position 102, an I at position 104, and a T at position 106; in said VL domain sequence, an I at position 20, a K at position 40, an S at position 69, and an S at position 102; in said VH domain sequence, E at position 64, A at position 65, G at position 68, V at position 81, A at position 101, S at position 106, in said VL domain sequence, I at position 20, S at position 69, and S at position 102; an I at position 34, an E at position 64, an A at position 65, an A at position 101, a T at position 106, and an F at position 112 in said VH domain sequence; a K at position 40, an A at position 91, and an S at position 102 in said VL domain sequence; an I at position 34, an E at position 64, an A at position 65, an A at position 101, an S at position 106, and an F at position 112 in said VH domain sequence; a K at position 40, an A at position 91, and an S at position 102 in said VL domain sequence; in said VH domain sequence, an I at position 34, an E at position 64, an A at position 65, a V at position 81, an A at position 99, an A at position 101, an S at position 106, in said VL domain sequence, an I at position 20, a K at position 40, an S at position 69, an S at position 102, and a Y at position 93; an I at position 34, an A at position 65, an A at position 101, an S at position 106, and an F at position 112 in said VH domain sequence; a K at position 40, an A at position 91, and an S at position 102 in said VL domain sequence; M at position 45, E at position 64, A at position 65, L at position 81, A at position 101, T at position 106 in the VH domain sequence, I at position 20, I at position 38, K at position 40, E at position 69, and S at position 102 in the VL domain sequence; S at position 30, M at position 45, A at position 65, G at position 68, V at position 81, A at position 101, T at position 106, F at position 112 in the VH region sequence, K at position 40, S at position 69, and Y at position 93 in the VL region sequence; S at position 30, M at position 45, E at position 64, A at position 65, G at position 68, V at position 81, A at position 101, S at position 106 in the VH domain sequence, K at position 40, and S at position 69 in the VL domain sequence; in said VH domain sequence, E at position 64, A at position 65, G at position 68, V at position 81, N at position 101, E at position 102, I at position 104, T at position 106, I at position 20, S at position 69, and S at position 102 in said VL domain sequence; A at position 65, G at position 68, V at position 81, N at position 101, E at position 102, I at position 104, S at position 106 in the VH domain sequence, I at position 20, S at position 69, and S at position 102 in the VL domain sequence; an I at position 34, an A at position 65, an A at position 99, an A at position 101, a T at position 106 in said VH domain sequence, a K at position 40, an A at position 91, and an S at position 102 in said VL domain sequence; and S at position 30, E at position 39, E at position 64, A at position 65, V at position 81, A at position 101, E at position 102, I at position 104, T at position 106 in the VH region sequence, M at position 20, K at position 40, and E at position 69 in the VL region sequence A polypeptide or polypeptide construct comprising a combination of amino acid substitutions selected from:
2. A polypeptide or polypeptide construct according to claim 1, comprising at least one further binding domain.
3. The polypeptide or polypeptide construct of claim 2 , wherein the at least one further binding domain binds to a cell surface antigen.
4. The polypeptide or polypeptide construct of claim 3 , wherein the cell surface antigen is a tumor antigen.
5. 5. The polypeptide or polypeptide construct of claim 4, wherein the tumor antigen is selected from the group consisting of BCMA, CD123, CD19, CD20, CD22, CD33, CD70, CDH19, CDH3, CLL1, CS1, CLDN6, CLDN18.2, DLL3, EGFRvIII, FLT3, MAGEB2, MART1, MSLN, MUC17, PSMA and STEAP1.
6. A polypeptide or polypeptide construct according to any one of claims 1 to 5, which is a single chain polypeptide that is at least bispecific.
7. A polynucleotide encoding a polypeptide or polypeptide construct according to any one of claims 1 to 6.
8. A vector comprising the polynucleotide of claim 7.
9. A host cell transformed or transfected with a polynucleotide according to claim 7 or a vector according to claim 8.
10. 10. A process for producing a polypeptide or polypeptide construct according to any one of claims 1 to 6, comprising culturing a host cell according to claim 9 under conditions allowing expression of the polypeptide or polypeptide construct according to any one of claims 1 to 6, and recovering the produced polypeptide or polypeptide construct from the culture.
11. A pharmaceutical composition comprising a polypeptide or a polypeptide construct according to any one of claims 1 to 6.
12. A polypeptide or polypeptide construct according to any one of claims 4 to 6 for use in a method for the prevention, treatment or amelioration of a disease selected from tumor diseases.
13. A kit comprising a polypeptide or polypeptide construct according to any one of claims 1 to 6, a polynucleotide according to claim 7, a vector according to claim 8 and / or a host cell according to claim 9.
